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Abstract I 
 
Abstract  
The reconstitution of myelin sheaths, so called remyelination, represents an innovative 
therapeutic goal in multiple sclerosis (MS), the most common inflammatory-
demyelinating disease of the central nervous system (CNS). Recently, the orphan G 
protein-coupled receptor (GPCR) GPR17, which is predominantly expressed in oli-
godendrocytes, has been identified as inhibitor of oligodendroglial differentiation, ar-
resting oligodendrocytes in an immature, non-myelinating stage. Moreover, GPR17 
expression is upregulated in human MS tissues, suggesting a key role of this receptor 
during the remyelination impairment that occurs in MS. However, the downstream sig-
naling pathway connecting GPR17 to oligodendroglial maturation arrest is still poorly 
understood.  
The present work confirms that GPR17 activation by the small molecule agonist 
MDL29,951 results in a reduction of mature oligodendrocytes in vitro, evident by their 
decreased intracellular myelin basic protein (MBP) levels. The GPR17-mediated matu-
ration block is crucially triggered by the Gαi/o pathway, which leads to an inhibition of 
two signaling cascades: (i) the adenylyl cyclase (AC)-cyclic adenosine monophosphate 
(cAMP)–protein kinase A (PKA)–cAMP response element-binding protein (CREB), 
and (ii) the AC-cAMP-exchange protein directly activated by cAMP (EPAC). Remark-
ably, these findings demonstrate for the first time an involvement of EPAC on oli-
godendrocyte myelination. In conclusion, GPR17 but also its downstream signaling 
effectors as elucidated in this study provides several drug targets to influence oligoden-
drocyte differentiation. 
Furthermore, knowledge about GPR17 pharmacology would benefit greatly from the 
identification of both its endogenous ligand(s) and/or selective antagonists. The activa-
tion of GPR17 by cysteinyl-leukotriene and purinergic ligands (UDP, UDP-gal, UDP-
glc, LTC4, and LTD4) is ten years after its initial publication still controversially dis-
cussed. In line with other laboratories that did not validate GPR17 as dualistic receptor 
for both ligand families, the data of the present work obtained in (i) G protein rear-
rangement, (ii) β-arrestin recruitment, and (iii) ERK1/2 phosphorylation assays confirm 
that GPR17 must still be regarded as an orphan receptor. Additionally, the present work 
invalidates the P2Y12 antagonists ticagrelor and cangrelor as GPR17 inhibitors. How-
ever, investigations on two structurally related CysLT2 receptor antagonists, 
HAMI3379 and Cay10633, strongly suggest that their basic chemical scaffolds will 
serve as valuable starting point for the generation of more potent and selective GPR17 
antagonists to inhibit signaling of this orphan receptor in MS.  
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Kurzfassung III 
 
Kurzfassung 
Die Regeneration von Myelinscheiden, die Remyelinisierung, repräsentiert ein innova-
tives therapeutisches Ziel bei Multipler Sklerose (MS), der häufigsten inflammatori-
schen demyelinisierenden Erkrankung des zentralen Nervensystems (ZNS). Differen-
zierte Oligodendrozyten sind für die Bildung von Myelinscheiden verantwortlich. Der 
orphane G Protein-gekoppelte Rezeptor (GPCR) GPR17, der prädominant in Oli-
godendrozyten exprimiert ist, blockiert deren Differenzierung zu myelinisierenden Oli-
godendrozyten. GPR17 ist darüber hinaus im Gewebe von MS Patienten überexpri-
miert, was implizieren könnte, dass der Rezeptor eine zentrale Rolle als Inhibitor der 
Remyelinisierung bei MS spielt. Wie GPR17 Oligodendrozytendifferenzierung auf mo-
lekularer Ebene blockiert, d.h. welche intrazellulären Signalwege involviert werden, ist 
jedoch kaum bekannt. 
Die vorliegende Arbeit bestätigt, dass die Aktivierung von GPR17 durch den syntheti-
schen Agonisten MDL29,951 in vitro eine Reduktion der Reifung von Oligodendrozy-
ten zur Folge hat, was durch eine verminderte Expression des intrazellulären Myelin 
Basic Proteins (MBP) detektierbar ist. Die GPR17-vermittelte Entwicklungsblockierung 
wird entscheidend durch den Gαi/o Signalweg beeinflusst. Dies beinhaltet die Hemmung 
von zwei Signalkaskaden: (i) die Adenylatzyklase (AC)-zyklischen Adenosinmono-
phosphate (cAMP) – Proteinkinase A (PKA) – cAMP response element-binding protein 
(CREB) und (ii) die AC-cAMP-Exchange Protein directly acitvated by cAMP (EPAC) 
Kaskade. Interessanterweise, zeigen die erhaltenen Ergebnisse zum ersten Mal eine Be-
teiligung des Guaninnukleotid-Austauschfaktors EPAC an der Myelinisierung durch 
Oligodendrozyten. Zusammenfassend bieten sowohl GPR17 als auch seine intrazellulä-
ren Effektorproteine diverse Ansatzpunkte, um die Differenzierung von Oligodendrozy-
ten therapeutisch zu beeinflussen.  
Zusätzlich würde die Identifizierung des endogenen Agonisten und/oder selektiver An-
tagonisten einen wertvollen Beitrag zur bisher rudimentären GPR17 Pharmakologie 
leisten. Die Aktivierung von GPR17 durch Cysteinyl-Leukotriene und Purin Liganden 
(UDP, UDP-gal, UDP-glc, LTC4 und LTD4) wird zehn Jahre nach der ersten Postulie-
rung noch immer kontrovers diskutiert. Im Einklang mit anderen Arbeitsgruppen, die 
nicht belegen konnten, dass GPR17 durch die genannten Substanzen aktiviert wird, be-
stätigen die Daten der vorliegenden Arbeit, mittels Assays zur (i) G Protein-
Umlagerung, (ii) β-Arrestin Rekrutierung und (iii) ERK1/2 Phosphorylierung, dass 
GPR17 immer noch als orphaner Rezeptor anzusehen ist. Darüber hinaus konnten die 
P2Y12 Antagonisten, Ticagrelor und Cangrelor, nicht als GPR17 Inhibitoren bestätigt 
werden. Im Gegensatz dazu konnten wir für zwei strukturell ähnliche CysLT2-
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Rezeptor-Antagonisten, HAMI3379 und Cay10633, eine Hemmung von GPR17 nach-
weisen, wodurch diese Substanzen als neue Ausgangspunkte für die Entwicklung von 
potenten und selektiven GPR17 Antagonisten angesehen werden könnten, um somit den 
GPR17 Signalweg in MS zu blockieren. 
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1 Introduction 1 
 
1 Introduction 
1.1 Multiple sclerosis (MS): a severe neurological disease  
Multiple sclerosis (MS) is an autoimmune disorder, which is characterized by inflam-
mation-mediated demyelination of the nerve cells in the central nervous system (CNS). 
In consequence, nerve cells lose their electric insulation and thus their ability to com-
municate with high speed. This results in a range of neurological symptoms, such as 
loss of sensitivity, muscle spasms, visual problems and, furthermore, cognitive and psy-
chiatric symptoms (Compston, Coles 2002). 
Worldwide, approximately 2.5 million people suffer from MS, representing the chronic 
immune-mediated disorder with a high prevalence in young adults. In Germany alone, 
the annual incidence rate is 3.5 - 5 cases per 100.000 population for this devastating 
disease (Neusser et al. 2014). MS causes great afflictions for both patients and their 
families. Furthermore, the cost for drug therapy and nursing care represent a considera-
ble burden for the global health care system. For instance, in the European Union alone, 
the estimated costs for the treatment of MS account 9 billion Euros every year (Frank-
lin, Ffrench-Constant 2008).  
Regrettably, no curative therapy for MS is available up to now. The current treatment 
strategies are aiming at elevating the life quality of patients, as the major part of the 
applied drugs belongs to the class of disease-modifying therapies. These treatments, as 
their name indicates, only help to control the progress of the diseases by modulation of 
the inflammatory processes. Thereby, the development of remedial therapies for MS 
represents a great challenge for the pharmaceutical industry (Aktas et al. 2010; Mari-
nelli et al. 2016).  
 Remyelination: the challenging therapeutic goal 1.1.1
Mature oligodendrocytes and Schwann cells provide myelin in the CNS and in the pe-
ripheral nervous system (PNS), respectively. Axons are wrapped by a myelin sheath, 
which allows a saltatory conduction of action potentials. This permits a 20-100 -fold 
faster transmission of action potentials compared to non-myelinated axons (Miller 2002; 
Kremer et al. 2016). MS is characterized by an inflammatory damage of oligodendro-
cytes and, consequently, by the loss of myelin sheaths in the CNS. The demyelination 
cascade terminates in degeneration of the axon or even the entire neuron, except remye-
lination, a spontaneous myelin repair process, occurs (Franklin, Ffrench-Constant 
2008). Although shorter and thinner myelin sheaths characterize myelin-repaired CNS 
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areas, they remain functional. Therefore, one important therapeutic goal against demye-
linating/dysmyelinating diseases would be to enhance intrinsic mechanisms that specifi-
cally drive remyelination and thereby avoid axonal loss. 
 
 
Figure 1. Process of demyelination and remyelination on neuronal axons in the 
CNS  
Demyelination may be followed by spontaneous remyelination, but under pathophysiological conditions, 
such as in MS, remyelination fails. If no remyelination occurs, the axon and even the entire neuron perish 
because they are unprotected. In contrast, if remyelination occurs newly formed myelin sheaths remain 
functional although they are thinner and shorter than those that were initially generated during CNS de-
velopment (modified from (Franklin, Ffrench-Constant 2008)).  
 
Myelination and remyelination in the CNS require the proliferation of oligodendrocyte 
precursor cells (OPCs), their migration into the unmyelinated area, and their final dif-
ferentiation into mature myelinating oligodendrocytes, the latter being probably of 
greatest relevance (Franklin 2002).  
During differentiation, OPCs pass through specific stages, i.e. precursor cells, imma-
ture, and mature oligodendrocytes, which are characterized by a well-defined expres-
sion pattern of surface proteins and a change in morphology. The main molecular mark-
ers for the precursor cell stage are the cell surface receptor platelet-derived growth fac-
tor receptor alpha (PDGFRα) and the sulfated neural/glial antigen 2 proteoglycan 
(NG2), located in the plasma membrane. Immature oligodendrocytes are characterized 
by the expression of O-Antigens (O4), which are sulfatides expressed on the oligoden-
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drocyte surface, and also NG2. Mature oligodendrocytes display a ramified morphology 
(Kremer et al. 2016) and surround axons with myelin sheaths, which are multi-lamellar 
sheets of their plasma membrane containing a characteristic composition of proteins and 
lipids. These include the myelin basic protein (MBP), the myelin-associated glycopro-
tein (MAG), the proteolipid protein (PLP) and the myelin oligodendrocyte glycoprotein 
(MOG) (Kremer et al. 2016). 
Notably, analysis of multiple sclerosis plaques revealed limited or inadequate remye-
lination in MS, suggesting that intrinsic repair mechanisms that specifically drive oli-
godendrocyte-mediated remyelination occur in the demyelinated CNS areas but they 
fail to prevent axon degeneration (Kuhlmann et al. 2008; Franklin, Ffrench-Constant 
2008). Therefore, MS therapy might benefit from the identification of oligodendrocyte 
intracellular mechanisms that allow overcoming MS remyelination failure, consequently 
becoming innovative targets to find groundbreaking pharmaceutical approaches to fos-
ter remyelination. 
Recent findings suggest that oligodendrocyte differentiation is influenced by a wide 
range of intracellular molecular pathways. For instance, pharmacological studies em-
ploying an antagonistic antibody against the Leucine rich repeat and Ig-like domain-
containing Nogo receptor interacting protein 1 (LINGO-1) and in vivo genetic analyses 
using a LINGO-1 knockout model (Mi et al. 2005; Mi et al. 2007; Pepinsky et al. 2011) 
showed that LINGO-1 has a critical role during myelination, blocking the development 
of oligodendrocytes. In fact, LINGO-1 is under clinical evaluation as a current innova-
tive target to treat MS. In addition, enzymes like phosphodiesterases 4 (Syed et al. 
2013) and 7 (Medina-Rodríguez et al. 2013), and a wide range of receptors are recog-
nized as potential targets to promote the endogenous efforts towards myelin regenera-
tion. For instance, nuclear estrogen receptor-β ligand treatment exhibited a direct neuro-
protective effect on oligodendrocyte differentiation and myelination (Crawford et al. 
2010). Furthermore, several guanine nucleotide-binding protein (G protein) coupled 
receptors (GPCRs) have been identified to have an impact on the pathogenesis of MS 
(Chen et al. 2009; Crawford et al. 2010; Ackerman et al. 2015). Thus, interference with 
these pathways may uncover new opportunities to treat and to cure demyelinating dis-
eases in which physiological remyelination fails.  
1.2 GPCR signaling and their role in differentiation of 
oligodendrocytes 
The GPCR superfamily represents the largest and most diverse family of cell surface 
receptors. GPCRs, also known as seven transmembrane receptors (7TMs), comprise 
around 800 members and represent ≈3% of the human genome. They play critical roles 
in a variety of biological processes in the human body, such as metabolism, contractili-
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ty, secretion, motility, transcription, and growth among others. Based on these wide-
spread functions, aberrant GPCR function may lead to diseases including cardiovascu-
lar, metabolic, neurodegenerative, psychiatric disorders, cancer and infectious diseases 
(Neves et al. 2002; Duc et al. 2015). GPCRs respond to a wide range of ligands from 
single photons to ions, odorants, amino acids, fatty acids, neurotransmitters or pep-
tides/polypeptides (Marinissen, Gutkind 2001; Insel et al. 2007; Millar, Newton 2010). 
The GPCR superfamily can be divided into five highly diverged classes: glutamate, 
rhodopsin, adhesion, frizzled/taste2, and secretin class (GRAFS), whereby the rhodop-
sin class represents the largest group with around 670 family members, including 388 
odorant receptors (Fredriksson et al. 2003; Lagerström, Schiöth 2008; Millar, Newton 
2010). 
Remarkably, about 36% of all available medications target GPCRs, which convert them 
into the most important class of drug targets (Rask-Andersen et al. 2011). However, so 
far marketed drugs target only approximately 10% of all known GPCRs, indicating their 
outstanding role in future drug discovery projects of pharmaceutical industry (Fang et 
al. 2015). In this context, Du and coworkers (Du, Xie 2012) have reviewed the expres-
sion of various GPCRs on different cell types in the CNS involved in the development 
and progression of MS, such as monocytes, macrophages, astrocytes, and oligodendro-
cytes, indicating the high potential of GPCRs as new drug targets in demyelinating dis-
eases. For instance, Fingolimod (Gilenya®) represents an innovative immunomodulat-
ing drug for treatment of MS, targeting the sphingosin-1-phosphate (S1P) receptor. It 
was the first orally administered disease-modifying drug that has been introduced in the 
German market in 2011. In the human body, the prodrug Fingolimod is metabolized to 
FTY720-phosphate (FTY720-P), which blocks migration of T-lymphocytes into the 
CNS, thus preventing their contribution to the autoimmune reaction. FTY720-P medi-
ates its effects by targeting the S1P receptors expressed on T-lymphocytes through a 
polypharmacological mechanism of action: initially the S1P1 receptor is activated by 
FTY720-P, but the activation is followed by the internalization of the receptor into the 
cell. This inhibits the T-lymphocyte’s capacity to respond to the S1P and thereby causes 
their retention in the lymph nodes (Matloubian et al. 2004; Groves et al. 2013; Gonza-
lez-Cabrera et al. 2014). 
GPCRs are also expressed during OPC migration, proliferation, and differentiation into 
mature myelinating oligodendrocytes, suggesting their involvement in the entire process 
of myelination, demyelination, and remyelination in the CNS. It is important to empha-
size that the expression patterns of GPCRs change during oligodendrocyte development. 
Therefore, 7TM-receptors could represent ideal therapeutic targets to interfere with the 
well-define development cascade of oligodendrocytes at each stage. For instance, upon 
activation by ATP and ADP, the purinergic receptor P2Y1 triggers the migration of 
OPCs. Muscarinic acetylcholine receptors (mAChRs) and β-adrenoreceptors have a 
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positive and a negative regulatory effect on OPC proliferation, respectively. Moreover, 
the mAChR subclasses M1 and M3 (Deshmukh et al. 2013) and the serotonin receptor 
subtypes 5-HT1A and 5-HT2A (Marinelli et al. 2016) are associated with arrest of oli-
godendrocytes in immature stages. Interestingly, the number of factors known to attenu-
ate oligodendrocyte differentiation exceeds the number of activators of oligodendrocyte 
maturation (Kremer et al. 2011). In line with the fact that a broad diversity of GPCRs 
are associated with differentiation of oligodendrocytes, several intracellular downstream 
effectors of GPCR signaling cascades have been also described to be involved during 
the development of oligodendrocytes. 
 Heterotrimeric G protein signaling and its downstream effectors 1.2.1
GPCRs are mediating their effects mainly by interacting with heterotrimeric guanine 
nucleotide–binding proteins (G proteins), thereby promoting a variety of intracellular 
signals. G proteins are composed of three subunits: Gα, Gβ, and Gγ. In its inactive con-
formation the Gα subunit is bound to GDP and forms a heterotrimer with the obligatory 
βγ dimeric complex. Agonist-stimulated or constitutively active GPCRs function as 
guanine-nucleotide exchange factor (GEF) and mediate the replacement of GDP for 
GTP. The conformational change within the heterotrimer is supposed to trigger dissoci-
ation of the Gα subunit from the Gβγ complex, although it is still under debate whether 
real dissociation or just conformational rearrangement occurs upon receptor activation 
(Hepler, Gilman 1992; Neves et al. 2002; Bünemann et al. 2003; Bodmann et al. 2015; 
Duc et al. 2015; Milligan, Kostenis 2006). Both the Gα and the Gβγ complex have the 
ability to trigger intracellular molecular cascades. Notably, both in the PNS and the 
CNS, myelination has been shown to be influenced by these intracellular signaling 
pathways. 
To date, the Gα subunits are subdivided into four major subclasses Gαi/o, Gαq/11, Gαs, 
and Gα12/13 due to their amino acid sequence homology (Pierce et al. 2002). 
 Gαq 1.2.1.1
Activation of Gαq stimulates phospholipase Cβ (PLCβ) isoforms, enzymes which cleave 
phosphatidylinositol (4,5)-bisphosphate (PIP2) into diacylglycerol (DAG) and inositol 
1,4,5-trisphosphate (IP3). Cytosolic IP3 activates IP3 receptors at the endoplasmic re-
ticulum which is followed by an increase of intracellular Ca2+ levels. In addition, DAG 
and intracellular Ca2+ levels can activate protein kinase C (PKC). The orphan very large 
G protein-coupled receptor 1 (VLGR1), also known as monogenic audiogenic seizure 
susceptible 1 (MASS1), is expressed in oligodendrocytes and has been associated with 
an increase in the myelination marker MAG in vitro via a PKA and PKC δ/θ-dependent 
pathway (Shin et al. 2013). Remarkably, in contrast, Baer and coworkers characterized 
PKC as negative modulator of oligodendrocyte differentiation (Baer et al. 2009). In the 
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latter study, a specific inhibitor of PKCα and β, Gö6976, counteracted the inhibitory 
influence of myelin basic extracts on oligodendrocyte development. These studies sug-
gest different regulatory functions of the various PKC isoforms on the maturation of 
oligodendrocytes.  
 Gαs and Gαi/o 1.2.1.2
Activated Gαs and Gαi/o stimulate or inhibit cAMP production, respectively, and thereby 
cAMP signaling. Recently, Mogha and co-coworkers investigated the role of the orphan 
adhesion GPCR GPR126 expressed on Schwann cells in the PNS. The receptor increas-
es intracellular cAMP levels in a Gαs-dependent manner to promote the development of 
Schwann cells (Monk et al. 2011; Mogha et al. 2013).  
The lysophosphatidic acid receptor 1 (LPAR1), also expressed in Schwann cells, has 
been recently identified as a key player in migration and peripheral nerve development 
via Gαi-dependent signaling (Anliker et al. 2013). Likewise, two GPCRs of the chemo-
kine receptor family, CXCR2 and CXCR4, were verified as regulators of oligodendro-
cyte maturation. Remarkably, even if both receptors are known as activators of Gαi pro-
teins, they show opposing effects on the development of oligodendrocytes: CXCR2 
impairs differentiation and CXCR4 has a positive regulatory effect. However, the mo-
lecular mechanisms of both receptors within the cell are poorly understood (Kerstetter 
et al. 2009; Patel et al. 2010).  
 Gα12/13 1.2.1.3
Activation of Gα12/13 modulates the activity of the small GTPase RhoA via a RhoGEF-
pathway (Siehler 2009). The orphan adhesion GPCR GPR56 promotes proliferation of 
OPCs via G12/13 signaling, followed by RhoA activation. Consequently, stimulation of 
GPR56 impairs the transition of OPC to mature oligodendrocyte (Ackerman et al. 
2015). Furthermore, the RhoA-Rho-associated kinase 2 (ROCK2) pathway was directly 
linked to less efficient maturation of oligodendrocytes (Baer et al. 2009). Importantly, 
the aforementioned LINGO-1 antibody (see 1.1.1) (Mi et al. 2005) acts by inhibiting 
RhoA to promote oligodendrocyte differentiation. 
 The second messenger cAMP and its downstream effectors 1.2.1.4
Intracellular accumulation of the second messenger cAMP is triggered by Gαs proteins 
and reduced by Gαi/o proteins. cAMP was the first discovered second messenger and 
mediates a wide range of cellular functions, such as calcium homeostasis, metabolism, 
secretion, muscle contraction, cell fate, and gene transcription (Schmidt et al. 2013). 
Importantly, cAMP triggers physiologically relevant processes by three cAMP effector 
proteins: (i) the protein kinase A (PKA), (ii) the exchange proteins directly activated by 
cAMP 1 and 2 (Epac1/2), and (iii) cyclic-nucleotide-gated ion channels (CNG channels) 
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(Vitali et al. 2015). Evidence to date demonstrates a major contribution of cAMP-
associated pathways in the maturation cascade of oligodendrocytes. Increase of intracel-
lular cAMP both directly by application of cAMP analogs and indirectly by activators 
of adenylyl cyclases and/or inhibitors of phosphodiesterases triggers the transition from 
OPCs to oligodendrocytes. In contrast, cAMP up-regulation has an inhibitory effect on 
OPC proliferation (Raible und McMorris 1993).  
PKA, the best studied effector protein of cAMP, directly activates the transcription fac-
tor cAMP-responsive element-binding protein (CREB) upon alteration of intracellular 
cAMP levels. Worth mentioning, CREB was identified and characterized only one year 
after the identification of the cAMP response element (CRE) (Montminy et al. 1986; 
Montminy und Bilezikjian 1987). PKA directly phosphorylates CREB at Ser133. The 
CREB protein is ubiquituously expressed in the human body and is part of the leucine 
zipper transcription factor family (Ortega-Martínez 2015). A number of excellent stud-
ies demonstrate that upregulation of myelin proteins, such as MBP, largely depend on 
the activation of the transcription factor CREB (Sato-Bigbee, DeVries 1996; Afshari et 
al. 2001).  
Further important cAMP targets are EPAC1 and 2, also named cAMP-GEFI and II, 
which have recently been discovered as essential cAMP targets by a database screen 
performed to elucidate the PKA-independent activation of the small G protein Rap 
(Rooij et al. 1998). EPAC is involved in several physiological processes, including cell 
proliferation, cell survival, and cell differentiation (Bos 2003; Roscioni et al.; Schmidt 
et al. 2013). Interestingly, a current study has described the involvement of EPAC in 
myelination via a GPR37-dependent mechanism (Yang et al. 2016). 
 β-arrestin recruitment and signaling  1.2.2
β-arrestins are multifunctional adaptor proteins which are important as GPCR activity 
modulators and indirect transducers. They are mostly known for their role in receptor 
desensitization and internalization. After phosphorylation of membrane-bound GPCRs 
by G protein-coupled receptor kinases (GRKs), β-arrestins are recruited, then sterically 
hindering further G protein coupling of the receptor (Shenoy, Lefkowitz 2011). Conse-
quently, the receptor is desensitized. Furthermore, increasing evidence has accumulated 
to suggest that β-arrestins have the capacity to mediate GPCR signaling in a G protein-
independent manner (Shukla et al. 2011). 
Interestingly, GRK2, GRK5, β-arrestin1, and β-arrestin2 undergo a well-defined expres-
sion pattern during the maturation process in rat oligodendrocytes (Daniele et al. 2014). 
These data suggest that GRKs and β-arrestins could have a particular impact on the de-
sensitization of GPCRs in the development of oligodendrocytes, but further studies are 
necessary to investigate this hypothesis (Daniele et al. 2014). 
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 Extracellular signal-regulated kinases 1 and 2 (ERK1/2) signaling - 1.2.3
mitogen-activated protein kinases 
Mitogen-activated protein kinases (MAPKs) belong to the highly important class of 
protein kinases and act as serine/threonine kinases. In all eukaryotic cells, the MAPK 
pathways are involved in various cellular processes, for instance cell growth, division, 
differentiation or apoptosis (Pearson et al. 2001; Luttrell 2003; Roux, Blenis 2004; Lu, 
Xu 2006). A wide range of studies also connected activation of GPCRs with cellular 
growth and cell differentiation via MAPKs. Particularly in oligodendrocytes, several 
lines of evidence also implicated a key role of MAPKs, especially c-Jun N-terminal 
kinase (JNK), extracellular signal-regulated kinases 1 and 2 (ERK1/2), extracellular 
signal-regulated kinase 5 (ERK5), and p38, during oligodendrocyte development (Chew 
et al. 2010; Xiao et al. 2012a). 
ERK1 and ERK 2 have a molecular weight of 43 kDa and 41 kDa, respectively, and are 
also called p42MAPK und p44MAPK (Pearson et al. 2001). These kinases revealed 
83% sequence homology and are ubiquitously expressed in the human body (Raman et 
al. 2007; Gonsalvez et al. 2015). ERK1/2 respond to a wide variety of stimuli, in partic-
ular to growth factors and phorbol esters, via receptor tyrosine kinase and PKC activa-
tion, but they are also involved in GPCR-mediated signaling (Roux, Blenis 2004; Ra-
man et al. 2007). ERK1/2 activation has a critical role in oligodendrocyte development, 
myelination, remyelination, and survival (Gonsalvez et al. 2015). In particular, ERK1/2 
long-term activation was associated with an increase of MBP expression (Xiao et al. 
2012a; Xiao et al. 2012b) . Importantly, ERK1/2 has a direct impact on the thickness of 
the formed myelin sheath (Ishii et al. 2012). To date, there is no direct demonstration 
that GPCRs could alter the intracellular phosphorylation level of ERK1/2 during oli-
godendrocyte differentiation. However, the phosphodiesterase 4 (PDE4) inhibitor 
rolipram, which increases intracellular cAMP levels, activates maturation of oligoden-
drocytes in vitro partially increasing the phosphorylation levels of ERK1/2 (Sun et al. 
2012). 
Activated ERK1/2 may translocate into the nucleus to induce phosphorylation of tran-
scription factors, as has been shown in various studies investigating the key role of 
ERK1/2 in the phosphorylation of the transcription factor CREB. The capacity to phos-
phorylate CREB represents the link between the cAMP-ERK1/2 pathway and upregula-
tion of myelin proteins during maturation of oligodendrocytes (Costes et al. 2006; Won 
et al. 2015; Gonsalvez et al. 2015; Liu et al. 2016).  
1.3 Orphan GPCRs 
More than 140 of the non-odorant GPCRs are so-called orphan receptors with a not yet 
known endogenous ligand (Fang et al. 2015; Shore, Reggio 2015; Civelli 2005). Orphan 
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GPCRs are assumed to represent promising drug targets, which may allow for develop-
ment of innovative pharmaceuticals with first-in-class mechanisms of actions (Shore, 
Reggio 2015). Orphan receptors are involved in a wide range of physio-pathologically 
relevant signaling cascades, implying that the discovery of their endogenous modulators 
will increase the knowledge about their relevance in the human body. One approach to 
investigate the physiological or pathophysiological role of an orphan receptor is to ana-
lyze knockout animals or transgenic animals (Tang et al. 2012).  
The International Union of Basic and Clinical Pharmacology (NC-IUPHAR) defines the 
criteria for deorphanization of GPCRs. One of the highly important criteria is that the 
proposed ligand/ligands activity at an orphan receptor should be validated from at least 
two independent research groups in refereed papers. Furthermore, the potency of the 
putative ligand/ligands should be plausible with a physiologic function of the receptor 
(Davenport et al. 2013; Garland 2013).  
The endogenous agonist identification of orphan GPCRs and consequently their deor-
phanization is one of the key goals to determine orphan GPCRs’ potential as new drug 
targets. Therefore, in the last years several deorphanization bioinformatic and biochem-
ical strategies have been developed: (i) identification of sequence similarities between 
receptors, (ii) definition of a relationship between receptor and the putative ligand ex-
pression profiles, (iii) identification of ligands in tissue extracts (also called orphan re-
ceptor strategy), and (iv) random testing of potential ligands on orphan receptors (also 
called reverse pharmacology) (Civelli et al. 1999; Civelli 2001; Tang et al. 2012). 
Several lines of evidence have implicated an important role for orphan GPCRs ex-
pressed in oligodendrocytes or Schwann cells, such as GPR17, GPR56, GPR126 and 
VLGR1, in proliferation, myelination, remyelination and demyelination (Chen et al. 
2009; Shin et al. 2013; Ackerman et al. 2015; Simon et al. 2016).  
 The G protein coupled receptor 17 (GPR17) 1.3.1
GPR17 belongs to the rhodopsin-like GPCRs and its gene was isolated for the first time 
in 1996 by Raport and co-workers using PCR-screenings on human genomic DNA as a 
template (Raport et al. 1996). The receptor sequence resembles those of the cysteinyl-
leukotriene (CysLT) and purinergic receptors (PY2R), implicating a phylogenetic prox-
imity between these two receptor classes and GPR17 (Bläsius et al. 1998; Ciana et al. 
2006). In particular, GPR17 shares an amino acid similarity of 21 to 48% with receptors 
of the purinergic and cysteinyl-leukotriene cluster, respectively (Fumagalli et al. 
2015b). Two splice variants of human GPR17 are known, whereby the long form is 
characterized by a 28 amino acid longer N-terminal part than the short form (Benned-
Jensen, Rosenkilde 2010).  
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Figure 2. Phylogenetic tree 
 
Phylogenetic tree pointing out the relation between the P2Y and CysLT receptor families and GPR17 
(modified from (Ciana et al. 2006)). 
 Expression of GPR17 1.3.1.1
GPR17 is predominantly expressed in the CNS, in particular in oligodendrocytes at a 
certain stage of development. Strikingly, the expression of GPR17 on neurons is still 
under debate (Bläsius et al. 1998; Lecca et al. 2008; Chen et al. 2009; Benned-Jensen, 
Rosenkilde 2010; Ren et al. 2015). Moreover, GPR17 is also detectable in tissues, 
which typically undergo ischemic damage, more precisely in kidney and heart and, in 
addition, at a low level in liver and lung. Furthermore, immunostaining of human pe-
ripheral blood monocytes appears GPR17 positive (Ciana et al. 2006; Benned-Jensen, 
Rosenkilde 2010). In contrast, Chen and co-works reported a restriction of GPR17 ex-
pression to the brain (Chen et al. 2009). 
The expression of GPR17 on rodent oligodendrocytes undergoes a well-defined time 
course in vitro. The receptor is absent in the early OPC stage. After this stage, GPR17 
expression increases along with co-expressed O4, a marker for immature oligodendro-
cytes. GPR17 is downregulated in mature oligodendrocytes expressing typical mye-
lination markers, such as MBP (Fumagalli et al. 2011). In vivo, the abundance of 
GPR17-positive cells in the murine spinal cord increases until postnatal day 7-14, but 
thereafter decreases drastically (Chen et al. 2009). 
The fact that GPR17 expression is inversely correlated to the MBP abundance within 
the oligodendrocytes suggests a critical role of this receptor in the final differentiation 
from immature into myelinating oligodendrocytes (Fumagalli et al. 2011). 
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Figure 3. GPR17 expression pattern in oligodendrocytes during development 
In an early stage of development, OPCs are GPR17-negative. During differentiation, oligodendrocytes 
start to express GPR17 and its expression reaches a maximum in pre-immature oligodendrocytes. Finally, 
no GPR17 expression occurs in mature myelinating oligodendrocytes (modified from (Fumagalli et al. 
2011)). 
 GPR17 activation and signaling 1.3.1.2
GPR17 was initially deorphanizd by Ciana et al. in 2006 and described as the elusive 
dualistic receptor that can be activated by endogenous ligands of the uracil-nucleotide 
and cysteinyl-leukotriene receptor families, in particular UDP, UDP-gal, UDP-glc, 
LTD4, and LTC4 (Ciana et al. 2006). However, Bläsius et al. described in 1998 that 
GPR17 is not activated by the typical P2Y receptor agonists by utilizing classical sec-
ond messenger assays (Bläsius et al. 1998). Furthermore, Heise and co-authors reported 
that GPR17 does not respond to LTD4 or LTC4 in 2000 (Heise et al. 2000). Additional-
ly, several independent laboratories have not been supportive of the concept of GPR17 
as dualistic receptor activated by uracil-nucleotides and cysteinyl-leukotrienes (Qi et al. 
2013; Hennen et al. 2013; Köse et al. 2014). Thus, the nature of the endogenous lig-
and(s) of GPR17 is still under debate. 
Recently, two additional classes of endogenous ligands have been proposed for this re-
ceptor. First, GPR17 activation by oxysterols has been reported. Oxysterols are de-
scribed as agonists at both Epstein Barr virus-induced gene receptor-2 (EBI2) and 
chemokine receptor CXCR2 (Sensi et al. 2014). Recently, GPR17 has also been de-
scribed to respond to stromal cell-derived factor 1 (SDF-1), a ligand of the two chemo-
kine receptors CXCR4 and CXCR7 (Parravicini et al. 2016).  
Noteworthy, MDL29,951 (2-carboxy-4,6-dichloro-1H-indole-3-propionic acid) has 
been recently reported as a small molecule synthetic agonist for GPR17. In particular, 
MDL29,951 specifically activated GPR17 in primary oligodendrocytes, which endoge-
nously express a variety of purinergic receptors. However, MDL29,951 was not compe-
tent to activate the purinergic cluster receptors, the histamine 3 receptor (H3R), the do-
pamine 2 receptor (D2R) as well as ATP-responsive immortalized cells (Hennen et al. 
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2013). Moreover, a radioactive form of MDL29,951 showed no binding to CHO-K1 
membranes, but specific binding to membranes stably expressing GPR17 (Köse et al. 
2014). Taken together, these studies verify MDL29,951 as specific small molecule ago-
nist at GPR17 in heterologous expression system and primary oligodendrocytes. 
GPR17, activated by the proposed endogenous ligands, has originally been described as 
Gαi-coupled receptor in 1321N1 cells (Ciana et al. 2006). Later, MDL29,951-activated 
GPR17 was characterized as promiscuous GPCR, engaging the entire set of intracellular 
adaptor proteins, which leads to intracellular second messenger alteration (Hennen et al. 
2013). In immature oligodendrocytes, MDL29,951 rapidly mobilized intracellular Ca2+ 
in a Gαi- and Gαq-dependent manner and depressed cAMP concentration via Gαi activa-
tion (Hennen et al. 2013). 
Considering the phylogenetic relationship of GPR17 to receptors of the purinergic and 
cysteinyl-leukotriene cluster, antagonists of both classes were tested as pharmacological 
tools to block GPR17 function. In the original deorphanization report, pranlukast and 
montelukast were reported to functionally inhibit LTD4-activated GPR17. Both are se-
lective CysLT1 receptor antagonists and are used in a wide range of inflammatory con-
ditions, in particular in asthma. Furthermore, cangrelor was shown to inhibit UDP-glc-
induced GPR17 activity (Ciana et al. 2006). In a follow-up study by the same group, 
ticagrelor was also characterized as GPR17 inhibitor. Both substances, cangrelor and 
ticagrelor, block P2Y12 receptors expressed on thrombocytes and thereby act as an-
tiplatelet drugs (Laine et al. 2016). Hennen and co-authors did not verify the antagonis-
tic properties of montelukast, but instead confirmed pranlukast as a GPR17 antagonist, 
albeit with rather low potency (pIC50 = 5.57 in calcium release assays at hGPR17). 
Therefore, the identification of a potent antagonist on GPR17 still remains an open task 
for pharmaceutical research. 
 GPR17 and its physiological function 1.3.1.3
The high level of GPR17 expression in the brain likely implicates a significant role in 
physiological processes in the CNS. 
Transgenic overexpression of GPR17, for example, results in myelinogenesis defects of 
developing mice in vivo. In line with this, GPR17 knockout revealed an early onset of 
oligodendrocyte myelination (Chen et al. 2009). In addition, pharmacological studies 
utilizing the small molecule agonist MDL29,951 uncovered an arrest of oligodendro-
cytes in a pre/immature stage mediated by GPR17 activation (Hennen et al. 2013). In 
former studies, Abbracchio and co-workers obtained contradictory results. Thus, 
GPR17 was first identified as promotor of oligodendrocyte differentiation by applying 
the putative endogenous ligands cysteinyl-leukotrienes and uracil nucleotides as well as 
by small interfering RNA (siRNA)-based gene silencing experiments (Ceruti et al. 
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2009). However, in a follow-up study, the same group described GPR17 as blocker of 
oligodendrocyte maturation, at least during the late stage of oligodendrocyte develop-
ment (Fumagalli et al. 2015a). 
Remarkably, whereas GPR17 is downregulated in spinal cord of adult mice, in demye-
linating lesions of the murine experimental autoimmune encephalomyelitis (EAE) mod-
el a significant increase was detectable by quantitative RT-PCR (Chen et al. 2009). In 
line with the murine in vivo data, analysis of human multiple sclerosis samples revealed 
a significant increase in GPR17 expression in multiple sclerosis plaques (Chen et al. 
2012). Taken together, these data support the notion that GPR17 impairs myelination of 
oligodendrocytes in the CNS; accordingly therapy of demyelinating diseases should 
benefit from a GPR17 antagonist (Hennen et al. 2013). 
Besides the important role of GPR17 in myelination, studies revealed GPR17 as a sig-
nificant protagonist in brain rejuvenation and food intake, as well as mediator of brain 
and spinal cord damage (Lecca et al. 2008; Ceruti et al. 2009; Ren et al. 2015; Mar-
schallinger et al. 2015). An increased basal proliferative activity in proliferation assays 
was observed in a neurosphere culture system of GPR17 knockout cells, suggesting a 
negative influence of GPR17 on brain rejuvenation (Marschallinger et al. 2015). More-
over, analyses of an agouti-related peptide (AgRP) expressing neuron-specific GPR17 
knockout mouse line suggested that GPR17 activation has a negative impact on food 
intake, leanness, and body fat (Ren et al. 2015). In contrast, Mastaitis and co-workers 
could not support the role of GPR17 in food intake (Mastaitis et al. 2015). Furthermore, 
GPR17 was recognized as a mediator of neuronal death at the early stage of ischemic 
damage by analyzing rodent ischemia and spinal cord injury models (Lecca et al. 2008; 
Ceruti et al. 2009).  
In addition to the role of the receptor in the brain, GPR17 has been also described as 
immune modulator in inflammatory lung disease by a ligand-independent mechanism. 
In vivo and in vitro data showed that GPR17 acts as regulator of functionality and ex-
pression of the type 1 cysteinyl leukotriene receptor (CysLT1), which is an important 
mediator of human bronchial asthma (Maekawa et al. 2009; Maekawa et al. 2010; Qi et 
al. 2013). 
Taken together, GPR17 exerts its main function in the brain. Particularly important for 
the investigations within the context of this thesis is its negative role in the maturation 
process of oligodendrocytes. 
1.4 Aims of the study 
In the last years, genetic and pharmacological studies verified the orphan GPR17 as 
negative modulator of oligodendrocyte differentiation and myelination. In addition, 
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GPR17 abundance is augmented in animal models of MS and active white matter 
plaques of MS patients. These two notions suggest an adverse impact of GPR17 on re-
myelination. However, the underlying molecular mechanisms engaged by GPR17 are 
still elusive. Detailed mechanistic insight into the GPR17 signal transduction circuitry 
from the plasma membrane to the nucleus is both desirable and required to firmly estab-
lish GPR17 as innovative, first-in-class target to foster remyelination in demyelinating 
diseases such as MS.  
Therefore, the first aim of the present study is to unveil which members of the hetero-
trimeric G protein family including their downstream effector proteins are activated by 
GPR17 to arrest oligodendrocytes in an immature stage. To this end, two cell lines, pri-
mary rat oligodendrocytes and immortalized murine oligodendrocytes (Oli-neu cells) 
were utilized as model systems in conjunction with MDL29,251, a precious pharmaco-
logical tool and surrogate ligand, that specifically and reliably activates GPR17 in both 
heterologous expression systems and in oligodendrocyte cell cultures.  
The identification of GPR17 endogenous activators would further support the develop-
ment of pharmacological agents targeting GPR17 for the treatment of demyelinating 
diseases. GPR17 has been described as a dualistic receptor responding to the established 
ligands of CysLT and P2Y receptors, cysteinyl-leukotrienes and uracil-nucleotides, re-
spectively. Although the original deorphanization report dates back to 2006, the scien-
tific community is still in doubt about functionality of the proposed endogenous ligands. 
Thus, the second aim of the present work is to challenge the dubitable endogenous lig-
ands. To monitor GPR17 functionality three different readouts, which analyze various 
endpoints in the signaling cascade were chosen: (i) Gαi protein rearrangement, (ii) β-
arrestin recruitment, and (iii) ERK1/2-phosphorylation.  
The negative influence of GPR17 on oligodendrocyte maturation strongly suggests that 
pharmacological inhibition may represent an innovative therapeutic strategy to foster 
“myelin repair”. Based on the phylogenetic relationship between GPR17 and P2Y12 as 
well as CystL1 receptors, selected antagonists for the latter (HAMI3379, CAY10633, 
ticagrelor, cangrelor) were investigated for their capacity to functionally interdict acti-
vation of GPR17 in recombinant and primary expression systems (third aim of this the-
sis).  
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2 Materials 
2.1 Cell culture 
 Mammalian cell lines 2.1.1
Table 1. Cell lines 
Name Biological 
source/Characteristic  
Producer/Owner  
Oli-neu brain OPC from mouse Kindly provided by Prof. J. Trotter 
(University of Mainz) 
HEK293 human embryonic kidney Research group of Prof. Dr. Evi 
Kostenis, Institute of Pharmaceuti-
cal Biology, University of Bonn, 
Germany 
3-HA-hGPR17-
HEK293 (hGPR17-
HEK293) 
human embryonic kidney 
 
Research group of Prof. Dr. Evi 
Kostenis, Institute of Pharmaceuti-
cal Biology, University of Bonn, 
Germany 
mGPR17-HEK293 human embryonic kidney 
 
Research group of Prof. Dr. Evi 
Kostenis, Institute of Pharmaceuti-
cal Biology, University of Bonn, 
Germany 
rGPR17-HEK293 human embryonic kidney 
 
Research group of Prof. Dr. Evi 
Kostenis, Institute of Pharmaceuti-
cal Biology, University of Bonn, 
Germany 
FLAG-hCysLT1-
HEK293 (CysLT1-
HEK293) 
human embryonic kidney  Research group of Prof. Dr. Evi 
Kostenis, Institute of Pharmaceuti-
cal Biology, University of Bonn, 
Germany 
P2Y14-HEK293 human embryonic kidney Research group of Prof. Dr. Evi 
Kostenis, Institute of Pharmaceuti-
cal Biology, University of Bonn, 
Germany 
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Name Biological 
source/Characteristic  
Producer/Owner  
3HA-hGPR17-
RLuc-GFP2-β-
arrestin2-HEK293 
(BRET-HEK293) 
human embryonic kidney Research group of Prof. Dr. Evi 
Kostenis, Institute of Pharmaceuti-
cal Biology, University of Bonn, 
Germany (Kindly provided by 
Stephanie Hennen) 
1321N1 brain astrocytoma from 
human 
Research group of Prof. Dr. Evi 
Kostenis, Institute of Pharmaceuti-
cal Biology, University of Bonn, 
Germany 
hGPR17-1321N1 brain astrocytoma from 
human 
Research group of Prof. Dr. Evi 
Kostenis, Institute of Pharmaceuti-
cal Biology, University of Bonn, 
Germany 
Primary rat OPCs  newborn rat pups Isolated from forebrains of Wistar 
rat pups at P0-P2 
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 Cell culture medium 2.1.2
 Media, buffer, supplements and growth factors 2.1.2.1
Table 2. Media, buffer, supplements and growth factors 
Name Product Number Company 
B27 supplement (B27) 17504-044 Thermo Scientific™ 
ciliary neurotrophic factor (CNTF) 450-50 PeproTech 
Dulbecco’s Modified Eagle Medi-
um (DMEM) 
41965 Thermo Scientific™ 
Fetal calf serum (FCS) P30-3702 PANTM Biotech GmbH 
G418, liquid (Geneticin, 100mg/ml) Ant-gn-5 InvivoGen 
Gentamicin 15750037 Thermo Scientific™ 
GlutaMAX 1674801 Thermo Scientific™ 
Hank’s balanced salt solution 
(HBSS) 
14025050 Thermo Scientific™ 
Horse serum, heat inactivated (HS) 26050070 Thermo Scientific™ 
Insulin 1258-014 Thermo Scientific™ 
L-thyroxine T-2376 Sigma-Aldrich 
N2 Supplement 1665870 Thermo Scientific™ 
Neurobasal Medium 21103049 Thermo Scientific™ 
Opti-MEM 1616013 Thermo Scientific™ 
Penicillin-Streptomycin solution 15140122 Thermo Scientific™ 
Recombinant human fibroblast 
growth factor-basic 
100-18B PeproTech 
Recombinant human PDGF-AA 100-13A PeproTech 
Sodium selenite S-5261 Sigma-Aldrich 
3,3′,5-Triiodo-L-thyronine sodium 
salt (T3) 
T-2752 Sigma-Aldrich 
Trypsin-EDTA (0.05%) 25300054 Thermo Scientific™ 
UltraPureTM Distilled water 10977 Thermo Scientific™ 
Zeocin R25001 Thermo Scientific™ 
 
 Cell specific culture medium 2.1.2.2
Oli-neu cells 
Constituent volume [ml] final concentration 
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Dulbecco’s Modified Ea-
gle Medium (DMEM) 
500  
Horse serum (HS) 
 
5 ≈1% 
Penicillin-Streptomycin 5 ≈100 U/ml Penicillin, 0.1 
mg/ml Streptomycin 
Insulin 625 µl 5 µg/ml 
Gentamicin 250 µl 25 µg/ml 
N2 supplement 5 ml ≈1% 
T3 400 µl 400 nM 
sodium selenite 370 µl 190 nM 
L-thyroxine 65 µl 520 nM 
 
Mixed glia Medium 
Constituent volume [ml] final concentration 
Dulbecco’s Modified Ea-
gle Medium (DMEM) 
500  
Heat-inactivated fetal calf 
serum (FCS) 
50 ≈10% 
Penicillin-Streptomycin 
 
5 ≈100 U/ml Penicillin, 0.1 
mg/ml Streptomycin 
 
Proliferation Medium OPCs 
Constituent volume [ml] final concentration 
Neurobasal 
 
50  
B27 1 ≈2% 
Penicillin-Streptomycin 
 
0,5 ≈100 U/ml Penicillin, 0.1 
mg/ml Streptomycin 
Glutamax 0,5 ≈1% 
Recombinant human fi- 50 10 ng/ml 
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broblast growth factor-
basic (1µg/ml) 
Recombinant human 
PDGF-AA(1µg/ml) 
50 10 ng/ml 
 
Differentiation induction medium 
Constituent volume [ml] final concentration 
Neurobasal 
 
50  
B27 
 
1 ≈2% 
Penicillin-Streptomycin 
 
0,5 ≈100 U/ml Penicillin, 0.1 
mg/ml Streptomycin 
Glutamax 0,5 ≈1% 
 
Recombinant cell lines 
1321N1 cells 
Constituent volume [ml] final concentration 
Dulbecco’s Modified Ea-
gle Medium (DMEM) 
500  
Fetal calf serum (FCS) 
 
50 ≈10% 
Penicillin-Streptomycin 
 
5 ≈100 U/ml Penicillin, 0.1 
mg/ml Streptomycin 
 
hGPR17-1321N1 
Constituent volume [ml] final concentration 
Dulbecco’s Modified Ea-
gle Medium (DMEM) 
500  
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Fetal calf serum (FCS) 
 
50 ≈10% 
Penicillin-Streptomycin 
 
5 ≈100 U/ml Penicillin, 0.1 
mg/ml Streptomycin 
G418 4  800 µg/ml 
 
HEK293 cells 
Constituent volume [ml] final concentration 
Dulbecco’s Modified Ea-
gle Medium (DMEM) 
500  
Fetal calf serum (FCS) 
 
50 ≈10% 
Penicillin-Streptomycin 
 
5 ≈100 U/ml Penicillin, 0.1 
mg/ml Streptomycin 
 
3HA-hGPR17-HEK293 (later named as hGPR17-HEK293) 
Constituent volume [ml] final concentration 
Dulbecco’s Modified Ea-
gle Medium (DMEM) 
500  
Fetal calf serum (FCS) 
 
50 ≈10% 
Penicillin-Streptomycin 
 
5 ≈100 U/ml Penicillin, 0.1 
mg/ml Streptomycin 
Zeocin 0.31 56 µg/ml 
 
rGPR17-HEK293, mGPR17-HEK293, hCysLT1-HEK293 and P2Y14-HEK293 
Constituent volume [ml] final concentration 
Dulbecco’s Modified Ea-
gle Medium (DMEM) 
500  
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Fetal calf serum (FCS) 
 
50 ≈10% 
Penicillin-Streptomycin 
 
5 ≈100 U/ml Penicillin, 0.1 
mg/ml Streptomycin 
G418 2.5 500 µg/ml 
 
hGPR17-BRET-HEK293 
Constituent volume [ml] final concentration 
Dulbecco’s Modified Ea-
gle Medium (DMEM) 
500  
Fetal calf serum (FCS) 
 
50 ≈10% 
Penicillin-Streptomycin 
 
5 ≈100 U/ml Penicillin, 0.1 
mg/ml Streptomycin 
G418 2.5 500 µg/ml 
Zeocin 0.31 56 µg/ml 
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2.2 Plasmids 
Table 3. Plasmids 
Plasmids Size (bp) Host  
pcDNA3.1+ 5428 Invitrogen™ 
hGPR17 in pcDNA3.1+ 1020 Research group of Prof. Dr. Evi 
Kostenis, Institute of Pharma-
ceutical Biology, University of 
Bonn, Germany 
hGαi1-91hRluc in pcDNA3.1+ 2039 Kindly provided by M. Bouvier. 
Department of Biochemistry, 
Institute for Research in Immu-
nology and Cancer, Université 
de Montréal, Montréal, Canada. 
GFP10-bGγ2 in pcDNA3.1+ 958 Kindly provided by M. Bouvier. 
Department of Biochemistry, 
Institute for Research in Immu-
nology and Cancer, Université 
de Montréal, Montréal, Canada. 
hGβ1 in pcDNA3.1+ 1032 Kindly provided by M. Bouvier. 
Department of Biochemistry, 
Institute for Research in Immu-
nology and Cancer, Université 
de Montréal, Montréal, Canada. 
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2.3 Antibodies 
 Primary Antibodies 2.3.1
Table 4. Primary antibodies 
Antibody Species Product Number Company 
Anti-β-actin rabbit BLD-622102 Biolegend 
Anti-EPAC1 
Anti-EPAC2 
mouse 4155 S 
4156 S 
Cell signaling Techno-
logy 
Anti-pERK 
Anti-t-ERK 
mouse 
rabbit 
5726 
9102 
Cell signaling Techno-
logy 
Anti-p-CREB 
Anti-t-CREB 
rabbit 
mouse 
9198 
9104 
Cell signaling Techno-
logy 
Anti-Gαi-3 (Anti-Gαi) rabbit Sc-626 Santa Cruz Biotechno-
logy 
Anti-Gαo rabbit SC-387 Santa Cruz Biotechno-
logy. 
Anti-Gαs rabbit Sc-823 Santa Cruz Biotechno-
logy. 
Anti-Gαq rabbit Sc-392 Santa Cruz Biotechno-
logy. 
Anti-GPR17 rabbit CAY-17087-1 Cayman 
Anti-MBP mouse LB-B8056-100 LifeSpan BioSciences 
 Secondary Antibodies 2.3.2
Table 5. Secondary antibodies 
Antibody Species Product Number Company 
Anti-mouse-HRP goat A4416 Sigma 
Anti-rabbit-HRP goat ABIN102010 Antikoerper-online 
2.4 Chemicals 
 Chemicals used in the present work 2.4.1
Table 6. Chemicals 
Substance Product Number Company 
8-CPT-cyclic AMP C010-100 BIIOLOG 
8-CPT-2`-O-Me-cAMP C 041 BIOLOG 
Acrylamid, Rotiphorese Gel 40 A5115.1 Roth 
Ammonium persulfate A3678 Sigma-Aldrich 
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Adenosine 5′-triphosphate disodium 
salt hydrate (ATP)  
A6419 Sigma 
Calcium chloride, dihydrate 21097 Fluka 
calcium ionophore A23187 1096801 Sigma-Aldrich 
Cangrelor 3312.F08601 The Medicines 
Company 
Carbachol 212385 Merck 
CAY10633 10532 Cayman chemical 
Coelenterazine 400A (Deep Blue C) C-320-10 Gold Biotechnology 
DMSO (cell culture) A1584 AppliChem 
Ethanol absolute 08-205 KMF 
ESI-05 M 092-05 Biolog 
Forskolin 1099 Tocris 
FuGENE HD Transfection Reagent E2312 Promega 
Glycerin 99% 11052 Grüssimh GmbH 
HAMI3379 10580 Cayman Chemical 
HEPES (4-(2-hydroxyethyl)-1- 
piperazineethanesulfonic 
acid) 
54457 Fluka 
Hydrochloric acid min. 37% 08-721 KMF 
IGEPAL® Ca-630 13021 Sigma-Aldrich 
Isobutylmethylxanthine (IBMX) 2845  Tocris 
Kaleidoscope Prestained Standard 161-0324 Bio-Rad 
LTC4 20210 Cayman Chemical 
LTD4 20310 Cayman Chemical 
MagicMark™ XP Western Protein 
Standards 
LC5602 Invitrogen 
Methanol 125678 Sigma-Aldrich 
MDL29,951 SEWO6645SC Maybridge 
NuPAGE® Antioxidant NP0005 Novex™ by Life 
Technologies 
NuPAGE® LDS Sample Buffer 
(4X) 
NP0007 Novex™ by Life 
Technologies 
NuPAGE® MOPS SDS Running 
Buffer (20X) 
NP0001 Novex™ by Life 
Technologies 
NuPAGE™ Novex™ 10% Bis-Tris 
Protein Gels, 1.5 mm, 10-well 
NP0315Box Novex™ by Life 
Technologies 
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NuPAGE® Sample Reducing Agent 
(10X) 
NP0009 Novex™ by Life 
Technologies 
NuPAGE® Transfer Buffer (20X) NP000P-6 Novex™ by Life 
Technologies  
PD174265 513040 Calbiochem 
Pertussis toxin (PTX) 2980 Sigma-Aldrich 
Protease inhibitor cocktail P8340 Sigma-Aldrich 
Potassium chloride 5346.2 Roth 
Potassium dihydrogen 
phosphate 
1.04873.5000 Merck 
Poly-L-ornithine hydrobromide 
(PLO) 
P3655 Sigma-Aldrich 
Poly-D-lysine hydrobromide (PDL) P6407 Sigma-Aldrich 
Pranlukast 10008319 Cayman chemical 
Propan-2-ol P-750715 Fisher Scientific 
Lipofectamine® RNAiMAX Trans-
fection Reagent 
13778030 Thermo Scientific™ 
Roti®-Block A151.2 Roth 
Rp-8-CPT-cAMPS C-011-05 BIOLOG 
S.O.C. medium 15544034 Thermo Scientific™ 
SDS Pellets CN30.3 Roth 
Sodium chloride 10112640 Fisher scientific 
Di-sodium hydrogen 
phosphate, anhydrous 
71640 Fluka 
Sodium hydroxide 12156 Grüssing GmbH 
Sp-6-Bnz-cAMPS B 040 BIOLOG 
Temed  2367.3 Roth 
Tris A2264 AppliChem 
Triton-X 93420 Fluka 
Tween  P-1379 Sigma-Aldrich 
UltraPureTM Distilled water 10977035 Thermo Scientific™ 
Uridine 5′- diphosphate disodium 
salt hydrat (UDP) 
94330 Sigma-Aldrich 
Uridine 5′-diphosphoglucose disodi-
um salt (UDP-glc) 
94335 Sigma-Aldrich 
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UDP-α-D-Galactose, Disodium Salt 
(UDP-gal) 
6700111 Calbiochem 
Yeast extract 2363.3 Roth 
 
Table 7. Not purchased compounds 
Substance function Source 
FR900359 Selective inhibitor of 
Gαq/11 (Schrage et al. 
2015) 
Kindly provided by 
AG König, Institute 
of Pharmaceutical 
Biology, University 
of Bonn, Germany 
Ticagrelor P2Y12 antagonist Kindly provided by 
Sven Nylander 
 Chemical structures 2.4.2
N
OH
O
Cl
Cl
H
Chemical Formula: C12H9Cl2NO4
HO
O
 
Structure 1. MDL29,951 (GPR17 Agonist) (Hennen et al. 2013) 
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Structure 2. Cangrelor (P2Y12 Antagonist) (Remko et al. 2016) 
 
Structure 3. Ticagrelor (P2Y12 Antagonist) (Remko et al. 2016) 
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Structure 4. Pranlukast (CysLT1 Antagonist) (Nakai et al. 1988) 
 
Structure 5. HAMI3379 (CysLT2 Antagonist) (Wunder et al. 2010) 
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O
O
O
COOH
N COOH
H
O
Chemical Formula: C34H39NO8  
Structure 6. CAY10633 (=BayCysLT2) (CysLT2 Antagonist) (Ni et al. 2011) 
2.5 Buffers and solutions 
 Water purification 2.5.1
Sterile UltraPure™ Distilled water was used for molecular and cell biological experi-
ments. Purified water was obtained with the A Milli-Q Water System and was used for 
all media and solutions. 
 Solutions 2.5.2
Solution 1  APS 10% (Ammonium persulfate) 
Component Total amount   Final concentration 
Ammonium persulfate 1 g 10% 
dH2O   ad 10 ml  - 
Aliquots were stored at -20 °C. 
 
Solution 2  2 M Calcium Chloride (used for calcium phosphate transfection) 
Component Total amount   Final concentration 
CaCl2 x 2H2O 14.7 g   2 M 
dH2O ad 50 ml  - 
Sterile filtration was used to sterilized solutions and 10 ml aliquots were stored at 4 °C.  
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Solution 3  DeepBlueC stock solutions (Coelenterazine 400A) 
Component Total amount   Final concentration 
DeepBlueC 50 µg   1 mM 
Ethanol ad 125 µl - 
 
Solution 4  DeppBlueC assay solutions 
Component Total amount   Final concentration 
DeepBlueC 75 µl   50 µM 
Ethanol 450 µl 30% 
HBSS (+20 mM Heppes) ad 1500 µl - 
 
Solution 5  Ethanol (70%) (Used for plasmid DNA preparation) 
Component Total amount   Final concentration 
Ethanol absolute (96%)  730 ml 70% 
dH2O   ad 1000 ml  - 
 
Solution 6  2X HBS (Used for calcium phosphate transfection) 
Component Total amount   Final concentration 
HEPES  5.95 g 50 mM 
NaCl 8.18 g 280 mM 
Na2HPO4 0.133 g 1.5 mM 
dH2O ad 500 ml - 
The solution was sterilized by sterile filtration and stored in aliquots of 50 ml at -20 °C. 
 
Solution 7  1 M HEPES 
Component Total amount   Final concentration 
HEPES 23.8 g 1 M 
dH2O ad 100 ml - 
NaOH q.s. - 
After regulation of the pH to 7.2-7.4 with NaOH, the solution was sterilized by sterile 
filtration and 10 ml aliquots were stored at -20 °C. 
 
Solution 8 Lysis buffer  
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Component Total amount   Final concentration 
TRIS 1M, pH 7.4  1500 µl 25 mM Tris 
NaCl 5M 1800 µl 150 mM 
EDTA 0.5M 120 µl 1mM EDTA 
Triton-X 600 µl 1% 
IGEPAL® 600 µl 1% 
dH2O ad 60 ml - 
1.5 ml aliquots were stored at -20 °C. 
 
Solution 9   1X PBS (used as wash puffer) 
Component Total amount   Final concentration 
KCl 0.2 g  2.7 mM 
KH2PO4 0.2 g 1.76 mM 
Na2HPO4  1.44 g 10 mM 
NaCl 8.0 g 137 mM 
dH2O ad 1000 ml  - 
HCl q.s  
HCl was added up to a pH of 7.4. 50 ml aliquots were autoclaved and stored at room 
temperature.  
 
Solution 10  20X PBS  
Component Total amount   Final concentration 
KCl 4 g 54 mM 
KH2PO4 4 g 35 mM 
NaCl 160 g 2.7 M 
Na2HPO4 12 H2O 57.60 g 160.2 mM 
dH2O ad 1000 ml   
HCl q.s  
Solution was stored at room temperature. 
 
Solution 11  Poly-D-lysine solution (used for coating) 
Component Total amount   Final concentration 
Poly-D-lysine 5.0 mg 0.1 mg/ml 
dH2O ad 50 ml - 
Solution was sterilized via sterile filtration and at stored at 4 °C. 
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Solution 12  Poly-L-ornithine solution  
Component Total amount   Final concentration 
Poly-L-ornithine hydro-
bromide 
5mg 0.1 mg/ml 
dH2O ad 50 ml - 
 
Solution 13  Sodium hydroxid (0.1 M) 
Component Total amount   Final concentration 
Sodium hydroxid 0.4 g 0.1 M 
dH2O ad 100 ml - 
 
Solution 14  10% Sodium dodecyl sulphate (SDS) 
Component Total amount   Final concentration 
SDS 10.00 g 10% 
dH2O ad 100 ml - 
Solution was stored at room temperature. 
 
Solution 15  Stripping buffer 
Component Total amount   Final concentration 
SDS 10 g  10% 
Glycin 1,88 g 25 mM 
dH2O ad 1000 ml - 
Solution was stored at room temperature. 
 
Solution 16  TE buffer (used for calcium phosphate transfection) 
Component Total amount   Final concentration 
Tris-HCl 0.61 g 10 mM 
EDTA 0.19 g 1 mM 
dH2O ad 500 ml - 
 
Solution 17 Tris 1.5 M  
Component Total amount   Final concentration 
Tris 181.785 g 1.5 M 
dH2O   ad 1000 ml - 
Adjusted pH to 8.8 with HCl and stored at room temperature. 
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Solution 18 Tris 1 M 
Component Total amount   Final concentration 
Tris 121.19g 1 M 
dH2O   ad 1000 ml - 
Adjust pH to 6.8 with HCl and stored at room temperature 
 
Solution 19 Washing buffer (Western blot analysis) 
Component Total amount   Final concentration 
Tween 1 ml 0.1% 
1X PBS ad 1000 ml - 
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2.6 Consumables  
Table 8. Consumables 
Consumables Product Number Company 
Assay plate, 384 well 784080 Greiner 
Blue 1000 µl tips   686290 Greiner bio-one 
Cell culture flasks, 25/75/175 cm2 430168/430729/431079 Corning 
Cell scraper 3926.90.97 Corning 
Centrifuge tubes, 15ml/50ml 430791/430829 Corning 
Compound plate, 384 well 3657 Corning 
Costar® 6 / 12 / 24 well plates 3506 / 3512 Corning 
Cryogenic vials 5000-1020 Nalgene® Ther-
mo Fisher Scien-
tific 
Culture dishes 21/55 cm2 430166 / 430167 Corning 
Culture dishes (untreated) 430591 Corning 
Disposable filter unit 0.2 µl FB30/0.2 CA-s Whatman® 
EPIC cell assay plate, 384 well 9027.90.50 Corning 
Gelloading 200µl tips B71932 Bioplastics 
Gel cassettes 1.5 mm NC2015 Thermo Fisher 
Scientific 
Microtubes snap lock, 1,5 ml/ 2ml 115105/115106 Labomedic 
Nitrocellulose membranes Hy-
bondTM-C Extra 
RPN203E GE Healthcare 
ParafilmTM 1447011 Labomedic 
Pasteur pipettes, glass 447016 Labomedic 
Oxygen crystal tips 10 µl 110727 Labomedic 
Whatman paper GB005 Biometra 
Yellow 200 µl tips  70.760.002 Sarstedt 
Sponge Pad for Blotting EI9052 Thermo Fisher 
Scientific 
Stripette® serological pipettes 4486 – 4490 Corning 
Tip, Gelloading B71932 Bioplastics BV 
 
2.7 Laboratory instruments and equipment 
Table 9. Instruments and equipment 
Instrument/equipment Type Company 
Autoclave  Varioklav® H+P  Labortechnik 
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Balances 
 
TE64 
(precision balance) 
TE6101  
BL310 
Satorius 
Camera CoolSNAP HQ2  
DFC 360 FX 
Photometrics  
Leica 
Centrifuges MiniSpin 
Galaxy Mini  
Centrifuge 5810 
Eppendorf VWR  
Eppendorf 
CO2 incubator 
(cell culture) 
Heraeus®HERAcell® 240 Thermo Fisher 
Scientific 
Counting chamber Neubauer Labomedic 
Detection System DeVision DBOX Detection-
System 
Decon 
Dry block heater Thermomixer® comfort Eppendorf 
Electronic pipet filler Easypet® Eppendorf 
Fluorescence microscope DM IL LED Fluo Leica 
objectives HI PLAN I 10X/0.22 PH1 
HI PLAN I 20X/0.30 PH1 HI 
PLAN I 40X/0.50 PH2 
Leica 
Freezer (-80 °C) Heraeus®Herafreeze® Thermo Fisher 
Scientific 
Freezer (liquid nitrogen) MVE 815P-190 
 
 
System monitor MVETec 3000 
Chart BioMedical 
Ltd. 
Chart BioMedical 
Ltd. 
Microplate readers Mithras LB940 Multimode 
Reader 
Tecan Sunrise (Photometer) 
FlexStation 3 Multimode 
Microplate Reader 
Berthold 
Technologies 
r-biopharm 
Molecular Devices 
Microscopes CKX31SF Olympus 
pH electrode InLab Sciences pro, Academia Mettler Toledo  
pH-meter SevenEasy™ Mettler Toledo 
Photo documentation systems De Vision DBOX Decon Sience Tec 
Pipettes 0.5-10 μl; 10-100 μl; 100- 
1000 μl 
Eppendorf 
Safety cabinets HeraSafe Thermo Fisher 
Scientific 
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Semi-automatic pipettor CyBi®-Selma Cybio 
UV/VIS spectrophotometer SmartSpecTM Plus BIO-RAD 
Vacuum pump system AP 15 Membrane Vacuum 
Pump 
HLC BioTech 
Vortex Reax Top Heidolph 
Water purification A Milli-Q Water System Merck Millipore 
XCell SureLock® Mini-Cell 
and XCell II™ Blot Module 
EI0002 Thermo Fisher 
Scientific 
 
2.8 Assay Kits 
Table 10. Kits applied in the following work 
Kit name Article number Company 
Amersham ECL prime Western Blotting Detec-
tion 
RPN2236 GE Healthcare 
Cell Titer-Blue Cell Viability Assay G8080 Promega 
NucleoBondR Xtra Maxi 740414.10 Macherey-Nagel 
 
Phospho-ERK (Thr202/Tyr204) Cellular Assay 
Kit (former name Cellul’erk kit) 
64ERKPEI Cisbio bioassays 
IP-One HTRF® assay kit 62IPAPEJ Cisbio bioassays 
Cylic cAMP cell-based assay kit  62AM4PEC Cisbio bioassays 
FLIPR Calcium 5 Assay kit 38220000 Molecular devic-
es 
PierceTM BCA Protein Assay Kit 23225 Thermo Scien-
tific 
2.9 Sterilization method 
To autoclave all heat-stable materials and solutions at 121 °C and 1.2 bar for 21 min, 
the Varioklav® (H+P Labortechnik AG, Oberschleisheim) was used. To sterilize tem-
perature-sensitive buffers and solutions, they were filtered through sterile filter pore 
width of 0.2 μm. 
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2.10 Software 
Table 11. Software 
Software  Company 
Application Suite 3.3.1 Leica 
ChemDraw PerkinElmer 
MikroWin2000 Berthold Technologies GmbH 
& Co. KG 
Gel-Pro Analyzer Media Cybernetics, L.P 
Gelscan software V6.0 Bioscitec 
GraphPad Prism6 GraphPad Software 
Microsoft Exel 2010 Microsoft® Corporation 
Microsoft PowerPoint 2010 Microsoft® Corporation 
Microsoft Word 2010 Microsoft® Corporation 
XFluor4 Microsoft® Corporation/Tecan 
sunrise 
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3 Methods 
3.1 Cell biological methods 
All cells were kept in cell incubators with a constant 96% humidified atmosphere and 
5% CO2 at 37 °C. Cell culture solutions and media were pre-warmed to 37 °C before 
application. To work under aseptic conditions, for every procedure a safety cabinet with 
laminar air flow was used. 
 Passaging cell lines  3.1.1
Recombinant cell lines and Oli-neu cells were passaged at least two times a week. To 
detach the cells from the flask, a solution of the serine protease trypsin (Trypsin-EDTA 
(0.05%)) was used. 
First, the medium was removed and adherent cells were washed once with 3 ml PBS. 
Then the Trypsin-EDTA solution was added to the cells (1-3 ml depending on the size 
of the flask) and flasks were incubated for at least 1 min at 37 °C. After detachment of 
the cells, trypsin reaction was stopped with a 4-fold higher volume of DMEM medium 
(containing 10% of either FCS (recombinat cells) or HS (Oli-neu cells)). An appropriat-
ed split ratio (1:2-1:10) was utilized depending on the cell line. In order to reach and 
maintain stable measurements, cells were used up to passage 80. 
 Cryopreservation and revitalization of cell lines 3.1.2
In cell biology laboratories the long term-storage of cells is required to revitalize and 
utilize cells at a later time point. To this end, cells were cryopreserved and stored          
at -196 °C. 
Freezing medium was freshly prepared by supplementing pure FCS or growth medium 
(containing 20% FCS) with 10% DMSO. The addition of DMSO serves as frost protec-
tion agent that prevents high size ice crystal formation and therby, cell death. Cells were 
cultured up to a density of 80-90% in 75 cm2 cell culture flasks and then detached as 
described (see 3.1.1). After trypsin reaction, cell suspension was centrifuged for at least 
4 min at 800 g. Growth medium was removed and the cell pellet was resuspended in 
1 ml freezing medium before being transferred into cryogenic vials covered by a 
styrofoam box and placed into a -80 °C freezer. This allows a maximal freezing rate of 
1 °C/min. Afterwards, vials were transferred into the liquid nitrogen tank (-196 °C) for 
long-term storage. 
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To revitalize the respective cell lines after long-term storage in the liquid nitrogen tank, 
cells were rapidly thawn in the water bath (37 °C) and then transferred into 10 ml of 
prewarmed medium. After centrifugation, medium was removed and the cell pellet was 
resuspended in respective cell line-specific growth medium without antibiotics. The 
medium was then changed to medium with antibiotics after 24-48 h culture at 37 °C. 
The cells were cultivated for at least 5 days before seeding for cell-based assays or to 
isolate proteins for Western blot analysis. 
 Cell counting 3.1.3
The cells were counted with the Neubauer counting chamber (also known as hemocy-
tometer) containing two compartments. The counting chamber is a thick crystal slide 
where a grid is added in the middle of each compartment. To count cells, the grid was 
covered by a cover glass and the compartments were loaded with 10 µl cell suspension. 
One compartment contains nine squares. Cells were counted in at least three squares by 
using a microscope and then the average was determined. Finally, the cell density was 
calculated by the following term: cell density [cells/ml] = counted cells x dilution factor 
x 104. 
 Coating cell culture dishes and plates 3.1.4
Before working with HEK293 and Oli-neu cells, culture dishes and plates were coated 
with poly-D-lysine (PDL). For primary rat oligodendrocytes poly-L-ornithine (PLO) 
was used as coating agent. The cell culture surfaces were completely covered with the 
solution and incubated for at least 1 h at 37 °C (up to 4 h for Oli-neu cells). Thereafter, 
PDL or PLO were removed and surfaces were washed at least twice with sterilized PBS 
or Milli-Q water and then dried under the safety cabinet with UV light. The prepared 
plates were kept for a maximum of seven days at 4 °C or were directly used.  
 Culture and differentiation of primary rat OPCs  3.1.5
To isolate primary rat OPCs from forebrains of Wistar rat pups at P0-P2, a differential 
detachment method was used as previously described (Chen et al. 2007; Hennen et al. 
2013). Cerebra were mechanically separated with a syringe and two different cannulae 
(first 1.2 × 40 mm and then 0.60 × 30 mm). Tissue suspension was centrifuged for 5 
min at 800 g. After removal of the medium, pellet was resuspended in growth medium 
and filtered through a 70 μm cell strainer. The suspension was then plated on PDL-
coated 75 cm² culture flasks in growth medium and medium was exchanged every sec-
ond day. To detach OPCs from astrocytes and microglia after 8-11 days in culture, 
mixed cultures were shaken (240 rpm) overnight. Then, the cell suspension was plated 
onto uncoated Petri dishes for 45 min to further purify the oligodendrocyte precursor 
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population (OPCs). OPCs were seeded into PLO-coated plates and cultured in prolifer-
ating Neurobasal medium supplemented with growth factors for 3-4 days. The medium 
was changed every second day. Thereafter, medium was switched to growth factor-free 
Neurobasal medium to induce spontaneous in vitro differentiation and GPR17 expres-
sion. 
 Transient transfection of recombinant cells 3.1.6
The term transfection describes a non-viral method to transfer DNA into eukaryotic 
cells. The method can be subclassified in stable and transient transfection. During a sta-
ble transfection the DNA is stably inserted into the host cell genome, while a transient 
transfection leads to a temporally limited transfer of plasmid DNA into the host cell. 
 Transient calcium phosphate transfection of HEK293 cells 3.1.6.1
The calcium phosphate precipitation method was used to transiently transfect HEK293 
cells. HEK293 cells were seeded 24 h before transfection at a density of 3 x106 cells per 
10 cm cell culture dish in growth medium to reach an approximate cell confluence of 
60-70% at the next day. In line with the established protocol, 20 µg plasmid DNA were 
mixed with 500 µl TE buffer followed by the addition of 60 µl 2 M CaCl2. The 
DNA/CaCl2 solution was added slowly to a gently vortexed round bottom falcon con-
taining 500 µl of 2X HBS-buffer to allow precipitation. After 10 min incubation time 
the solution was carefully added to the cells and the cell culture dish was prudently 
swiveled. To avoid cell toxicity, the medium was changed after 4-6 h. 48 h after trans-
fection HEK293 cells were analyzed by cell-based assays. 
 Transient transfection of HEK293 cells with FuGENE HD 3.1.6.2
(Promega) 
The non-liposomal FuGENE® HD transfection reagent allows the transfection of eu-
karyotic cells. The reagent was applied according to the manufacturer`s instructions. 
24 h before transfection, HEK293 cells were seeded on 6 cm cell culture dishes at a 
density of 2 x 106 cells to achieve 50 % confluence on the day of transfection. The 
transfection solution was prepared by adding 6 µg of the respective DNA to 500 µl 
Opti-MEM. Afterwards, 18 µl FuGENE® HD reagent was gently added to the solution. 
FuGENE® HD DNA/Opti-MEM solution was then incubated for 2-5 min. This mixture 
was applied to the cells and 48 h after transfection cell-based assays were performed.  
 RNA interference 3.1.7
RNA interference is a knockdown method to silence a gene by mRNA degradation. In 
the present study, this method was used to knockdown GPR17. Before transfection, Oli-
neu cells were seeded and incubated for 24 h in the presence of 1 µM PD174265. Oli-
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neu cells were transfected using the transfection reagent Lipofectamine RNAiMAX and 
50-100 nM scrambled siRNA (Qiagen, Cat no.1027280) or a siRNA designed to silence 
mouse and rat GPR17 (5-CCCGGTTGGTTTATCACTTCT-3, Qiagen, Cat no. 
SI04661524) according to the manufacturer`s instructions. GPR17 knockdown of Oli-
neu cells was analyzed after 24-48 h by Western blotting or Ca2+ flux assay. 
3.2 Cell-based assays  
In order to determine the signaling of GPR17, various cell-based assays were applied 
using recombinant cells stably expressing human, rat or mouse GPR17 and primary rat 
oligodendrocytes as well as Oli-neu cells, both endogenously expressing GPR17. 
 Label-free dynamic mass redistribution assay 3.2.1
The dynamic mass redistribution (DMR) method is a recently established holistic ap-
proach to analyze changes in the distribution of cellular contents or intracellular parti-
cles in living cells in real-time (Schröder et al. 2010; Schröder et al. 2011). In the pre-
sent study this highly profound technology was used to investigate the MDL29,951-
triggered whole cell signaling in primary rat oligodendrocytes and Oli-neu cells. The 
DMR method was recently applied to determine the signaling of various GPCRs in an 
immortalized human neural progenitor cell line and this has been performed in depend-
ence of the differentiation stage of these cells (Pai et al. 2012). Primary cells are diffi-
cult to analyze by classical biochemistry methods, which are based on transfection with 
labeled constructs to verify intracellular signaling pathways, therefore the DMR tech-
nology is a suitable tool to study endogenously expressed GPCR signaling in both im-
mortalized and primary cells. Moreover, due to a lower receptor level, the functional 
analysis of GPCRs endogenously expressed in primary cells require a highly sensitive 
assay, which is ideally fulfilled by the holistic DMR method. 
 Theoretical background of dynamic mass redistribution 3.2.1.1
The DMR method is applied to analyze ion channels, GPCRs and receptor tyrosine ki-
nases (Sun et al. 2014). Stimulation/activation of these proteins results in cellular pro-
cesses that are associated with mass relocations. The highly sensitive DMR technique 
detects these dynamic mass redistributions in the cellular matter by using a waveguide 
grating (RWG) biosensor that is localized at the bottom of every well of a special mi-
crotiter plate (Fang et al. 2006; Fang et al. 2007). Polarized broadband light is passed 
through the bottom of this plate and a change of the wavelength of outgoing light is 
recorded over minutes up to hours. Thereby, the reflected wavelength (resonant wave-
length) depends on the optical density of the cell layer within approximately 150 nm 
from the well bottom. Consequently, after stimulation of cells by test compounds a dy-
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namic mass redistribution is caused in the cellular matter and this in turn results in a 
shift of the outgoing resonant wavelength relative to the baseline value that is recorded 
in picometer (pm) (Schröder et al. 2011). 
 Experimental procedure of dynamic mass redistribution assay 3.2.2
DMR was recorded in real-time in differentiated Oli-neu cells and primary rat oli-
godendrocytes applying the Corning Epic system. In order to record optical traces, 
3,000 OPCs per well were seeded for 4 days in proliferation medium on 384-well fi-
bronectin-coated biosensor microtiter plates. To induce differentiation, the medium was 
changed to medium without growth factors. Oli-neu cells were seeded in the presence of 
1 µM PD174265 at a density of 18,000 cells per well. On the assay day, cells were 
washed twice with HBSS containing 20 mM HEPES and leaved with an end volume of 
30 µl buffer per well. To stabilize readings, the mircotiter plate was incubated for 1 h in 
the DMR reader at 28 °C. In the meanwhile, 4-fold higher concentrated compound solu-
tions were prepared and transferred into a 384-well compound source plate and also 
incubated at 28 °C for 20 min to reach thermal equilibrium. The sensor plate was 
scanned to record a baseline optical signature for 5 min and then compound solutions 
were transferred into the biosensor plate by using the Cybi-SELMA semi-automated 
electronic pipetting system. Optical changes were recorded for at least 3,200 s. To in-
hibit Gαi signaling, pertussis toxin (PTX) (100 ng/ml) was added 16 h before the meas-
urement. 
 Data determination 3.2.3
All DMR signals were buffer corrected using the GraphPad Prism 5 software. Repre-
sentative DMR traces are illustrated from one experiment measured in triplicates. Each 
experiment was repeated at least three times. Concentration-response curves are derived 
from the maximum wavelength shift at each compound concentration. 
 Bioluminescence resonance energy transfer 3.2.4
Bioluminescence resonance energy transfer (BRET) is a biophysical method to study 
protein-protein interaction and dynamic changes in protein conformation in living cells 
in real-time.  
The approach is based on a nonradioactive transfer of energy and represents a naturally 
occuring physical phenomenon used by marine animals. The energy transfer takes place 
between three components (i) a bioluminescence donor, (ii) an oxidated substrate, and 
(iii) an energy acceptor (Ward, Cormier 1979). 
Energy transfer occurs after substrate oxidation when the distance between the energy 
donor and the energy acceptor amounts between 10-100 Å. The advantage of this ap-
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proach over various biophysical methods is the possibility to measure protein-protein 
interaction in living cells in real time (Pfleger, Eidne 2006).  
In the field of GPCR investigation, BRET studies are used to analyze the interaction of 
a receptor with G proteins, of a receptor with β-arrestin or of two receptors (hetero- or 
homodimerization) (Mercier et al. 2002; Pfleger, Eidne 2006). 
 Theoretical background of BRET2 3.2.4.1
In the present study, the BRET2 approach was used to study Gαi protein rearrangement 
and β-arrestin2 recruitment in living cells. BRET2 and BRET1, the latter also referred as 
original technique, differ in the choice of donor, substrate, and acceptor. BRET2 uses 
Renilla reniformis luciferase (Rluc), originally isolated from the sea pansy, as energy 
donor with an emission peak at 400 nm after oxidation of the substrate DeepBlueC and 
GFP, firstly isolated from jellyfishes Aequorea Victoria, as an energy acceptor emitting 
light at 515 nm (Ward, Cormier 1979). 
 Experimental procedure of the BRET2 assays 3.2.4.2
In order to detect β-arrestin2 recruitment, BRET2 assays were performed in HEK293 
cells stably expressing hGPR17-Rluc and GFP2-β-arrestin2 as already described by 
Hennen et al. (Hennen et al. 2013).  
Furthermore, to analyze the direct interaction between the Gαi subunit and the γ subunit, 
HEK293 cells were transiently transfected by FuGENE HD transfection (see 3.1.6.2) 
with Gαi1-91Rluc and GFP10-Gγ2 along with the complementary Gβ1 subunit and 
hGPR17 (Gales et al. 2006) (see Table 12). Transiently transfected cells were analyzed 
after 48 h.  
 
Table 12. Transiently transfected DNA amount 
Plasmid  hGPR17 hGαi1-
91hRluc 
GFP10-bGγ2 hGβ1 pcDNA3.1. 
DNA amount 3,25 2,25 0,75 1,75 2,5 
 
Before the assays, HEK293 cells were detached by trypsinization (see 3.1.1, counted, 
once washed with PBS and centrifuged. Thereafter, the cell pellet was resuspended in a 
suitable volume of assay buffer (HBSS, 20 mM Hepes) to reach a density of 1 x 106 
cells per ml. To stabilize readings, cell suspension was distributed to 96-well white mi-
crotiterplate (170 µl/well) and incubated at 28 °C for 20 min while shaking (180 rpm). 
In the meanwhile, DeepblueC substrate (50 µM) was freshly prepared. After the incuba-
tion time, cells were shaken in the presence of agonist (10 µl) for (i) 1 min to detect 
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conformational change of the G-protein subunits or for (ii) indicated time points to 
measure the time-dependent β-arrestin2 recruitment after receptor activation. In order to 
measure the protein-protein interaction, 20 µl substrate (final concentration 5 µM) were 
injected to the cell suspension by using the multimode reader. Two seconds after sub-
strate injection light emission at 400 and 515 nm was measured sequentially using the 
Mithras LB 940 reader. 
 Data evaluation of BRET2 assay 3.2.4.3
MikroWin200 software was used to collect the data directly after measuring by the 
benchtop reader. Results were calculated as the ratio of emitted light by the energy ac-
ceptor GFP (515 nm) over Rluc catalyzed light emission (400 nm) (referred as BRET-
ratio). To elaborate the ligand-promoted net BRET the Graphpad prism software was 
used to calculate the difference between the BRET ratio obtained in the absence (buffer 
value) and in the presence of indicated agonists. β-arrestin2 recruitment was pictured as 
kinetic. 
 HTRF technology (ERK1/2 phosphorylation, IP1 accumulation and 3.2.5
cAMP alteration assay) 
Homogeneous Time Resolved Fluorescence (HTRF) combines the standard fluores-
cence resonance energy transfer technology (FRET) with the time resolved measure-
ment (TR). The significant advantage of the HTRF technique is the increased sensitivity 
and fewer false positive as well as false negative results (Degorce et al. 2009). Cisbio 
discovered various numbers of assay kits to investigate GPCR signaling (second mes-
senger accumulation and downstream kinase assays), new biomarkers, and protein-
protein interactions based on the HTRF technique. In order to explore the signaling be-
havior of GPR17, in the present study the HTRF method was used to determine the al-
teration in IP1 production, cAMP production, and ERK1/2 phosphorylation after activa-
tion of GPR17.  
 Theoretical background of HTRF technology 3.2.5.1
Emission of HTRF is detected at two different wavelengths, donor emission at 620 nm 
and acceptor emission at 665 nm. Based on FRET, an energy transfer to an energy ac-
ceptor occurs after excitation of an energy donor, required for the transfer is a close 
proximity between donor and acceptor (Degorce et al. 2009). As energy donor Europi-
um ions or Terbium ions (Eu3+ or Tb3+) are used, complexed with three molecules 
bispyridin to a cryptate, which build a three dimensional cage structure around the Eu3+ 
or Tb3+ . The cage structure is necessary as light collecting device, because Eu3+ or Tb3+ 
are not fluorescent by its own. Eu3+ or Tb3+ are excited by light with a wavelength of 
320 nm. Europium and Terbium belong to the lanthanides and consequently to the rare 
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earth elements (Degorce et al. 2009). The long half-life of the fluorescent signal cir-
cumvents the measurement of the short-life auto fluorescence, the main disadvantage of 
the FRET technology. D2, an organic motif of approximately 1000 Da, was developed 
as an energy acceptor of the second generation ( (Degorce et al. 2009). To avoid steric 
hindrance problems, it is 100 times smaller than the first generation of acceptors 
(Degorce et al. 2009).  
 
 ERK1/2 phosphorylation assay principle  3.2.6
The activation of several GPCRs leads to a downstream ERK1/2 phosphorylation. To 
investigate the increase of phosphorylated ERK1/2 after GPR17 stimulation the Cel-
lul’erk kit was applied. This ERK1/2 kit utilizes the HTRF technology in a sandwich 
immunoassay. Anti-phospho-ERK1/2 antibodies labeled with d2 or Eu3+-cryptate bind 
to pERK1/2 and the short distance between donor and acceptor consequently leads to an 
energy transfer based on FRET. The intensity of the emitted light is proportional to the 
amount of phosphorylated kinase.  
 IP1 accumulation assay principle 3.2.7
Activation of a Gαq-coupled GPCR leads to an increase in the activity of the enzyme 
phospholipase C (PLC), which induces the inositol phosphate cascade. IP3 is one of the 
main cascade metabolites that triggers the release of calcium from intracellular stores. 
The measurement of the increase in IP3 as a second messenger of the Gαq pathway is 
limited due to its extreme instability. However, the degradation of the sub-metabolite 
inositol-1-phosphate (IP1) by inositol monophosphatase can be inhibited by lithium 
chloride addition (Trinquet et al. 2006). Based on this, IP1 represents a more suitable 
second messenger to investigate the Gαq pathway. The applied IP1 accumulation HTRF 
assay kit is based on a competitive immunoassay between in cells accumulating IP1 and 
d2-labeled IP1. Anti-IP1 antibody labeled with Tb3+-cryptate is applied as fluorescence 
donor. The assay kit allows measurement of agonist and antagonist effects on Gαq-
coupled receptors in various cellular backgrounds (Zhang, Xie 2012). 
 cAMP alteration assay principle  3.2.8
GPCRs have the ability to activate Gαi/o and/or Gαs proteins. A class of intracellular 
enzymes, the adenylyl cyclases, is directly influenced by these G protein classes. The 
adenylyl cyclase catalyzes the production of cAMP. Gαs proteins lead to adenylyl 
cyclase activation, whereas Gαi/o proteins attenuate the cAMP production. Among in-
tramolecular ring formation ATP is converted into cAMP and inorganic pyrophosphate 
(Marinissen, Gutkind 2001). In order to measure a decrease of the intracellular cAMP 
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levels, the cells were preincubated with forskolin to stimulate the intracellular cAMP 
production and in consequence to make the decrease in cAMP levels feasible. The 
cAMP assay kit is based on a competitive immunoassay between in cells accumulating 
cAMP and d2-labeled cAMP, similar to the IP1 assay kit. Anti-cAMP antibody labeled 
with Eu3+-cryptate is used as a fluorescence donor. 
Furthermore, intracellular cAMP levels are rapidly degraded by phosphodiesterases. To 
avoid the degradation during the measurement isobutylmethylxanthine (IBMX), a phos-
phodiesterase inhibitor, was added to the respective assay buffer.  
 Experimental procedure - ERK1/2 phosphorylation assay  3.2.9
The HTRF Cellul’erk kit was applied to investigate receptor-mediated ERK1/2 phos-
phorylation in different cell lines (i) HEK293 cells stably expressing hGPR17, 
hCysLT1, and hP2Y12 receptor, (ii) 1321N1 cells stably expressing hGPR17 and native 
1321N1 cells, (iii) Oli-neu endogenously expressing GPR17 after induction of differen-
tiation, and (iv) primary rat oligodendrocytes as well endogenously expressing GPR17 
in the differentiation stage.  
The increase in phosphorylated ERK1/2 levels was measured according to the manufac-
turer’s instructions (two plate assay protocol). In brief, cells were seeded into a clear 96-
well cell culture plate coated with PLO or PDL. HEK293 cells, 1321N1 cells and Oli-
neu were seeded at a density of 40,000 cells per well. To induce differentiation, Oli-neu 
cells were cultured for 24 h in medium containing 1 μM PD174265. OPCs were seeded 
in proliferating media at a density of 5,000 cells per well and cultured for 3-4 days and 
differentiation for two days. The different PTX added 18 h before the assay  
Before the assay, cells were washed with HBSS buffer supplemented with 20 mM 
HEPES and starved for 4 h in serum-free medium. The starvation time was followed by 
agonist incubation at 37 °C for certain times. Thereafter, the agonist was removed and 
cells were lysed in 50 μl of the supplemented lysis buffer. Plates were incubated while 
shaking for 30 min at room temperature and then frozen overnight. After transfer of 16 
μl lysate to a white 384-well plate, d2-labeled anti-phospho-ERK1/2 (2 μl) and Eu3+-
cryptate-labeled anti- ERK1/2 (2 μl) were added to the wells and the plate was incubat-
ed for 2 h in the dark at room temperature. Time-resolved FRET signals were measured 
after excitation at 320 nm. Data analysis was based on the fluorescence ratio emitted by 
the d2-labeled anti-phospho-ERK1/2 (665 nm) over the light emitted by the Eu3+-
cryptate-labeled anti-ERK1/2 (620 nm), measured by the Mithras LB 940 reader (Bock 
et al. 2012).  
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 Experimental procedure - IP accumulation 3.2.10
Changes of the intracellular second messenger IP1 in HEK293 cells stably expressing 
hGPR17, rGPR17 and mGPR17 were quantified by following the manufacturer`s in-
structions. The cells were detached and washed once with PBS. After centrifugation (4 
min 800 g), the cell pellet was resuspended in stimulation buffer (HBSS, 10 mM 
HEPES, 50 mM LiCl) and dispensed in a 384-well microplate at a density of 100,000 
cells per well. In order to stabilize the readout, cells were preincubated for 30 min at 
37 °C before compound addition. 
To analyze the antagonist abilities of the different compounds, the cells were incubated 
at 37 °C with 3.5 µl of different concentrations (3-fold) of the proposed GPR17 antago-
nist diluted in stimulation buffer. After 30 min a fixed MDL29,951 concentration corre-
sponding to the EC80 on the respective GPR17 receptor ortholog  (hGPR17 = 1 µM, 
rGPR17 = 3 µM and mGPR17 = 10 µM) (Hennen et al. 2013) was added to the cells. 
The reaction was stopped after 30 min of agonist incubation by addition of lysis buffer 
containing the assay-specific components (d2-labeled IP1 and anti-IP1 antibody labeled 
with Tb3+-cryptate). The plate was incubated for 60 min at room temperature and after-
wards time-resolved FRET signals were measured after excitation at 320 nm using the 
Mithras LB 940 multimode reader.  
 Experimental procedure - cAMP alteration 3.2.11
Alteration of the intracellular second messenger cAMP was analyzed using the HTRF 
cAMP dynamic 2 kit according to the manufacturer’s instructions in Oli-neu cells. 
30,000 cells per well were cultured in PDL-coated 48-well tissue culture plates for 48 h 
using medium containing 1 µM PD174265. At the assay day, cells were treated for 20 
min in assay buffer (HBSS supplemented with 20 mM HEPES and 1 mM IBMX) and 
afterwards stimulated with 3 µM forskolin in the presence of respective MDL29,951 
concentrations. To stop the reaction after 20 min stimulation at 37 °C, 40 µl of HTRF 
assay lysate buffer were added to the cells. Then lysates were frozen overnight.  
In order to detect intracellular cAMP levels, 10 µl of the samples were transferred to a 
384-well plate and both assay components, d2-labeled cAMP and anti-cAMP antibody 
labeled with Eu3+-cryptate, were added. Before time-resolved FRET signals were meas-
ured (excitation at 320 nm) by using the Mithras LB 940 reader, the plate was incubated 
for 60 min at room temperature.  
 Data evaluation of HTRF assay kits 3.2.12
According to the manufacturer`s instruction the measured data were elaborated utilizing 
the Microwin2000 and the Graph pad prism software.  
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Data analysis was made based on 10,000 × [emission (665 nm)/emission (615 nm)], 
meaning light emitted by d2 (acceptor fluorophore)-labeled component over the light 
emitted by the Eu3+-cryptate-labeled antibody. Intracellular IP1 levels were normalized 
to the maximum of MDL29,951-mediated GPR17 activation. Levels of phosphorylated 
ERK1/2 were normalized to ERK1/2 phophorylation values obtained with the highest 
compound concentration. Alteration of intracellular cAMP levels was normalized to the 
values achieved with 3 µM forskolin. 
 Calcium accumulation assay 3.2.13
 Calcium accumulation assay principle 3.2.13.1
In order to identify receptor-dependent calcium release from intracellular stores, such as 
the endoplasmic reticulum, the Calcium 5 assay kit was used. Calcium ions regulate a 
broad range of cellular processes and therefore they represent one of the key second 
messengers in mammalian cells. During a dye uptake step, the cytosol of the cells is 
loaded with the calcium-sensitive fluorescent dye. GPCR stimulation results in a recep-
tor-dependent release of calcium ions from intracellular stores. The fluorescent signal 
increases proportionally to the intracellular calcium concentration. 
 Experimental procedure of calcium release assay 3.2.13.2
Intracellular Ca2+ mobilization was quantified according to the manufacturer’s instruc-
tions with the Calcium 5 Assay kit. Oli-neu cells were seeded 24-48 h before the assay 
in the absence and in the presence of 1 µM PD174265 at a density of 70,000 cells per 
well into black 96-well PDL-coated tissue culture plates with clear bottom. Further-
more, to investigate the Gαi/o involvement in the GPR17-mediated calcium signal, 16 h 
before the assay PTX (100 ng/ml) was added to the cells. On the assay day, cells were 
loaded with the Calcium 5 indicator dye for 30 min and time-dependent calcium release 
was measured after the addition of respective concentrations of MDL29,951 by the 
FlexStation 3 Multimode Microplate Reader. Emission was measured at a wavelength 
of 525 nm (excitation 485 nm). In order to quantify the Ca2+ flux, changes in fluores-
cence units were converted in concentration-response curves. 
 Cell viability assay 3.2.14
 Cell viability assay principle of the CellTiter-Blue kit 3.2.14.1
The applied cell viability assay (also known as resazurin reducing assay (RR-assay)) is 
based on a fluorescence method. The assay uses the capacity of living cells to reduce 
the redox dye resazurin (7-hydroxy-3H-phenoxazin-3-one 10-oxide) into resorufin (7-
hydroxy-3H-phenoxazin-3-one), a fluorescent end product. Loss of the ability to metab-
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olize the indicator dye is detectable by a decrease in fluorescence signal. The RR-assay 
represents an ideal system to identify anti-proliferating and cytotoxic compounds (Riss 
et al. 2015).  
 Experimental procedure of cell viability assay 3.2.14.2
CellTiter-Blue kit Oli-neu cells were seeded at a density of 25,000 cells per well into 
black 96-well PDL-coated plates with clear bottom. On the next day, cells were incu-
bated with 0.1% dimethyl sulfoxide (DMSO) served as negative control (100% cell via-
bility) or indicated compounds diluted in medium containing 1 µM PD174265 for 48 h. 
As a positive control etoposide, a topoisomerase 2 inhibitor, was used. To detect the 
capacity of the cell to reduce the redox dye as indicator for cell viability, cells were in-
cubated for 3 h at 37 °C with 20 µL of the CellTiter-Blue reagent. Fluorescence emis-
sion was measured at 590 nm after excitation at 560 nm by using a FlexStation 3 Mul-
timode Microplate Reader. The detectable fluorescence signal is proportional to the via-
bility of the cells. Data were expressed as the percentage of cell viability relative to 
DMSO control.  
3.3 Methods in molecular biology 
 Heat shock transformation  3.3.1
Transformed bacteria are used for plasmid storage and replication. Transformation is a 
non-viral molecular biology method to introduce DNA into competent bacteria cells. 
The method applies the natural competence of bacteria to insert external DNA. There-
fore, 
XL-blue E. coli cells were pretreated with rubidium chloride to force cell compe-
tence/enable permeation of DNA and then these chemical competent bacteria could be-
stored at -80 °C. For transformation 100 µl of competent XL-1 blue bacteria were 
thawed on ice and about 50 ng plasmid DNA was added to the bacteria. The DNA/cell 
suspension was mixed carefully and afterwards incubated for approximately 30 min on 
ice. The incubation time was followed by a heat shock at 42 °C in a water bath for 30-
60 s. Thereafter, suspension was incubated for 2 more minutes on ice before the addi-
tion of 300 µl SOC medium. In order to develop encoded antibiotic resistance, suspen-
sion was incubated at 37 °C for 60 min while shaking (220 rpm) in an incubator. Then, 
a volume of 50 µl-300 µl was plated on 37 °C prewarmed LB agar plates, which were 
prepared in advance containing the respective antibiotic. 
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  Cryoconservation of bacterial strains  3.3.2
To store bacterial host cell lines of the various plasmids, cells were cryoconservated by 
mixing 800 µl of bacterial suspension with 200 μl of glycerin and storing at -80 °C. In 
order to reactivate the bacterial cell line for preparative plasmid isolation, one drop of 
the glycerin cell suspension was added to prewarmed (37 °C) LB medium containing 
the appropriated amount of respective antibiotic. 
 Preparative isolation of plasmid DNA 3.3.3
The applied approach isolates plasmid DNA based on the anion change chromatog-
raphy. 
To purify plasmid DNA with a high yield for transfection experiments, plasmid isola-
tion kit NucleoBond Xtra Maxi was utilized according to the manufacturer`s protocol. 
The kit contains all needed buffers and solutions. To this end, 300 ml LB (+ 100 µg/ml 
ampicillin) was inoculated with the bacteria harboring the respective plasmid (either one 
colony from LB agar plate or 100 µl of the glycerol stock) and incubated overnight at 
37 °C under shaking (220 rpm). After removing of the supernatant bacteria were lysed 
for 5 min, neutralized and the clarified lysate was added to the prepared anion-exchange 
column. The plasmid DNA was bonded to the column and then impurities were washed 
out. Afterwards, the DNA was eluted from the column and precipitated with isopropa-
nol. The isolated DNA was washed with 70% Ethanol, resuspended in DNAse/RNAse 
free water and stored at -20 °C for further use. 
 Determination of nucleic acid concentration by photometrical 3.3.4
method 
Commonly the photometrical method is applied to analyze DNA concentrations in solu-
tion. To determine the DNA concentration, the optical density of the solution at 260 nm 
is measured and used in the following term: 
ܥ (μ݃/݈݉) =  ܱܦ260 × ܦ × ܴ 
 
OD260 Optical density at 260 nm 
D Dilution factor 
R Conversion factor (for DNA 50) 
To determine the purity of the DNA solution, the quotient of the optical density at 260 
and 280 nm was calculated. A ratio between 1.6 to 2.0 is required to neglect impurities. 
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 Analysis of protein expression by Western blot 3.3.5
 Lysate preparation 3.3.5.1
In order to analyze protein expression by Western blot analysis, proteins were isolated 
from respective cell lines. OPCs were seeded in proliferating medium into 6- or 12-well 
PLO-coated tissue culture plates (80.000-120.000 cells per well). After 3-4 days the 
culture medium was changed to growth factor-free medium to induce differentiation and 
GPR17 expression. On the next day medium was supplemented with 20 ng/ml T3 and 
10 ng/ml CNTF together with the analyzed compounds. Oli-neu cells were seeded at a 
density of 300,000 cells per well into 12-well PDL–coated tissue culture plates in Sato 
medium. On the next day, cells were incubated with indicated compounds and 1 μM 
PD174265. At specified times cells were washed twice with ice-cold PBS and lysed in 
ice-cold lysis buffer supplemented with protease inhibitor mixture. Lysates were rotated 
20 min at 4 °C and centrifuged at 15,000 g at 4 °C for 10 min. 
 Determination of the protein content of lysates 3.3.6
In order to analyze the proteins in a quantitative manner, protein amount of lysate sam-
ples was analyzed by PierceTM BCA Protein Assay Kit according to the manufacturer`s 
protocol. The assay kit is based on a two-step color reaction (known as bicinchoninic 
acid protein assay), first the protein biuret reaction and then the bicinchoninic acid 
(BCA) protein reaction by Smith 1985 (GORNALL et al. 1949; Smith et al. 1985). In 
the biuret reaction Cu2+ is reduced to Cu1+ by proteins in alkaline medium and results in 
a weak blue color. The second step is the chelation of Cu1+ and BCA leading to an in-
tensive purple color. 
In brief, 10 µl of each sample were diluted with 40 µl (1:5 dilution) of 0.1 M NaOH and 
a bovine serum albumin (BSA calibration) standard (0 µg/µl - 10 µg/µl BSA) was pre-
pared. 200 µl of the freshly mixed protein detection reagent were added to each sample. 
After 30 min at 37 °C, the absorption of the BCA/Cu1+ complex was measured at 
560 nm and the protein concentrations were calculated by using the BSA standard 
curve.  
 Production of separating gel and stacking gel 3.3.6.1
In order to analyze the protein lysates, the gels for electrophoresis were prepared. For 
two separating gel, the following solutions were mixed and added to an empty gel cas-
sette. 
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Table 13. 10% separating gel (amounts/quantities for two gels) 
Component Total amount   
Milli Q H2O 9.6 ml 
Acrylamid 5 ml 
TRIS (1.5 M) 5 ml 
SDS (10%) 200 µl 
APS (10%) 100 µl 
Temed 10 µl 
 
Table 14. 5% stacking gel (amounts/quantities for two gels) 
Component Total amount   
Milli Q H2O 3.65 ml 
Acrylamid 0.625 ml 
TRIS (1 M) 0.630 ml 
SDS (10%) 50 µl 
APS (10%) 30 µl 
Temed 5 µl 
 
Gels were covered with isopropanol. After 30 min of polymerization time, the solutions 
from Table 2 were mixed, added as well to the gel cassette and a 10-tooth comb was 
applied. 
 SDS-Polyacrylamide-Gel-Electrophoresis (SDS-PAGE) 3.3.7
After detection of the protein amount of lysates, 7.5 to 15 μg of protein were separated 
by 10% SDS-polyacrylamide gel electrophoresis. Therefore, protein samples were 
mixed with NuPage Sample Reducing Agent (10X) and sample buffer (2-4X). The run-
ning buffer was added to the chamber and in the inner chamber additionally blended 
with 500 µl NuPage Antioxidant. As molecular weight markers 5 µl Kaleidoscope 
standard and 2.5 µl Magic Marker standard were used. The prepared samples were add-
ed to the gel and separated for approximately 3 h at 60 V. 
 Western blot analysis 3.3.8
In order to transfer the proteins to nitrocellulose membrane, electroblotting was per-
formed for 2 h at 25 V in Nupage Transfer Buffer (including 20% methanol) using the 
blotting module. After blotting, membranes were rinsed two times with washing buffer 
(PBS + 0.1% Tween 20) and then blocked with Roti-Block for at least 1 h at room tem-
perature and then incubated overnight with antibody diluted in Roti-Block. The respec-
tive antibody dilutions are listed in Table 15. 
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Table 15. Antibody dilutions 
Antigene Dilution 
MBP 1:5000 
GPR17 1:5000 
ERK 1:2500 
p-ERK 1:2500 
CREB 1:2500 
p-CREB 1:1000 
Gαs 1:3000 
Gαq 1:3000 
Gαo 1:5000 
Gαi 1:5000 
EPAC 1:1000 
β-actin 1:2500 
Secondary Antibody  
Anti-mouse-HRP 1:10000 
Anti-rabbit-HRP 1:10000 
 
On the next day membranes were washed three times with washing buffer and were 
then incubated for 1 h at room temperature with the respective horseradish peroxidase-
conjugated secondary antibody diluted in Roti-Block (Table 15). The immunoreactive 
proteins were visualized by chemiluminescence using Amersham ECL Prime Western 
Blotting Detection Reagent according to the manufacturer`s recommendations and 
quantified by densitometry using Gelscan software. To normalize for equal loading and 
protein transfer, membranes were washed or stripped and reprobed with an antibody 
against the standard β-actin.  
 Stripping of nitrocellulose filters 3.3.9
Antibodies binding to nitrocellulose filters were removed (stripped) by washing for 
20 min with stripping buffer at room temperature. Afterwards, membranes were washed 
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once with PBS for 10 min and then three times (5 min each) in washing buffer (PBS + 
0.1% Tween 20) and subsequently blocked with Roti Block (60 min, RT). 
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4 Results 
4.1 Oli-neu cells as a suitable model system 
Recently, it has been reported that GPR17 overexpression in vivo and in vitro blocks 
differentiation of oligodendrocytes, and thus, GPR17 has been proposed as a cell intrin-
sic timer of myelination (Chen et al. 2009). Subsequently, this prediction has been con-
firmed by arresting primary mice oligodendrocytes in an immature stage, preventing 
their differentiation and maturation, by pharmacological stimulation of the receptor with 
MDL29,951 (Hennen et al. 2013). 
Primary oligodendrocytes represent the perfect in vitro system to analyze GPR17 sig-
naling and its influence on differentiation and myelination in a physiological cellular 
background. However, the low amount of cells after tissue preparation and their slow 
metabolism often limits experimental analyses of intracellular processes in this cell line 
(Winterstein et al. 2008; Fratangeli et al. 2013). Thus, to circumvent this difficulty, in 
the following study Oli-neu cells were applied as model system in addition to primary 
oligodendrocytes. Oli-neu cells are murine oligodendroglia precursor cells, which have 
the capacity to undergo differentiation after chemical induction (Jung et al. 1995) and to 
express GPR17 similar to primary oligodendrocytes (Fratangeli et al. 2013). 
 
 Induction of Oli-neu cell differentiation 4.1.1
Various chemical compounds, such as dexamethasone, di-butyryl-cyclic-AMP and 
PD174265, have the ability to induce Oli-neu cell differentiation to a different extent 
and thereby to trigger expression of myelin proteins (Jung et al. 1995; Gobert et al. 
2009; Fratangeli et al. 2013). In the following study, the selective epidermal growth 
factor receptor inhibitor PD174265 was used to differentiate Oli-neu cells, as recently 
described by Gobert and co-workers (Gobert et al. 2009). Oli-neu cell differentiation is 
detectable by morphological changes (dendrocyte outgrowth) and expression of typical 
myelination markers, such as MBP and PLP (Dugas et al. 2006; Burda et al. 2013). 
 
 Morphological change of Oli-neu cells during differentiation 4.1.1.1
Burda et al. described the morphological shift in differentiating oligodendrocytes from 
simple bipolar to their complete ramified morphology (Burda et al. 2013). To investi-
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gate the morphological change in the applied model cell system, bright field pictures 
were analyzed to identify the effects of PD174265 on dendrocyte outgrowth. 
Oli-neu cells cultured in control medium (Sato medium) exhibited a typical bipolar oli-
godendrocyte progenitor cell (OPC) shape (Figure 4, A). After 48 h incubation with 
PD174265, Oli-neu cells stopped proliferating and displayed the characteristic polipolar 
morphology of differentiating oligodendrocytes (Figure 4, B), thus confirming Oli-neu 
cell differentiation after treatment with PD174265. 
 
w/o PD174265
 
Figure 4. PD174265-induced morphological changes in Oli-neu cells 
Bright field microscope pictures showing Oli-neu cells cultured for 48 h in Sato medium either untreated 
(A) or in the presence of 1 μM PD174265 (B). Scale bar = 20 µm. 
 
 Endogenous Expression of GPR17 in Oli-neu cells 4.1.1.2
Highly relevant for the following study is the GPR17 expression pattern in Oli-neu 
cells. Recently, Fratangeli and co-workers published that GPR17 is expressed in Oli-neu 
cells during differentiation in the immature stage, similar to the GPR17 expression ob-
served in primary oligodendrocytes (Fumagalli et al. 2011; Fratangeli et al. 2013). To 
verify these data under the present experimental condition, GPR17 expression was ana-
lyzed by Western blotting, comparing lysates from Oli-neu cells cultured in prolifera-
tion (Sato medium) and differentiating culture conditions (Sato medium + 1µM 
PD174265), respectively. 
Immunoblotting analysis disclosed an absence of GPR17 in proliferating Oli-neu cells 
cultured under control conditions without PD174265 over 72 h. In contrast, in cell ly-
sates cultured in culture medium containing PD174265 a specific 47 kDa GPR17 im-
munoreactive band was initially detectable after 24 hours (approximately 23% of the 
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GPR17 expression after 72 h) and raised during the following days (Figure 5, A and B). 
After 48 h, the GPR17 expression amounted approximately 54% of the total expression 
measured after 72 h. The obtained data confirm the previous findings that GPR17 is up-
regulated in Oli-neu cells in the early stage of differentiation (Fratangeli et al. 2013).  
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Figure 5. GPR17 expression in Oli- neu cells after addition of PD174265 
(A) Illustrative Western blot analysis of GPR17 expression in Oli-neu cells cultured for 24 h, 48 h or 72 h 
in the absence and in the presence of 1 µM PD174265. (B) Quantitative evaluation of the intensity of the 
47-kDa immunoreactive band corrected by beta-actin from three separated experiments. Data were kindly 
provided by Stephanie Hennen, Institute for Pharmaceutical Biology, University of Bonn, Germany. 
 
 Expression of the myelin basic protein in Oli-neu cells 4.1.1.3
Analysis of GPR17 role in myelination in the applied model cell system requires the 
expression of typical myelination markers, such as MBP. It has been previously de-
scribed that after addition of PD174265, Oli-neu cells start to express MBP to a high 
extent (Fratangeli et al. 2013).  
To validate the former findings, protein lysates of differentiating cells (presence of 
PD174265) and proliferating cells (absence of PD174265) were compared to determine 
MBP levels by protein blot analysis. As shown in Figure 6, quantitative comparison of 
protein samples revealed a lack of MBP in proliferating cell samples over 72 h. Howev-
er, upon treatment of the cells with 1µM PD174265 for 72 h, MBP levels increased over 
the time. After 24 h the intracellular MBP levels amounted approximately 59% and af-
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ter 48 h ≈73% of the 72 h-expression level. These data suggest that Oli-neu cells start to 
differentiate into myelinating MBP expressing cells after induction with PD174265. 
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Figure 6. Expression of the myelination marker MBP in Oli-neu cells 
(A) Representative protein blot of lysates prepared form Oli-neu cells cultured for 24 h, 48 h, and 72 h in 
the absence and in the presence of PD174265. Intracellular MBP levels were detected by anti-MBP anti-
body reprobed for beta-actin. (B) Quantitative evaluation of western blot from three separate experiments. 
Data were kindly provided by Stephanie Hennen, Institute for Pharmaceutical Biology, University of 
Bonn, Germany. 
 
 G protein expression during Oli-neu cell proliferation and maturation 4.1.1.4
A previous study has determined the expression of the entire set of Gα subunits in pri-
mary rat OPCs and oligodendrocytes by protein blotting and immunocytochemistry 
(Mir, Le Breton 2008). In order to analyze the expression of Gαi, Gαq, Gαs, and Gαo in 
Oli-neu cells during proliferation and differentiation, Oli-neu cells were cultured for 
48 h in the absence and in the presence of 1 µM PD174265 to induce differentiation and 
Gα subunit expressions were quantified by Western blot analyses with specific antibod-
ies. In both stages of development - proliferating and differentiating - Oli-neu cells ex-
pressed the whole panel of Gα subunits (Figure 7, A-D). These data indicate that G pro-
tein signaling to all four main pathways is feasible in Oli-neu cells. 
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Figure 7. G protein subunit expression in differentiating and proliferating Oli-neu 
cells 
Protein lysates of Oli-neu cells cultured in the absence and in the presence of 1 µMPD174265 for 48 h 
were analyzed by Western blot applying antibodies against (A) Gαs, (B) Gαq, (C) Gαo, and (D) Gαi. 
 
 Specific activation of GPR17 in Oli-neu cells by MDL29,951 4.1.2
To investigate the functionality of GPR17 in Oli-neu cells, we took advantage of 
MDL29,951, the first small molecule agonist of GPR17. MDL29,951 was recently de-
scribed as a potent and specific agonist for GPR17 in both heterologous cell systems 
and primary rat oligodendrocytes (Hennen et al. 2013; Köse et al. 2014). A series of 
classic second messenger assays in Oli-neu cells were performed, to determine the ca-
pacity of MDL29,951 to activate GPR17 and to quantify the contribution of the differ-
ent G proteins to the receptor signaling in this cell line. 
 GPR17 mediated calcium release in Oli-neu cells 4.1.2.1
Recently, Hennen and coauthors defined that the Gαq pathway activates the mobilization 
of Ca2+ from intracellular stores in primary rat oligodendrocytes in a GPR17-dependent 
manner. In order to investigate potential Gαq-coupling of MDL29,951-activated GPR17 
in Oli-neu cells, calcium release assays were performed. A robust and concentration-
dependent Ca2+ release from intracellular stores was detectable in Oli-neu cells treated 
with increasing concentrations of MDL29,951 cultured in medium with PD174265 for 
24-48 h. Ca2+ release was undetectable in proliferating Oli-neu cells cultured in the ab-
sence of PD174265, which did not have a detectable abundance of GPR17 (Figure 8, 
A).  
Moreover, to analyze the contribution of the various G protein pathways to the calcium 
release, cells were incubated for 16 h with the Gαi/o pathway inhibitor PTX. Pretreat-
ment with PTX decreased the GPR17 mediated calcium influx but did not completely 
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block calcium release (Figure 8, B). Taken together, these data suggest that, in contrast 
to primary oligodendrocytes (Hennen et al. 2013), GPR17 signals to both Gαi/o and Gαq 
proteins to release Ca2+ from intracellular stores in Oli-neu cells.  
 
Figure 8. Calcium release from intracellular stores in Oli-neu cells 
(A) MDL29,951 concentration-effect curves of intracellular Ca2+ release in Oli-neu cells cultured in the 
absence or in the presence of PD174265 derived from the maximum peak of real-time traces from three 
separate experiments. (B) PTX influence on MDL29,951-induced Ca2+ release in PD174265-
differentiated Oli-neu cells. Data were kindly provided by Stephanie Hennen and Stefanie Blättermann, 
Institute for Pharmaceutical Biology, University of Bonn, Germany. 
 
To further verify the agonist specificity of MDL29,951, GPR17 expression was de-
creased in differentiating Oli-neu cells by transfection with a small interfering siRNA. 
Analysis of GPR17 expression levels in control cells compared to GPR17 knockdown 
cells revealed a decrease in the intensity of the GPR17 immunoreactive band in cells 
transfected with siRNA specific for GPR17 (Figure 9).  
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Figure 9. GPR17 knockdown by siRNA transfection in Oli-neu cells 
(A) Effect of scrambled siRNA (siSc) and GPR17-siRNA (siGPR17) on GPR17 expression as pictured on 
a protein blot. (B) GPR17 expression levels represented in a bar diagram derived from Western blots 
upon GPR17 knockdown from five independent experiments. ***, p<0.001. Data were kindly provided 
by Stefanie Blättermann, Institute for Pharmaceutical Biology, University of Bonn, Germany. 
 
Accordingly, MDL29,951-induced Ca2+ flux was reduced upon GPR17-siRNA cell 
transfection. Ca2+ release triggered by both the receptor-independent calcium ionophore 
A23187 and adenosine 5-triphosphate (ATP), through activation of endogenous P2Y 
receptors, was unaffected (Figure 10), indicating that siRNA transfection had no influ-
ence on the capacity of Oli-neu cells to release Ca2+ from intracellular calcium stores. 
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Figure 10. Effect of GPR17-siRNA knockdown on calcium release from intracellu-
lar stores in Oli-neu cells  
Effect of scrambled siRNA (siSc) and GPR17-siRNA (siGPR17) knockdown on ATP-, A23187-, and 
MDL29,951-triggered Ca2+ release in Oli-neu cells treated with PD174265. Data were kindly provided by 
Stefanie Blättermann, Institute for Pharmaceutical Biology, University of Bonn, Germany. 
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 GPR17-mediated inhibition of cAMP accumulation  4.1.2.2
Additionally, the influence of GPR17 on intracellular cAMP accumulation was ana-
lyzed in order to investigate the Gαi/o and Gαs coupling of GPR17. 
The amount of forskolin-stimulated intracellular cAMP was concentration-dependently 
decreased by the GPR17 agonist MDL29,951 in Oli-neu cells cultured for 24 h with 
PD174265. In contrast, in proliferating Oli-neu cells (cultured without PD174265), 
which do not express GPR17, no decrease was detectable (Figure 11). This verified that 
MDL29,951-mediated lowering of cAMP levels is GPR17-dependent. Furthermore, 
cAMP accumulation was not detectable at higher concentrations of the GPR17 agonist. 
These data reveal that GPR17 activates Gαi/o but not Gαs protein signaling in Oli-neu 
cells endogenously expressing GPR17, although Gαs protein are present in this cellular 
background (Figure 7A).  
Altogether, the data of the first part of the present work lend further support to the no-
tion that GPR17 engages Gαi/o and Gαq proteins for downstream signaling in primary rat 
oligodendrocytes and Oli-neu cells. Importantly, for further investigations of the present 
study, Oli-neu cells express GPR17 in a similar time-dependent manner during differen-
tiation similar to that seen in primary oligodendrocytes (Hennen et al. 2013), and 
MDL29,951 has the capacity to specifically activate GPR17 in Oli-neu cells. Further-
more, during differentiation, Oli-neu cells express the typical differentiation marker 
MBP. Thus, the obtained data validate Oli-neu cells as suitable model system to study 
the pathways engaged by GPR17 to arrest oligodendrocyte differentiation and mye-
lination. 
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Figure 11. MDL29,951-decreased cAMP accumulation in Oli-neu cells expressing 
GPR17 
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Alteration of forskolin-stimulated intracellular cAMP-levels triggered by MDL29,951 in Oli-neu cells in 
the absence (n = 3) and in the presence (n = 6) of PD174265.  
 
4.2 GPR17 signaling pathway in oligodendrocytes 
 Gαi/o proteins as major contributors to the GPR17 signaling in 4.2.1
oligodendroglial cells  
The results of the classical second messenger assays revealed a contribution of both 
Gαi/o and Gαq proteins and their effector proteins to GPR17 signaling in primary rat oli-
godendrocytes (Hennen et al. 2013) and Oli-neu cells. In order to determine whether 
both G protein pathways play equivalent roles after GPR17 activation in oligoden-
droglial cells, their unmitigated cell activity was inspected.  
 Global cell response analyzed by dynamic mass redistribution 4.2.1.1
To this end, GPR17 global cell responses in Oli-neu and primary rat oligodendrocytes 
were determined by dynamic mass redistribution (DMR). This non-invasive label-free 
method uncovers the whole cell activity after receptor stimulation and was described as 
ideal approach to analyze GPCR signaling in living cells, detecting the signaling path-
ways of all four G protein subfamilies (Schröder et al. 2010; Schröder et al. 2011). Fur-
thermore, to analyze the contribution of Gαi/o proteins to the GPR17-mediated whole 
cell responses, PTX was applied to pharmacologically block Gαi/o signaling (Schröder et 
al. 2010).  
In differentiated Oli-neu cells, DMR was analyzed after addition of MDL29,951 in in-
creasing concentrations in the absence and in the presence of PTX. As shown in Figure 
12, MDL29,951 triggered a concentration-dependent and robust DMR response in Oli-
neu cells. Moreover, after incubation of the cells for 16 h with PTX, the whole-cell re-
sponse was completely abolished (Figure 12, A and B). 
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Figure 12. MDL29,951-triggered DMR recordings in Oli-neu cells 
(A) Representative concentration-dependent DMR recordings of the GPR17 agonist MDL29,951 in Oli-
neu cells cultured for 24 h with PD174265 in the absence and in the presence of PTX. (B) Concentration-
response curves derived from different DMR traces as in (A) from seven independent experiments. Data 
were in part provided by Stephanie Hennen, Institute for Pharmaceutical Biology, University of Bonn, 
Germany. 
Corresponding observations were made in primary rat oligodendrocytes incubated for 
24 h in medium without growth factors to induce their differentiation. MDL29,951 
prompted concentration-dependent stable optical traces that after incubation of the cells 
for 16 h with PTX were largely abrogated (Figure 13).  
The obtained results support the notion that the wavelength shift resulted mainly from a 
Gαi/o -mediated signaling event in both cell lines. Thus, these data drive the hypothesis 
that in oligodendrocytes, the Gαi/o cascade is the main pathway triggered by GPR17, 
responsible for the negative impact of GPR17 on oligodendrocyte differentiation. 
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Figure 13. MDL29,951-triggered DMR recordings in primary rat oligodendrocytes 
(A) Characteristic DMR traces of MDL29,951-triggered responses in primary rat oligodendrocytes in the 
absence and in the presence of PTX, cultured for 24 h in medium without growth factors to induce differ-
entiation. (B) Concentration-response curves calculated from six independent experiments. Data were in 
part provided by Stephanie Hennen, Institute for Pharmaceutical Biology, University of Bonn, Germany. 
 
 GPR17 arrested oligodendrocytes in an immature stage via Gαi/o 4.2.2
 Influence of MDL29,951 on Oli-neu cell differentiation 4.2.2.1
To validate the hypothesis that GPR17 acts as a negative modulator of oligodendrocyte 
maturation via the Gαi/o signaling cascade, Oli-neu cells were first incubated in the ab-
sence and in the presence of 10 µM MDL29,951 for 48 h, while cultured with 1 µM 
PD174265 to induce their differentiation, and subsequently Western blot analyses were 
performed to quantify MBP expression. As shown in Figure 14, evaluation of the im-
munoblottings revealed an average of approximately 38% lower MBP abundance in 
Oli-neu cells treated with MDL29,951, which indicated that GPR17 activation mediated 
a maturation block in this cell model. 
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Figure 14. GPR17-mediated decrease in MBP expression levels in Oli-neu cells 
(A) Illustrative Western blot of MBP downregulation mediated by 10 µM MDL29,951 compared with 
untreated cells in Oli-neu cells differentiated with 1 µM PD174265. (B) Densitometric analysis of MBP 
immunoreactive bands, quantified from eight independent experiments. ***, p<0.001. 
 
 Influence of MDL29,951 on primary rat oligodendrocyte 4.2.2.2
differentiation 
To further verify the obtained data, which assumed that GPR17 mediates a maturation 
block, immature primary rat oligodendrocytes were incubated for 48 h in the absence 
and in the presence of MDL29,951 in culture medium containing thyroid hormone T3 to 
induce differentiation. Densitometric analysis exhibited an average reduction of approx-
imately 25% in MBP expression levels after addition of the GPR17 agonist MDL29,951 
(Figure 15). Therefore, the obtained data in both cell lines confirmed that GPR17 acti-
vation arrests oligodendrocytes in an immature, less differentiated stage and, conse-
quently, that GPR17 has a negative impact on oligodendrocyte development. 
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Figure 15. Depression of MBP expression triggered by GPR17 in primary rat oli-
godendrocytes 
(A) Representative Western blot illustrating lower levels of MBP from primary rat oligodendrocytes 
cultured in differentiation medium containing T3 in the presence of 30 µM MDL29,951 in contrast to 
control cells. (B) Quantification from six independent protein blot analyses. *, p<0.05. 
 
 Engagement of Gαi/o on GPR17-mediated MBP decrease 4.2.2.3
Current evidence supports the idea that Gαi/o-coupled GPCRs act as inhibitors of oli-
godendrocyte maturation, such as the chemokine receptor CXCR2 or the thrombin re-
ceptor PAR1 (Kerstetter et al. 2009; Yoon et al. 2015). 
The DMR analysis in the present study verified that GPR17 mainly signals via Gαi/o 
proteins in oligodendrocytes. In order to investigate whether GPR17 blocks oligoden-
drocyte maturation by a Gαi/o protein-dependent pathway, the MBP expression of prima-
ry rat oligodendrocytes and Oli-neu cells was analyzed in the absence and in the pres-
ence of PTX.  
Oli-neu cells were first incubated with PTX for 16-20 h, before induction of differentia-
tion with 1µM PD174265 for 48 h. Immunoblotting quantification analyses of MBP 
expression displayed that incubation with PTX counteracted the decrease of MBP ex-
pression triggered by the GPR17 agonist MDL29,951 (Figure 16). The obtained data 
suggest that the Gαi/o pathway mainly triggers the arrest of differentiation mediated by 
GPR17 in Oli-neu cells.  
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Figure 16 Influence of PTX on MBP expression in Oli-neu cells 
(A) Western blot analysis of intercellular MBP levels representative for the counteracting effect of PTX 
on the GPR17-mediated effect on the MBP expression. (B) Qualitative evaluation of twelve independent 
protein analyses. *, p 0.05; ***, p 0.001. 
Comparable results were obtained in primary rat oligodendrocytes, where PTX had the 
ability to counteract the MDL29,951-mediated reduction of MBP expression (Figure 
17).  
Together, these findings indicate that MDL29,951-activated GPR17 engages Gαi/o pro-
teins to reduce MBP expression in primary rat oligodendrocytes and Oli-neu cells, to 
finally arrest oligodendrocytes in an immature stage. Because Gαi/o proteins mainly in-
hibit the enzyme adenylate cyclase, thus decreasing intracellular cAMP production, the 
present data suggest a major role of cAMP in the GPR17 signaling cascade to arrest 
oligodendrocyte differentiation. 
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Figure 17. Influence of PTX on MBP expression in primary rat oligodendrocytes 
(A) Representative Western blot analysis of MBP, then reprobed for beta-actin, in primary rat oligoden-
drocytes after 16 h of incubation with PTX in the absence and in the presence of 30 µM MDL29,951. (B) 
Quantitative analysis of MBP expression in primary rat oligodendrocytes from eight independent experi-
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ments. *, p<0.05. Data were in part provided by Stephanie Hennen, Institute for Pharmaceutical Biology, 
University of Bonn, Germany. 
 GPR17-mediated regulation of intracellular cAMP levels affects MBP 4.2.3
expression levels 
cAMP is a second messenger involved in key signal transductions within the cell. Ade-
nylate cyclase converts adenosine triphosphate (ATP) into cAMP and pyrophosphate 
(PPi), and thereby the intracellular cAMP concentration is increased. In the last years, 
different independent groups have evaluated the essential role of intracellular cAMP 
modulation on the demanding oligodendrocyte differentiation process. High intracellu-
lar cAMP levels trigger the transition of OPCs to mature oligodendrocytes, thereby in-
ducing oligodendrocyte myelination (Pleasure et al. 1986; Raible, McMorris 1990; 
Pende et al. 1997). Consequently, indirect increase of the intracellular cAMP levels by 
phosphodiesterase inhibitors mediates a high abundance of myelinating oligodendro-
cytes in culture (Syed et al. 2013). 
To further substantiate the GPR17-Gαi/o-cAMP signaling pathway, the effect of cAMP 
on MBP expression upon GPR17 stimulation was investigated. To this end, differentiat-
ing Oli-neu cells were incubated together with MDL29,951 in the absence and in the 
presence of the membrane permeable, lipophilic, and non-hydrolysable cAMP analog 8-
(4-chlorophenylthio)-adenosine-3´,5´-cAMP (8-CPT-cAMP). As seen in Figure 18, the 
cAMP analog overcame the decrease in MBP levels upon GPR17 activation, displaying 
no significant effects in its own right. Similar results were obtained in primary rat oli-
godendrocytes, where 8-CPT-cAMP - ineffective when applied alone - also counteract-
ed GPR17-induced MBP depression (Figure 19). 
Taken together, these results strongly suggest that GPR17 activation mediated a de-
crease of intracellular cAMP levels in order to keep oligodendrocyte in an immature, 
not myelinating stage, in line with the previous findings correlating cAMP concentra-
tion and oligodendrocyte differentiation. Interestingly, intracellular concentration of 
cAMP is an important stimulus to regulate the activity of two main effector proteins, the 
cAMP-dependent protein kinase A (PKA) and the Rap1 guanine-nucleotide-exchange 
factor directly activated by cyclic AMP (EPAC). Consequently, a new analysis was ini-
tiated to uncover the putative role of both downstream effectors upon GPR17 activation 
that results in arrest of oligodendrocyte maturation. 
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Figure 18. Expression of MBP is promoted by treatment of Oli-neu cells with 8-
CPT-cAMP in the presence of MDL29,951 
(A) Illustrative protein analysis of MBP levels in Oli-neu in the absence (w/o) and in the presence of 
1 µM of the cAMP analog 8-CPT-cAMP (cAMP). (B) Quantitative analysis of ten independent protein 
blots. *, p<0.05; ***, p<0.001. 
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Figure 19. MBP expression is triggered by 8-CPT-cAMP in the presence of 
MDL29,951 in primary rat oligodendrocytes  
(A) Representative Western blot of MBP levels in differentiating oligodendrocytes treated for 48 h in 
medium with triiodothyronine (T3) and 30 µM MDL29,951 in the absence (w/o) and in the presence of 1 
µM 8-CPT-cAMP (cAMP). (B) Calculation of MBP levels from five isolated experiments in primary rat 
oligodendrocytes illustrating that the cAMP analog triggered MBP expression in the presence of 
MDL29,951. *, p<0.05; **, p<0.01. 
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 Investigation of the PKA-pCREB pathway 4.2.4
PKA function has been extensively studied in the last years. Changes in the intracellular 
levels of cAMP regulate PKA activity, leading to phosphorylation of both cytosolic 
targets and nuclear transcription factors. Interestingly, recent studies have described the 
positive influence of PKA activity on oligodendrocyte differentiation (Sato-Bigbee et al. 
1999; Shiga et al. 2005). 
 GPR17 stimulation results in decreased PKA activity 4.2.4.1
To investigate whether the alteration of cAMP levels mediated by GPR17 leads to a 
change in the PKA activity that subsequently primes a decrease in MBP expression, the 
effect of N6-benzoyladenosine-3,5-cyclic monophosphate (SP-6-Bnz-cAMPs) a selec-
tive cell-permeable PKA activator on GPR17-mediated MBP depression was analyzed 
by immunoblot quantification. To this end, both Oli-neu and primary rat oligodendro-
cytes were pre-incubated with SP-6-Bnz-cAMPs in two different concentrations (20 µM 
and 2 µM) in the absence and in the presence of the GPR17 agonist. As shown in Figure 
20, both concentrations did not significantly affect MBP expression levels in their own 
right, but counteracted the MDL29,951-mediated decrease of MBP levels in Oli-neu 
cells. Equivalent results were obtained in rat oligodendrocytes (Figure 21). 
Taken together, the data indicate that a downstream signaling consequence of GPR17 
activation is a reduction of PKA activity, which finally impairs oligodendrocyte differ-
entiation. These findings are in keeping with published observations describing a rela-
tionship between PKA activity and differentiation of oligodendrocytes (Sato-Bigbee et 
al. 1999; Shiga et al. 2005). 
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Figure 20. PKA activation triggered MBP expression in Oli-neu cells and overcame 
the GPR17 agonistic effect  
(A) Illustrative western blot of MBP expression, afterwards reprobed for β-actin expression from Oli-neu 
cell lysates in the absence and presence of 10 µM MDL29,951 showing that SP-6-Bnz-cAMPS overcame 
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the negative effect of MDL29,951 on MBP expression. (B) Evaluation of MBP expression from eight 
independent experiments.  
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Figure 21. Activated PKA stimulated MBP expression in primary rat oligodendro-
cytes cells and counteracted GPR17-mediated effect 
(A) Illustrative blot of MBP levels, the same membrane was as well reprobed for beta-actin, from oli-
godendrocytes incubated in the absence and presence of 20 µM or 2 µM Sp-6-Bnz-cAMPS for 48 h to 
counteract the MDL29,951 (30 µM) effect. Culture medium contained T3 to induce differentiation. (B) 
Evaluation of the relative MBP expression from nine independent experiments in oligodendrocytes dif-
ferentiated for 48 h with T3. *, p<0.05. 
 Effects of GPR17 stimulation on CREB phosphorylation 4.2.4.2
Regulation of gene expression in oligodendrocytes is crucial to successfully control the 
challenging processes of maturation and differentiation. It has been discovered that lev-
els of the intracellular second messenger cAMP affect gene expression via the activa-
tion of transcription factors that bind to DNA regulatory regions carrying specific con-
sensus sequences (Sato-Bigbee et al. 1994; Sands, Palmer 2008). 
An important pathway in oligodendrocyte differentiation is the phosphorylation of the 
transcription factor CREB by PKA at Ser133. This results in the binding of CREB to 
the DNA regulatory region cyclic AMP response element (CRE), which leads to the 
regulation of MBP gene expression (Sato-Bigbee, Yu 1993; Sato-Bigbee et al. 1994; 
Sato-Bigbee et al. 1999).  
To investigate whether GPR17 stimulation in primary rat oligodendrocytes has an influ-
ence on CREB activation, the level of intracellular CREB phosphorylation in the ab-
sence and in the presence of 30 µM MDL29,951 was measured after 48 h treatment. A 
significant decrease of p-CREB in cells stimulated with the GPR17 agonist was detect-
able in comparison to untreated cells by immunoblotting quantification analyses (Figure 
25). Notably, pre-incubation with different PKA activator concentrations (Sp-6-Bnz-
cAMPS) counteracted the GPR17-dependent p-CREB reduction. Taken together, the 
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results revealed a key role for GPR17 in diminishing MBP expression by engaging the 
cAMP-PKA-CREB cascade. In particular, inhibition of the AC after GPR17 activation 
decreases intracellular cAMP levels, which in turn depresses PKA activity and, in con-
sequence, reduces intracellular phosphorylated CREB levels.  
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Figure 22. Activation of PKA overcame the MDL29,951-mediated decrease in 
CREB phosphorylation 
(A) Representative Western blot of phosphorylated CREB (p-CREB), afterwards reprobed for total CREB 
levels (t-CREB). Primary rat oligodendrocytes were cultured with T3 in the absence and presence of 30 
µM MDL29,951 with two different concentrations of Sp-6-Bnz-cAMPS for 48 h. Western blot analysis 
exhibited both the significant decrease of CREB phosphorylation upon GPR17 activation and promotion 
of CREB phosphorylation by cotreatment with the PKA activator. (B) Evaluation of phosphorylated to 
total CREB ratios from seven independent experiments in oligodendrocytes differentiated for 48 h. **, 
p<0.01. 
 Influence of GPR17 on ERK1/2 phosphorylation 4.2.5
PKA is also known to phosphorylate CREB through a second downstream mechanism, 
by activation of the mitogen-activated protein kinase (MAPK) cascade, which in turn 
phosphorylates CREB (Costes et al. 2006; Smith et al. 2010; Syed et al. 2013). Extra-
cellular signal-regulated kinase 1 and 2 (ERK1/2) are members of the MAPK family of 
protein kinases, which are involved in several cellular processes such as survival, dif-
ferentiation and proliferation (Costes et al. 2006). Interestingly, ERK1/2 are key signal-
ing intermediates playing an essential role in promoting early development and mye-
lination of oligodendrocytes (Xiao et al. 2012b; Fyffe-Maricich et al. 2011). 
 ERK1/2 phosphorylation in heterologous cell expression system 4.2.5.1
To investigate whether ERK1/2 are GPR17 effector proteins, GPR17-dependent 
ERK1/2 phosphorylation (pERK1/2) was first analyzed in a HEK293 cell background. 
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As shown in Figure 23, A, a robust time-dependent increase in ERK1/2 phosphorylation 
was detectable, peaking within 2 min and returning to baseline after 30 min.  
Notably, after pre-incubation with the Gαq-selective inhibitor FR900359, the ERK1/2 
phosphorylation was completely abolished, whereas pre-incubation with the Gαi/o inhib-
itor PTX partially abolished the ERK1/2 phosphorylation (Figure 23, B). These results 
indicate that in HEK293 cells GPR17 used both Gαq and Gαi pathways to phosphorylate 
ERK1/2, suggesting an astounding order to regulate intracellular ERK1/2 phosphoryla-
tion: Gαq-mediated ERK activation occurs upstream to that mediated by Gαi. 
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Figure 23. GPR17-mediated ERK1/2 phosphorylation in heterologous cell expres-
sion system 
(A) Kinetics of ERK1/2 phosphorylation in HEK293 cells stably expressing GPR17 after treatment with 
10 µM MDL29,951 (n = 3). (B) Phosphorylation of ERK1/2 in hGPR17 HEK239 cells after MDL29,951 
stimulation, pretreated with FR900359 (1 µM), PTX (50 ng/ml), or both. 
 ERK1/2 activation in oligodendroglial cell lines  4.2.5.2
To further analyze whether activated GPR17 endogenously expressed in oligodendro-
cytes conducts modifications in intracellular p-ERK1/2 levels similar to those observed 
in HEK293 cells, primary rat oligodendrocytes and Oli-neu cells were stimulated with 
MDL29,951 over time. 
In Oli-neu cells receptor activation resulted in a robust and rapid pERK1/2 increase of 
transient nature, with a maximum peak after 7-10 min that reversed quickly toward 
baseline (Figure 24, A). Comparable results were obtained in primary rat oligodendro-
cytes; MDL29,951 induced an earlier transient signal of pERK1/2 after 5 min, which 
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returned to baseline after 30 min (Figure 24, B). Therefore, these data confirm a transi-
ent ERK1/2 phosphorylation also in native expression systems after GPR17 activation. 
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Figure 24. Kinetics of the phosphorylation of ERK1/2 triggered by MDL29,951 in 
oligodendroglial cell lines 
Time-dependent ERK1/2 activation in Oli-neu cells (A) and primary rat oligodendrocytes (B) mediated 
by MDL29,951. Data in (B) were kindly provided by Stephanie Hennen, Institute for Pharmaceutical 
Biology, University of Bonn, Germany. 
 
To determine the underlying molecular mechanism of short-term ERK1/2 phosphoryla-
tion in Oli-neu cells, cells were pre-incubated with the Gαq inhibitor FR900359 and the 
Gαi/o inhibitor PTX. Notably, pre-treatment with PTX completely abolished ERK1/2 
phosphorylation whereas FR900359 showed no influence on the maximum peak of 
pERK1/2 after 10 min (Figure 25, A). Neither PTX nor FR900359 affected viability of 
Oli neu cells because FCS-mediated ERK phosphorylation was unaltered when cells 
were pre-treated with these inhibitors (Figure 25, B). In conclusion, in Oli-neu cells, 
GPR17-mediated ERK1/2 phosphorylation is completely Gαi-dependent with the Gαq 
pathway having no impact on intracellular p-ERK1/2 levels. 
Altogether, these results provide evidence that MDL29,951-stimulated GPR17 induces 
ERK1/2 phosphorylation in a G protein-dependent manner both in heterologous cell 
expression systems and in oligodendroglial cell systems endogenously expressing 
GPR17, albeit via engagement of different Gα subfamilies in a manner depending on 
the cellular background. 
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Figure 25. Effect of G protein selective inhibitors on ERK1/2 phosphorylation trig-
gered by GPR17 in Oli-neu cells 
(A) ERK1/2 phosphorylation in Oli-neu cells triggered by MDL29,951 after pre-treatment with 
FR900359 (1µM), PTX (50 ng/ml), or both. (B) ERK1/2 phosphorylation mediated by 10% fetal calf 
serum (FCS) in oligodendrocytes after pre-treatment with FR900359 (1 µM) or PTX (50 ng/ml) com-
pared to buffer pretreatment (n = 2-3). 
 
Recent publications have supported a direct correlation between long-term increase of 
intracellular phosphorylated ERK1/2 and oligodendrocyte differentiation (Fyffe-
Maricich et al. 2011; Xiao et al. 2012a; Xiao et al. 2012b). To investigate whether long-
term alteration of ERK1/2 phosphorylation in oligodendrocytes is also associated with 
activation of GPR17, p-ERK1/2 levels were quantified in primary rat oligodendrocytes 
and Oli-neu cells after incubation with MDL29,951 for 24 h and 48 h. However, in Oli-
neu cells, no GPR17-mediated alteration on p-ERK1/2 levels was detectable after 24 h 
or 48 h (Figure 26).  
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Figure 26. ERK1/2 long-term activation in Oli-neu cells in the presence of 
MDL29,951  
(A) Long-term phosphorylation of ERK1/2 time course in Oli-neu cells mediated by 10 µM MDL29,951 
for 10 min, 24 and 48 h compared with the phosphorylation peak detected upon 7 min treatment (n = 2-5).  
 
Likewise, in primary rat oligodendrocytes, although over the time the phosphorylation 
of ERK1/2 surged, longer incubations with 30 µM MDL29,951 were not associated 
with an increase or decrease of pERK1/2 (Figure 27, A and B). 
Taken together, these data provide evidence that MDL29,951-stimulated GPR17 trig-
gers phosphorylation of ERK1/2 at short time points but does not induce sustained long-
term ERK activation, which is considered as key factor for efficient enhancement of 
oligodendrocyte differentiation. Thus, GPR17 unlikely affects oligodendrocyte differen-
tiation by an ERK1/2-dependent pathway. 
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Figure 27. ERK1/2 long-term activation in primary rat oligodendrocytes is not af-
fected by MDL29,951 
(A) Representative Western blot analysis of alteration of phosphorylated ERK1/2 (p-ERK1/2), reprobed 
for total ERK1/2 levels (t-ERK1/2), in differentiating primary rat oligodendrocytes in the presence and 
absence of MDL29,951 after 24 and 48 h incubation. (B) Quantitative assessment of pERK1/2 alteration 
triggered by 30 µM MDL29,951 in primary rat oligodendrocytes (n = 5-6). 
 
 The exchange factor directly activated by cAMP (EPAC) as a 4.2.6
downstream effector protein of GPR17 activation 
For a long time PKA was described as the exclusive effector protein of cAMP, but in 
1998 Rooij identified a second alternative cAMP target, the Rap1 guanine-nucleotide-
exchange factor directly activated by cyclic AMP (EPAC) (Rooij et al. 1998). The es-
tablished existence of a distinct EPAC-dependent signaling pathway led to suggest in-
volvement of this downstream effector in several cellular processes. In the last years, it 
has become obvious that a wide range of physiological and pathophysiological process-
es within the same cell can be synergistically or antagonistically coordinated by both 
PKA and EPAC. Because the presence of EPAC in oligodendrocytes and its potential 
impact on their development are unknown, the effect of EPAC on MBP expression was 
next analyzed in oligodendroglial cell lines. 
 
 Role of EPAC in oligodendrocyte differentiation  4.2.6.1
Initially, to examine whether EPAC is expressed in oligodendrocytes, EPAC levels in 
primary rat oligodendrocytes were determined after 24 h, 48 h, and 72 h of differentia-
tion by Western blot analyses. As shown in Figure 28, specific immunoreactive bands 
were detectable at each time point, demonstrating that EPAC is expressed in oligoden-
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drocytes over time during their differentiation. These results support the assumption that 
EPAC might also play a role during the differentiation processes of oligodendrocytes. 
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Figure 28. EPAC expression during oligodendrocyte differentiation 
(A) Primary rat oligodendrocytes were differentiated with T3 for 24, 48, and 72 h; samples were then 
analyzed by Western blot for EPAC expression with specific antibodies against EPAC1/2 (EPAC). (B) 
Bar diagram of EPAC abundance during oligodendrocyte differentiation from four different experiments. 
 
Next, to test whether EPAC activity is altered upon GPR17 stimulation, the influence of 
increasing concentrations of the cell permeable selective EPAC activator 8-(4-
Chlorophenylthio)-2’-O-methyl-cAMP (8-CPT-2´-O-Me-cAMP) was tested on the 
MDL29,951-induced depression of MBP expression in primary rat oligodendrocytes. 
Treatment with 8-CPT-2´-O-Me-cAMP overcame the GPR17-mediated decrease on 
MBP expression without any influence on this oligodendrocyte differentiation marker 
on its own (Figure 29).  
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Figure 29. 8-CPT-2´-O-Me-cAMP, an activator of EPAC, overcame the GPR17-
mediated depression of MBP expression in primary rat oligodendrocytes 
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(A) Representative Western blot of MBP levels in differentiating primary rat oligodendrocytes incubated 
for 48 h with 30 µM MDL29,951 in the absence and presence of 20 µM and 2 µM of the EPAC activator 
8-CPT-2´-O-Me-cAMP (EPAC-A). (B) Assessment of MBP levels from six independent experiments in 
primary rat oligodendrocytes displaying that treatment with 8-CPT-2´-O-Me-cAMP supports MBP ex-
pression in the presence of the MDL29,951. *, p<0.05. 
 
Consistent with these data, the EPAC activator also rescued the decrease of MBP ex-
pression in Oli-neu cells (Figure 30). Therefore, the achieved data indicate that cAMP 
reduction triggered by MDL29,951 alters EPAC function as a downstream signaling 
consequence of GPR17 activation.  
 
Figure 30. The EPAC activator 8-CPT-2´-O-Me-cAMP counteracted the GPR17-
induced reduction of MBP in Oli neu cells 
(A) Representative Western blot investigating MBP expression levels in differentiating Oli-neu cells 
treated for 48 h with 10 µM MDL29,951 in the absence (w/o) and presence of two different concentra-
tions of 8-CPT-2´-O-Me-cAMP (EPAC-A) 20µM and 2 µM. (B) Calculation of MBP expression in Oli-
neu cells from nine independent experiments. **, p<0.01. 
 
 Essential role of EPAC signaling in oligodendrocyte differentiation 4.2.6.2
The obtained data suggest that EPAC activation could play an important role during 
oligodendrocyte differentiation. Therefore, to confirm this hypothesis, immature prima-
ry rat oligodendrocytes were cultured for 24 h, 48 h, and 72 h in absence and in pres-
ence of 10 µM ESI-05 (4- methylphenyl- 2, 4, 6- trimethylphenylsulfone), a membrane-
permeant specific EPAC inhibitor. 
Incubation of primary rat oligodendrocytes for 48 h and 72 h with ESI-05 led to a sig-
nificant decrease in MBP expression compared with the solvent-treated cells, thus indi-
cating an arrest of oligodendrocytes in a less differentiated stage. Compared to parallel 
untreated cells, the EPAC inhibitor reduced the MBP levels by approximately 30% after 
48 h treatment and by approximately 60% after 72 h (Figure 31).  
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Figure 31. Influence of the EPAC inhibitor ESI-05 on differentiation of primary rat 
oligodendrocytes  
(A) Illustrative Western blot displaying the influence of 10 µM ESI-05 (EPAC-I) on the expression levels 
of MBP, reprobed for beta-actin, in differentiating primary rat oligodendrocytes after 24 h, 48 h, and 72 h 
of culturing in medium containing T3 to facilitate maturation compared with control cells. (B) Quantifica-
tion of the immunoreactive bands of MBP expressed in primary rat oligodendrocytes after 48 h and 72 h 
incubation with ESI-05. Average of five independent experiments. *, p<0.05; **, p<0.01.  
To exclude that the negative effect on MBP expression is not due to a toxic effect of the 
compound, the influence of the EPAC inhibitor on Oli-neu cell viability was tested over 
48 h. No influence of the EPAC inhibitor on cell viability was measured compared to 
the DMSO 0.1%-treated cells (negative control), thus confirming a true pathway inhibi-
tion and not just a toxic effect. The toxic effect of etoposide served as positive control, 
demonstrating a 30% decrease of oligodendrocyte viability (Figure 32). 
 
Figure 32. ESI-05 does not affect cell viability of Oli-neu cells  
Analysis of viability of Oli-neu cells after treatment for 48 h with 10 µM of the EPAC inhibitor ESI-05 
(EPAC-I) compared with the influence the topoisomerase II inhibitor etoposide (50 µM) as positive con-
trol.  
Moreover, to verify the downstream role of PKA and EPAC in the signaling cascade 
upon the cAMP decrease triggered by GPR17 stimulation, MBP expression analyses 
were carried out in primary rat oligodendrocytes incubated for 48 h with medium con-
taining T3 and MDL29,951. To counteract the MBP depression triggered by the GPR17 
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agonist, the stable cAMP analog 8-CPT-cAMP was added to the cells. In addition, cells 
were co-treated in the absence and in the presence of either the EPAC inhibitor ESI-05 
or the selective PKA inhibitor, 8-(4-Chlorophenylthio) adenosine-3', 5'-cyclic mono-
phosphorothioate, Rp- isomer (Rp-8-CPT-cAMPS). As shown in Figure 33, Western 
blot analyses confirmed again that 8-CPT-cAMP counteracted the negative influence of 
the GPR17 agonist on MBP expression (see also Figure 19). 
 
Figure 33. EPAC and PKA involvement in the downstream signaling of GPR17 
(A) Western blot analysis of the influence of 10 µM of the EPAC inhibitor ESI-05 (EPAC-I) and 10 µM 
of the PKA inhibitor RP-8-CPT-AMPS (PKA-I) on MBP expression in primary rat oligodendrocytes 
cultured for 48 h in differentiation medium containing T3 and 30 µM MDL29,951, in the absence and in 
the presence of 1 µM 8-CPT-cAMP (cAMP). (B) Quantitative calculation of MBP immunoreactive bands, 
corrected by beta-actin, from five independent experiments. *, p<0.05. 
 
Furthermore, both inhibitors, ESI-05 and Rp-8-CPT-cAMPS, blocked the counteracting 
effect of the cAMP-analog on GPR17-triggered MBP reduction to a similar extent. 
Therefore, these results confirm that PKA and EPAC are downstream effectors of 
cAMP and reveal that both proteins act as key modulators of MBP expression in the 
GPR17-dependent signaling pathway. 
In summary, the obtained data lead to the assumption that the effector protein EPAC 
plays a not yet recognized and essential role in the challenging differentiation processes 
of oligodendrocytes. Furthermore, they also demonstrate that the low levels of cAMP 
triggered by GPR17 stimulation diminish both the PKA/CREB and EPAC signaling 
pathways in order to arrest oligodendrocyte differentiation and maturation. 
4.3 Analysis of proposed GPR17 endogenous ligands 
GPR17, which is phylogenetically related to purinergic and cysteinly-leukotriene recep-
tors, has been described as being activated by compounds of both endogenous ligand 
classes (Ciana et al. 2006; Hennen et al. 2013). However, a number of independent 
studies did not or just partially confirm the original deorphanization research article 
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(Bläsius et al. 1998; Heise et al. 2000; Maekawa et al. 2009; Benned-Jensen, Rosenkilde 
2010; Wunder et al. 2010; Qi et al. 2013; Hennen et al. 2013; Köse et al. 2014). Thus, 
pharmacology of the proposed endogenous ligands of GPR17 is still under debate. 
In order to reveal whether GPR17 represents the elusive orphan receptor that is activat-
ed by both ligand classes, GPR17-mediated cell responses were monitored over time by 
using classical second messenger assays recording intracellular events such as Gαi, Gαq, 
and Gαs activation, as well as β-arrestin recruitment. 
 Direct G protein rearrangement mediated by GPR17  4.3.1
To investigate the direct ligand-induced rearrangement of the Gαβγ complex mediated 
by GPR17, agonist-promoted decreases in BRET2 signals were studied in HEK293 cells 
co-expressing the energy acceptor Gγ2-GFP (green fluorescent protein) and the partner 
energy donor Gαi-Rluc (renilla reniformis luciferase enzyme) together with unlabeled 
hGPR17 and Gβ1. BRET
2 signal-decrease is a consequence of the G protein heterotri-
mer reshaping triggered by GPR17 activation. This reshaping results in an increase of 
the distance between the N-terminus of Gγ2 and the Gαi subunit, creating the route for 
GDP exit and GTP entry (Gales et al. 2006). In this context it is important to note that 
GPR17 strongly couples to Gαi/o proteins in recombinant cell systems (Hennen et al. 
2013). The advantage of this readout is that the agonist response occurs upstream and is 
not modulated by other signaling events that may affect measurements further down-
stream of the receptor. Consequently, this assay monitors early GPR17 activation of the 
putative endogenous ligands, which is then followed by enzyme activation involved in 
the second messenger production. Incubation of the HEK293 cells with 1 µM 
MDL29,951 exhibited a robust signal after 1 min. In contrast, the proposed endogenous 
ligands UDP, UDP-glc, UDP-gal, LTC4, and LTD4 did not lead to any heterotrimer 
conformational change, as shown in Figure 34.  
Taken together, the obtained results confirmed the robust MDL29,951-mediated GPR17 
activation, but could not verify pairing of the proposed endogenous ligands with 
GPR17. 
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Figure 34. Molecular rearrangement within the Gαi-βγ heterotrimer  
GPR17-mediated conformational change of the Gαi-subunit relative to the γ-subunit induced by tested 
compounds as an indicator of G protein activation. HEK293 cells were transiently transfected to co-
express hGPR17, Gαi1-91Rluc, and GFP10-Gγ2 along with the complementary subunit Gβ1. The rear-
rangement was recorded after 1 min of compound incubation with indicated concentrations of the pro-
posed endogenous ligands (10 µM UDP, 10 µM UDP-glc, 10 µM UDP-gal, 0,1 µM LTD4 and 0,1 µM 
LTC4). The data were compared to the recently characterized small molecule agonist at GPR17, 
MDL29,951. Maximal BRET2 signal-decrease after incubation with MDL29,951 (1 μM) was set to -
100%. Data are shown as means ± S.E.M. from three to eight independent experiments. 
 
 β-arrestin recruitment mediated by GPR17 4.3.2
β-arrestin was initially reported as a mediator of GPCR desensitization and downregula-
tion. It has also been described as a scaffold able to orchestrate G protein signaling to 
various GPCR effector proteins, including MAPKs and phosphoinositide 3-kinase 
(PI3K) (Povsic et al. 2003; Rajagopal et al. 2010). Notably, β-arrestin recruitment by 
GPCRs is described as occurring both dependently and independently of G protein sig-
naling (Rajagopal et al. 2005; Kenakin, Christopoulos 2013). Therefore, it might be 
possible that the proposed endogenous ligands for GPR17 could signal by a G protein-
independent pathway. 
It has been documented that MDL29,951-activated GPR17 mediates β-arrestin recruit-
ment in a recombinant transfected cell model (Hennen et al. 2013). Accordingly, to de-
tect G protein-dependent and -independent signaling of proposed endogenous ligand-
activated GPR17, the β-arrestin recruitment after GPR17 activation was recorded. The 
receptor- β-arrestin interaction was analyzed by a BRET2 assay in HEK293 cells co-
expressing the energy donor hGPR17-Rluc and the energy acceptor β-arrestin2-GFP2. 
GPR17 fused to Rluc maintains functionality and is expressed in the cell membrane as 
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previously described by Hennen and coauthors in 2013 (Hennen et al. 2013). In agree-
ment with previous findings, MDL29,951 recruited β-arrestin in a time-dependent man-
ner, with a maximum peak after 1-5 min and returning to approximately 25% of the 
maximal value after 60 min. In contrast, neither uracil-nucleotides nor cysteinly-
leukotrienes triggered significant GPR17-dependent β-arrestin recruitment over 60 min 
in the indicated high concentrations (Figure 35).  
Taken together, the obtained data do not confirm that either uracil-nucleotides or cyste-
inly-leukotrienes activate GPR17 in this readout. This is in contrast to previous results 
by Daniele et al., which showed an association of GPR17 with β-arrestin after cell incu-
bation with UDP-glc and LTD4 (Daniele et al. 2014). 
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Figure 35. β-arrestin recruitment in HEK293 cells stably expressing hGPR17 
β-arrestin recruitment was measured by a BRET2 signal, which occurred between hGPR17-Rluc and 
GFP2–β-arrestin2 in stably transfected HEK293 cells at indicated time points (1.5, 5, 10, 15, 30, and 
60 min). Cells were stimulated with 1 µM MDL29,951, 10 µM UDP, 10 µM UDP-gal, 10 µM UDP-
glc, 0.1 µM LTC4 or 0.1 µM LTD4. Data are shown as means ± S.E.M. from three to four independent 
experiments. 
 
 Proposed endogenous ligands did not induce GPR17-dependent 4.3.3
ERK1/2-phosphorylation 
ERK1/2 belong to the class of mitogen-activated kinases, which are involved in a wide 
range of cellular processes, such as cell proliferation and differentiation. The MAP-
kinase cascade can be activated by Gαi/o, Gαs, and Gαq as well as β-arrestin by direct or 
indirect mechanisms. This depends on the coupling ability of the upstream GPCR and 
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the cellular background (Zheng et al. 2008). Thus, a large variety of receptor upstream 
effects converge activating ERK1/2 as a detectable phosphorylation process. Hence, its 
measurement represents an ideal way to detect amplified low GPCR response. 
MDL29,951-activated GPR17 mediated robust ERK1/2 phosphorylation in primary and 
immortalized cells, as previously shown in the present work. Accordingly, taking ad-
vantage of the ERK1/2 phosphorylation assay, further analysis of the controversial en-
dogenous ligands of GPR17 was carried out. Based on previous data, which reported a 
time-dependent ERK1/2 phosphorylation by UDP-glc- and LTD4-activated GPR17 in 
1321N1 cells (Daniele et al. 2014), these cells stably expressing hGPR17 were chosen 
as cellular background for this assay. 1321N1 cells expressing hGPR17 were incubated 
with the cysteinyl-leukotrienes and uracil-nucleotides, and the ERK1/2 phosphorylation 
was compared to cells challenged with MDL29,951 at different time points (Figure 36). 
In agreement with preceding results (Hennen et al. 2013), MDL29,951 stimulated a ro-
bust and rapid ERK1/2 phosphorylation over time with a maximum peak after 1-5 min 
in cells expressing hGPR17. After 30 min the signal declined to the basal level. In con-
trast, GPR17 stimulation with the putative endogenous agonists did not lead to an in-
crease in ERK1/2 phosphorylation over 60 min. 
 
Figure 36. 1321N1 cells stably expressing hGPR17 were unresponsive to the pro-
posed endogenous ligands in the ERK1/2 phosphorylation assay 
ERK1/2 phosphorylation kinetics (time points: 1, 5, 10, 20, 30 and 60 min) were measured in hGPR17-
1321N1 cells after treatment with 10 µM MDL29,951 or the proposed endogenous ligands (10 µM UDP, 
10 µM UDP-gal, 10 µM UDP-glc, 0.1 µM LTC4 and 0.1 µM LTD4). Data are shown as means ± S.E.M. 
from four independent experiments. 
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As a control, native 1321N1 cells were incubated with 10 µM MDL29,951 over 60 min 
to analyze the receptor specificity of MDL29,951 signal. As shown in Figure 37, 
MDL29,951 did not induce ERK1/2 phosphorylation. The correctness of assay condi-
tions and viability of the analyzed cells were controlled by stimulation with fetal calf 
serum (FCS) and carbachol. Carbachol activates endogenously-expressed muscarinic 
receptors while FCS components activate endogenous growth factor receptors. As 
shown in Figure 37, in contrast to MDL29,951 both FCS and carbachol induced a ro-
bust ERK1/2 signal after 5 min in native 1321N1 cells. 
 
Figure 37. Increase of intracellular ERK1/2 phosphorylation in native 1321N1 cells 
1321N1 cells were incubated with a medium containing 100 µM of the muscarinic agonist carbachol, 
10% FCS or 10 µM MDL29,951. Native 1321N1 cells responded to carbachol and serum but did not 
respond to MDL29,951. ERK1/2 phosphorylation was recorded at indicated time points. Data are shown 
as means ± S.E.M. from two to three independent experiments. 
 
In order to confirm the activity of LTC4 and LTD4, HEK293 cells stably expressing the 
CystLT1 receptor, which represents the established target for LTD4 and LTC4, were 
incubated with both ligands and ERK1/2 phosphorylation was determined after indicat-
ed time points. As expected, LTD4 and LTC4 triggered an increase in phosphorylated 
ERK1/2 mediated by the CysLT1 receptor with a maximum peak after 2 min and 5 min, 
respectively. Then, ERK1/2 phosphorylation declined to basal levels after 60 min of 
incubation (Figure 38, A). In order to analyze the receptor specificity of the ERK1/2 
signal, native HEK293 cells were stimulated for 2 min with LTD4 and for 5 min with 
LTC4. Neither LTD4 nor LTC4 triggered any ERK1/2-phosphorylation in native 
HEK293 cells, demonstrating the CysLT1 specificity for these compounds (Figure 38, 
B). 
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Figure 38. ERK1/2 phosphorylation in HEK293 cells stably expressing CysLT1 
receptor over the time (A) and in native HEK293 (B). 
(A) ERK1/2 phosphorylation kinetics (time points: 1, 5, 10, 20, 30, and 60 min) were recorded in 
CysLT1-HEK293 cells after treatment with 0,1 µM LTD4 and LTC4. (B) ERK1/2 phosphorylation was 
measured in native HEK293 cells after incubation with LTD4 for 2 min or LTC4 for 5 min and was com-
pared to the carbachol-mediated ERK1/2 activation. Data are shown as means ± S.E.M. from four inde-
pendent experiments.  
 
Likewise, to confirm the uracil-nucleotides functionality and to test the specificity of the 
receptor response, the signal of HEK293 cells stably expressing P2Y14, which repre-
sents an entrenched target for uracil-nucleotides, was compared with the signal of native 
HEK293 in the ERK1/2 phosphorylation assay. Both cell lines were incubated for 5 min 
with either 10 µM UDP, UDP-gal or UDP-glc.  
In contrast to the lack of signal detected in native HEK293 cells, the P2Y14 receptor 
stably expressed in the same cell system triggered an intracellular activation of the 
MAP-kinase cascade, measured as a significant increase of phosphorylated ERK1/2, 
after stimulation with UDP, UDP-gal, and UDP-glc (Figure 39). This demonstrated that 
the tested uracil-nucleotides are functional under the present assay conditions.  
Taken together, the obtained data indicate that neither uracil-nucleotides nor cysteinyl-
leukotrienes have the capacity to activate ERK1/2 in a cell system stably expressing 
GPR17, which is in contrast to the effect observed with MDL29,951.  
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Figure 39. Level of phosphorylated ERK1/2 in native HEK293 cells compared to 
P2Y14-HEK293 cells 
Incubation with UDP, UDP-gal, and UDP-glc (10 µM) resulted in a phosphorylated ERK1/2 increase in 
P2Y14-HEK293 cells, in contrast native HEK293 cells did not respond to the uracil-nucleotides. Data are 
shown as means ± S.E.M. from four independent experiments. *, p<0.05; ****, p<0.0001. 
 
In conclusion, the results obtained in: (i) G protein rearrangement, (ii) β-arrestin re-
cruitment, and (iii) ERK1/2 phosphorylation assays are in line with previous studies 
which could not confirm that GPR17 responds to UDP, UDP-glc, UDP-gal, LTC4, and 
LTD4. Therefore, these findings support all literature refuting GPR17 putative endoge-
nous ligands and, consequently, GPR17 as a dualistic receptor activated by uracil-
nucleotides and cysteinyl-leukotrienes (Bläsius et al. 1998; Heise et al. 2000; Maekawa 
et al. 2009; Wunder et al. 2010; Benned-Jensen, Rosenkilde 2010; Qi et al. 2013; Hen-
nen et al. 2013; Köse et al. 2014). 
4.4 Analysis of potential antagonists of GPR17 
Recent studies recognized GPR17 as a negative modulator of oligodendrocyte matura-
tion and differentiation; consequently, GPR17 was proposed as an innovative therapeu-
tic target in demyelinating diseases like MS. In particular, the therapy of demyelinating 
diseases would benefit from a potent GPR17 antagonist.  
 P2Y receptor inhibitors as potential antagonists for GPR17 4.4.1
The original GPR17 deorphanization report by Ciana and coauthors identified the 
P2Y12 receptor antagonist cangrelor, the P2Y1 receptor antagonist MRS2179 and the 
CysLT1 receptor antagonists pranlukast and montelukast as potent inhibitors of UDP-
glc-activated human and rat GPR17 (Ciana et al. 2006). The experimental procedure 
adopted by the authors was the [35S]GTPγS binding assay. Cangrelor has been charac-
terized as a potent antagonist with an IC50 value in the nanomolar range. Moreover, a 
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second P2Y12 receptor antagonist, ticagrelor, was also described as a GPR17 inhibitor 
(Gelosa et al. 2014).  
Several follow-up studies by the same group confirmed the antagonist capacity of the 
described P2Y receptor and CysLT1 receptor antagonists. On the other hand, Hennen 
and coauthors confirmed that pranlukast effectively attenuates the activation of mouse 
and rat GPR17 receptors triggered by MDL29,951, but failed to recapitulate the antago-
nist properties of montelukast at MDL29,951-activated GPR17 (Hennen et al. 2013). 
Therefore, the true potential of these compounds to act as antagonists is currently un-
clear. 
In the initial studies, the antagonist properties were investigated based on uracil-
nucleotide- and cysteinyl-leukotriene-activated GPR17 signaling. However, both cyste-
inyl-leukotrienes and the uracil-nucleotides have been shown to be inactive GPR17 ag-
onists in the present work. Therefore, further investigations of the real nature of the 
proposed antagonists are necessary. Toward this goal, cangrelor and ticagrelor have 
been here analyzed as potential antagonists of MDL29,951-mediated GPR17 signaling. 
Three GPR17 receptor orthologs were tested: the human, the rat, and the mouse. 
Pranlukast, which was shown as inhibitor of MDL29,951-mediated GPR17 signaling at 
all three receptor orthologs (Hennen et al. 2013), has been selected as reference antago-
nist in the following experiments.  
In order to analyze the potency of cangrelor and ticagrelor to antagonize MDL29,951-
activated GPR17 response, a classical second messenger assay was chosen, the IP1 ac-
cumulation assay. It has been described that MDL29,591-activated mGPR17, rGPR17, 
and hGPR17 robustly couple to Gαq proteins to increase intracellular IP1 levels (Hen-
nen et al. 2013). 
 Analysis of the antagonist properties of cangrelor and ticagrelor at 4.4.1.1
the three GPR17 orthologs 
Initially, hGPR17-HEK293 cells were pre-incubated (30 min, 37 °C) with pranlukast 
and the two purine receptor antagonists, followed by a stimulation with MDL29,951 (1 
µΜ = EC80) for 30 min. As depicted in Figure 40, pranlukast caused a partial inhibition 
of the receptor response but could not completely abolish the GPR17 signaling. In con-
trast, cangrelor and ticagrelor exhibited no significant reduction of the GPR17-mediated 
intracellular IP1 accumulation. Thus, the obtained results confirmed the antagonist po-
tency of pranlukast but did not verify the published antagonist capability of cangrelor 
and ticagrelor at the hGPR17.  
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Figure 40. Alteration of IP1 levels in HEK293 cells stably expressing human 
GPR17 
Concentration-dependent inhibition of intracellular IP1 levels by ticagrelor, cangrelor, and pranlukast 
were analyzed in HEK293 cells stably expressing hGPR17 upon stimulation by MDL29,951. Data were 
expressed as percentages of IP1 levels induced by 1 μM MDL29,951 in the absence of the potential an-
tagonists. Data are shown as means ± S.E.M. from three to four independent experiments. 
 
The current literature describes noticeable differences between ligand potencies among 
species-specific orthologs of GPCRs, which complicates use of compounds from in vivo 
studies at the human to in vivo studies in animal models (Milligan 2011; Strasser et al. 
2013). Accordingly, in the next experiment the P2Y12 receptor antagonists cangrelor 
and ticagrelor were tested in HEK293 cells stably expressing the mouse and the rat 
GPR17 receptor orthologs. The antagonists were tested against the approximated EC80 
of MDL29,951 at the rat and the mouse receptors (Hennen et al. 2013). In line with the 
data obtained from hGPR17-HEK293 cells, pranlukast, but not cangrelor or ticagrelor, 
effectively inhibited the function of MDL29,951-activated mouse or rat GPR17 (Figure 
41). The obtained results confirmed pranlukast as an effective antagonist for all three 
receptor orthologs, but neither cangrelor nor ticagrelor could be verified as 
MDL29,951-activated GPR17 inhibitors. 
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Figure 41. Intracellular IP1 levels in HEK293 cells stably expressing rat GPR17 (A) 
or mouse GPR17 (B) 
MDL29,951-mediated IP accumulation was recorded in the presence of increasing concentrations of 
cangrelor, ticagrelor or pranlukast in HEK293 cells stably expressing (A) rGPR17 or (B) mGPR17. Data 
were expressed as percentages of IP1 levels induced by 3 μM MDL29,951 at rat receptor (A) or 10 µM 
MDL29,951 at the mouse receptor in the absence of the potential antagonists. Data are shown as means ± 
S.E.M. from three to five independent experiments. 
 CysLT2 receptor antagonists as candidates for GPR17 inhibition 4.4.2
A potent inhibitor of GPR17 may represent an excellent drug candidate to reduce the 
GPR17-mediated arrest of oligodendrocyte maturation and, in consequence, to foster 
remyelination in demyelinating diseases. However, in the present study, the proposed 
antagonists either showed a low potency to inhibit MDL29,951-stimulated GPR17 
(pranlukast) or were completely inactive (ticagrelor and cangrelor). Thus, identification 
of a potent GPR17 antagonist remains an open challenge.  
Recently, two selective and potent CystLT2 receptor antagonists have been described in 
the literature, HAMI3379 and Cay106333. HAMI3379 was defined in 2010 as the first 
potent and selective antagonist at the CysLT2 receptor by Wunder and co-authors 
(Wunder et al. 2010). Furthermore, CAY106333, also known as BayCysLT2, was char-
acterized as selective CysLT2 receptor antagonist in 2011 by Ni and co-workers (Ni et 
al. 2011). Based on the phylogenetic relationship of GPR17 to receptors of the CysLT 
receptor cluster and the inhibition of GPR17 by pranlukast, known as a CysLT1 recep-
tor antagonist, these two selective CysLT2 receptor antagonists were tested for their 
inhibitory properties at GPR17. 
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 Potential antagonist effects of the CystLT2 receptor antagonist at 4.4.2.1
the three GPR17 receptor orthologs 
In order to assess the potency of HAMI3379 and CAY106333, intracellular IP1 levels 
of HEK293 cells stably transfected with the hGPR17 were recorded after incubation 
with these compounds. Compared to pranlukast, the two specific CysLT2 receptor an-
tagonists exhibited a more potent inhibition of the human GPR17-mediated signal 
(Figure 42). As shown in Table 16, the rank order of the IC50 values of the three inves-
tigated substances was: HAMI3379 ≈ CAY10633 > pranlukast. Although the IC50 val-
ues of HAMI3379 and CAY10633 are comparable, HAMI3379 almost completely in-
hibited the effect of hGPR17 on IP1 accumulation. In contrast, after incubation with 
30 µM CAY10633, hGPR17 still retained ≈40% of its activity. The obtained results 
clearly highlight HAMI3379 as the most promising hGPR17 antagonist followed by 
CAY10633. 
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Figure 42. Alteration of IP1 levels in HEK293 cells stably expressing hGPR17 
IP1 accumulation inhibition curve of HAMI3379 and CAY10633 in the presence of 1 µM MDL29,951 
(EC80) was recorded in hGPR17-HEK293 cells after pre-incubation with the indicated concentrations of 
the proposed inhibitors for 30 min. Data were expressed as percentages of IP1 levels induced by 1 μM 
MDL29,951 in the absence of an antagonist. Data are shown as means ± S.E.M. from three to seven inde-
pendent experiments. 
 
Table 16. LogIC50 values of the potential antagonists 
Substance HAMI3379 CAY10633 Pranlukast 
LogIC50 -5,3 -5,4 -4,9 
 
Pharmacological study of potential medical compounds combines in vitro analysis with 
ex vivo and in vivo experiments. Therefore, in drug development it is essential to ana-
lyze both the human receptor and the rodent receptor orthologs to verify whether the 
compounds are suitable for animal models. Consequently, the antagonist potencies of 
HAMI3379 and CAY10633 were next analyzed at the mouse and the rat GPR17 in the 
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IP1 accumulation assay, and compared to the result achieved by incubating the cells 
with pranlukast. As shown in Figure 43, HAMI3379 and CAY10633 inhibited GPR17 
signaling mediated by MDL29,951 on both receptor orthologs, with HAMI3379 show-
ing the highest potency. However, at both receptor orthologs neither HAMI3379 nor 
CAY10633 completely abolish MDL29,951-mediated signaling in the investigated con-
centrations. As indicated in the Table 17, although both CysLT2 receptor antagonists 
inhibited the mouse and the rat receptor, they showed highest potency at the human re-
ceptor. The rank order of the substances is characterized by a minimal difference in the 
IC50 values: (i) mGPR17: HAMI3379 > pranlukast > CAY10633, (ii) rGPR17: 
HAMI3379 > pranlukast > CAY10633. The rank order at the mouse and the rat receptor 
is similar to that obtained at the hGPR17. Taken together, our data show that 
HAMI3379 exhibited the best antagonist properties at all three receptor orthologs. 
 
Figure 43. Decrease of intracellular IP1 levels in HEK293 cells stably expressing rat 
GPR17 (A) and mouse GPR17 (B) 
The inhibitory effects of increasing concentrations of the CysLT2 receptor antagonist set (CAY10633 and 
HAMI3379) were analyzed at MDL29,951-stimulated rGPR17 (A) or mGPR17 (B) by IP1 accumulation 
assays. Data were expressed as percentages of IP1 levels induced by 3 μM MDL29,951 at rat receptor (A) 
and 10 µM MDL29,951 at the mouse receptor (B) in the absence of the potential antagonists. Data are 
shown as means ± S.E.M. from three to five independent experiments. 
 
Table 17. LogIC50 values of the potential antagonists at rGPR17 and mGPR17 
expressed in HEK293 cells 
Substance HAMI3379 CAY10633 Pranlukast 
rGPR17 (LogIC50) -4,9 -4,6 -4,4 
mGPR17(LogIC50) -5,1 -4,7 -5,0 
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In summary, the achieved results obtained by IP1 accumulation assays show for the first 
time that HAMI3379 and CAY10633 act as antagonists at all three GPR17 receptor 
orthologs. Further studies are needed to evaluate the potential of these compounds in 
primary cell systems and to elucidate whether their chemical structures can be used as 
lead for designing GPR17 antagonists with higher potency. 
 
96 5 Discussion 
 
5 Discussion 
Demyelination is a pathophysiological process that occurs in inflammatory demyelinat-
ing diseases, such as MS, and is characterized by the damage of the specific multi-
layered membrane located around neuronal axons (Franklin, Ffrench-Constant 2008). 
Current treatment strategies for demyelinating diseases focus on immunological attack 
modulation. However, long-term functional recovery requires successful myelin repair. 
In consequence, over the last few years it has become evident that remyelination repre-
sents an attractive therapeutic approach in neuroinflammatory demyelinating diseases 
(Franklin, Ffrench-Constant 2008; Kotter et al. 2011). Generation of myelin in the CNS 
requires transition from OPCs to myelinating/mature oligodendrocytes. A precise mo-
lecular mechanistic cascade regulates this maturation process and is influenced by a 
wide range of positive and negative stimuli. However, the molecular mechanisms that 
inhibit remyelination under pathological conditions are poorly understood. Thus, a bet-
ter understanding of the signaling cascades and identification of novel targets regulating 
OPC differentiation could provide new avenues for therapeutic approaches.  
5.1 GPR17: its signaling in oligodendrocytes 
The orphan receptor GPR17 impairs differentiation of immature oligodendrocytes to 
myelinating oligodendrocytes in vivo and in vitro. In particular, genetic studies of 
GPR17 in mice revealed that development of oligodendrocytes is arrested at an imma-
ture stage in animals overexpressing GPR17. On the other hand, mice with a deficiency 
in GPR17 expression showed an early onset of myelination (Chen et al. 2009; Hennen 
et al. 2013). In addition, pharmacological receptor stimulation blocks oligodendrocyte 
differentiation in in vitro studies (Hennen et al. 2013). 
Importantly, qRT-PCR analyses revealed a GPR17 upregulation in demyelinated lesions 
of MS patients that is not present in white matter samples from non-neurological pro-
bands. Furthermore, GPR17 abundance increases in an experimental autoimmune en-
cephalomyelitis (EAE) model (Chen et al. 2009). Thus, GPR17 inhibition by an antago-
nist or antagonizing antibody has been proposed as a potential approach to treat demye-
linating diseases. 
The role of GPR17 in myelination is specific to the CNS; no evidence to date has shown 
its expression on Schwann cells in the PNS. This fact further supports the concept of 
multiple signaling systems regulating CNS and PNS myelination independent of each 
other (Brinkmann et al. 2008). GPR17 affects myelination by triggering nuclear translo-
cation of the differentiation inhibitors 2 and 4 (ID2 and ID4) and by upregulating the 
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expression of ID2 (Chen et al. 2009). Beyond this, very little is known about the intra-
cellular signaling events after GPR17 activation which impair the transition from imma-
ture to mature oligodendrocytes.  
Consequently, the establishment of GPR17 as a therapeutic target would benefit from 
the identification and rigorous validation of GPR17 effector proteins. In addition, this 
may provide a deeper insight into the GPR17-mediated myelination block, and may 
allow to unravel additional innovative therapeutic candidates to treat demyelinating dis-
eases, such as MS. 
 GPR17: a negative regulator of myelination and maturation of 5.1.1
oligodendrocytes 
In the current literature, an increasing number of in vitro and in vivo studies are investi-
gating the impact of GPCRs expressed on the oligodendrocyte cell surface on oligoden-
drocyte myelination. For instance, the adhesion orphan receptor GPR56 blocks oli-
godendrocyte differentiation in an early stage of development (Ackerman et al. 2015). 
In contrast, other GPCRs, such as the cannabinoid receptors CB1 and CB2, act as posi-
tive modulators of the oligodendrocyte maturation process (Gomez et al. 2011; Tomas-
Roig et al. 2016). In the present work, the pharmacological investigation of the activat-
ed GPR17 reveals an attenuation of intracellular MBP expression in primary rat oli-
godendrocytes and Oli-neu cells. The impairment of MBP expression is known to be an 
indicator of opposing action on oligodendrocyte maturation. Consistent with former 
findings by Hennen et al. and Chen et al. (Chen et al. 2009; Hennen et al. 2013), the 
obtained data characterized GPR17 as inhibitor of oligodendrocyte differentiation.  
 Specific G protein coupling of GPR17 in oligodendrocytes 5.1.2
A previous study (Hennen et al. 2013) investigated the coupling of MDL29,951-
activated GPR17 in heterologous cell systems. In HEK293 cells, the entire repertoire of 
G protein pathways (Gαi/o, Gαq, Gαs) is activated by hGPR17 (Hennen et al. 2013). In 
contrast, although Gαi, Gαo, Gαq, and Gαs are expressed in primary rat oligodendrocytes 
(Mir, Le Breton 2008), GPR17 couples only to Gαi/o and Gαq (Hennen et al. 2013). In 
line with these former findings, GPR17 exclusively couples to Gαi/o and Gαq proteins in 
Oli-neu cells, which endogenously express GPR17 and the four main Gα-subunits. This 
has been demonstrated by an MDL29,951-induced cAMP decrease and a partially PTX-
insensitive calcium flux. Non-appearance of intracellular cAMP level increase confirms 
the absence of Gαs signaling after GPR17 activation. Taken together, the obtained data 
confirm a cellular background-dependent coupling of GPR17. Cellular background-
dependent pharmacology is a widely spread and well-known phenomenon. Differences 
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in the stoichiometry of the number of signaling proteins may cause a functional discrim-
ination of ligands across cell lines (Kenakin, Christopoulos 2013).  
The coupling preference of GPR17 expressed in oligodendroglial cells is in line with the 
already described negative impact of Gαi and Gαq proteins on oligodendrocyte devel-
opment in the CNS. For instance, CXCR2, a Gαi-coupled chemokine receptor, is a 
negative regulator of oligodendrocyte maturation (Hall et al. 1999; Kremer et al. 2011). 
In addition, the muscarinic M1 and M3 receptors, which both preferentially couple to 
Gαq, are also obstructers of oligodendrocyte differentiation. Accordingly, in a PLP-
induced EAE animal model, the muscarinic receptor antagonist benztropine induces 
remyelination (Deshmukh et al. 2013). Moreover, inhibition of protein kinase C (PKC), 
which is a known sensor of Gαq activation, promotes OPC differentiation (Baer et al. 
2009). 
 GPR17 engages Gαi/o protein to regulate MBP expression 5.1.3
In the present work, the analysis of the MDL29,951-induced DMR signals verifies a 
major contribution of the Gαi/o-cascade in both oligodendroglial cell lines to the GPR17 
signaling. This contribution was evidenced by a large reduction of the DMR response 
after preincubation with the Gαi/o inhibitor PTX. Accordingly, down-regulation of MBP 
protein levels triggered by pharmacologically-activated GPR17 was rescued in both 
oligodendroglial cell lines after treatment with PTX. Taken together, the experimental 
data confirmed the predominant role of Gαi/o proteins in the differentiation arrest medi-
ated by the GPR17 signaling cascade. 
 GPR17-mediated influence of intracellular cAMP levels on MBP 5.1.4
expression 
The crucial role of the Gαi/o pathway engaged by GPR17 supports the hypothesis that an 
alteration of intracellular cAMP levels may be a major cause of the oligodendrocyte 
differentiation blockade triggered by GPR17. Elegant studies spanning decades of work 
with many different biochemical methods robustly demonstrated the positive influence 
of increased intracellular cAMP concentration on oligodendrocyte differentiation. In 
particular, Sato-Bigbee and co-workers determined a positive influence of the cAMP-
analog dibutyryl-cAMP on myelination by quantifying the MBP expression. Consistent 
with this study, a favorable impact of AC activators on differentiation induction has also 
been confirmed in Oli-neu cells (Joubert et al. 2010). In addition, PLP and MAG, which 
are also typical markers of oligodendrocyte differentiation and myelination, are upregu-
lated by increasing intracellular concentrations of cAMP (Ye et al. 1992). In line with 
these findings, myelin protein extracts have been shown to attenuate oligodendrocyte 
differentiation by a cAMP-decreasing mechanism because the effect was rescued by 
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addition of dibutyryl-cAMP or the phosphodiesterase-4 inhibitor rolipram (Syed et al. 
2013).  
In agreement with these former investigations, in the present study a stable cAMP ana-
log (8-CPT-cAMP) rescues the negative impact of activated GPR17 on the intracellular 
MBP levels. The obtained data verified that GPR17 involves the second messenger 
cAMP to control myelination of oligodendrocytes. Interestingly, a very recent study 
determines a similar cAMP-dependent mechanism to control oligodendrocyte mye-
lination/maturation elicited by another GPCR named GPR37 (Yang et al. 2016) 
 GPR17-mediated influence of PKA on myelination in 5.1.5
oligodendrocytes 
cAMP triggers physiological and pathophysiological effects by activating PKA and the 
more recently discovered enzymes EPAC1 and 2. Previous studies revealed a positive 
influence of PKA on oligodendrocyte development (Sato-Bigbee et al. 1999; Shiga et 
al. 2005). Interestingly, PKA is also an important enzyme affecting oligodendrocyte 
precursor cell migration into demyelinated lesions (Takahashi et al. 2013). The results 
of the present study show that incubation of primary rat oligodendrocytes and Oli-neu 
cells with Sp-6-Bnz-cAMPs, a PKA activator, rescues the MDL29,951-mediated MBP 
decrease. In line with previous studies, the obtained data confirm the positive influence 
of PKA activity on myelination and link GPR17 to the inhibition of the cAMP-PKA 
cascade in oligodendrocytes.  
Therapeutic approaches targeting the cAMP system are still capturing the attention of 
the pharmaceutical industry. The main focus is the manipulation of the cAMP-
degradation system with selective or non-selective PDE inhibitors (Zhang et al. 2005). 
Roflumilast, for instance, was the first selective PDE4 inhibitor marketed in Germany 
for the treatment of the chronic obstructive pulmonary disorder (Wedzicha et al. 2016). 
Furthermore, phosphodiesterases were already recognized as drug targets for the treat-
ment of neurodegenerative disorders of the CNS (Menniti et al. 2006). In addition, the 
cAMP effector, PKA, has been documented as a promising target in the treatment of 
cancer, heart disease, and dysfunctional immune cells (Skalhegg et al. 2005; Dhalla, 
Müller 2010; Sapio et al. 2014). However, the drug development of medicaments influ-
encing the cAMP pathway remains challenging because cAMP and PKA are ubiqui-
tously expressed in the human body and are involved in a broad spectrum of intracellu-
lar processes. Thus, direct alteration of cAMP or rather PKA signaling in drug therapy 
may result in potential adverse effects (Zhang et al. 2005) 
Nevertheless, pharmacological therapy may benefit by targeting the cAMP pathway in a 
tissue-specific manner by cAMP-modulating GPCRs. In demyelinating diseases, the 
inhibition of GPR17, which is highly expressed in the CNS in MS, may represent an 
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excellent approach to increase intracellular cAMP levels and therefore, the PKA activity 
in a tissue-specific manner to foster remyelination. 
 CREB a major transcription factor in myelination  5.1.6
Elevation of intracellular cAMP concentrations triggers generation of active transcrip-
tion factors and MAP kinases (MAPKs). Both cAMP effector classes, for instance, 
phospho-CREB and phospho-ERK1/2 are known to be involved in the mature oli-
godendrocyte development. Transcription factors control gene expression by binding to 
DNA regulatory regions, which are carrying specific consensus sequences (Sato-Bigbee 
et al. 1994; Sands und Palmer 2008). 
In oligodendrocytes, phosphorylated CREB activates the CRE sequence present in the 
MBP promoter to trigger its expression. In 1993, Sato-Bigbee and co-workers described 
for the first time the expression of the transcription factor CREB in oligodendrocytes. 
Their work formed the basis for the investigation of the major role of CREB in mye-
lination (Sato-Bigbee, Yu 1993). In addition, the direct influence of phosphorylated 
CREB on MBP expression was demonstrated by utilizing antisense RNA against CREB 
(Sato-Bigbee, DeVries 1996). Accordingly, compromised CREB phosphorylation has 
been observed in the presence of myelin associated inhibitors (Syed et al. 2013). More-
over, the impaired oligodendrocyte differentiation and myelination after GSK3β-
(glycogen synthase kinase 3 beta) pathway activation is linked to the CREB phosphory-
lation (Azim, Butt 2011). In line with the crucial role of PKA in oligodendrocyte devel-
opment, an increase in CREB phosphorylation levels has been shown to be a conse-
quence of enhanced PKA activity in oligodendrocytes (Sato-Bigbee et al. 1999; Afshari 
et al. 2001). 
In accordance with these findings, in the present study GPR17 activation was linked to a 
decrease in CREB phosphorylation in primary rat oligodendrocytes. In addition, the 
achieved data reveal that the selective PKA activator Sp-6-Bnz-cAMPs has the capacity 
to counteract the GPR17-triggered negative effect on CREB phosphorylation. Taken 
together, the obtained results confirm the activation of CREB by PKA and associate 
GPR17 to the PKA-CREB pathway.  
 ERK1/2 long-term phosphorylation in primary oligodendrocytes 5.1.7
MAPKs, in particular ERK1/2, are key players in oligodendrocyte development. Inter-
estingly, ERK1/2 long-term activation, but not short-term activation, is directly linked 
to the MBP expression in oligodendrocytes. Accordingly, ERK1/2 was identified as an 
important component in oligodendrocyte differentiation (Xiao et al. 2012a; Xiao et al. 
2012b). Remarkably, deletion of ERK2, but not of ERK1, altered the timing of oli-
godendrocyte maturation in vivo (Fyffe-Maricich et al, 2011). It is also known that 
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ERK1/2 utilize CREB-phosphorylation to increase oligodendrocyte differentiation 
(Syed et al. 2013). 
In the present study, activated-GPR17 in oligodendroglial cells does not mediate any 
long-term alteration of ERK1/2 phosphorylation. Importantly, the obtained results veri-
fy that ERK1/2 phosphorylation is not involved in the GPR17 triggered oligodendrocyte 
maturation arrest. Consequently, the data confirm the assumption of a direct GPR17-
Gαi/o-adenylyl cyclase-PKA-CREB pathway. 
 ERK1/2 short-term phosphorylation in various cellular backgrounds 5.1.8
Although no GPR17-dependent ERK1/2 long-term activation occurs, a robust GPR17-
dependent short-term increase of ERK1/2 levels was detectable in primary rat oligoden-
drocytes and mouse Oli-neu cells, similar to that observed in HEK293 cells over-
expressing the human GPR17 (Hennen et al. 2013). The investigation of the molecular 
mechanism that underlies the short-term ERK1/2 phosphorylation reveals an engage-
ment of different G protein pathways in Oli-neu cells compared with HEK293 cells. In 
HEK293 cells, the ERK1/2 phosphorylation is hierarchically mediated: Gαq-mediated 
phosphorylation arises upstream to that mediated by Gαi. In contrast, in Oli-neu cells 
ERK1/2 short-term activation is Gαi-mediated and completely Gαq-independent. Thus, 
GPR17 engages different G proteins to regulate ERK1/2 activation, depending on the 
cellular background (Hennen et al. 2013). 
 EPAC expression in oligodendrocytes 5.1.9
In addition to PKA, the EPAC activity is also influenced by intracellular cAMP level 
alteration. Remarkably, increasing intracellular cAMP concentration can independently 
activate either PKA, EPAC, or both, depending on the cellular background. A growing 
number of recent studies describe both synergistic and antagonistic effects of EPAC and 
PKA on a variety of processes in different cells, such as axon guidance and phosphory-
lation of AKT in primary cortical neurons (Nijholt et al. 2008; Murray et al. 2009). In 
addition, EPAC has a regulatory role in the differentiation of several cell types, for in-
stance in osteoclasts and Schwann cells (Mediero et al. 2014). Interestingly, activated 
EPAC alters cAMP-mediated effects from a proliferative to an anti-proliferative/neurite 
outgrowth-promoting signal in neuroendocrine PC12 cells (Kiermayer 2005).  
In consequence, the present work investigated the influence of EPAC on oligodendro-
cyte myelination. Previous studies unveiled the expression pattern of EPAC1 and 
EPAC2 in different tissues (Rooij et al. 1998). While EPAC1 is ubiquitously expressed, 
EPAC2 expression is predominant in the brain and in secretory cells, including the pan-
creas and testis. Remarkably, EPAC1 is broadly expressed at low levels in the adult 
brain, but it is strongly and selectively expressed in regions of the developing brain. On 
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the contrary, EPAC2 is robustly expressed in the mature as well as in the neonatal brain 
(Rooij et al. 1998). The results of the present study determined that EPAC1 and 2 are 
expressed in oligodendrocytes during their differentiation. This is a first indication for 
an involvement of EPAC in oligodendrocyte development.  
 EPAC plays a functional role during OPC differentiation 5.1.10
Boomkamp and co-authors previously reported the positive influence of EPAC on mye-
lination in spinal cord injury (Boomkamp et al. 2014). Furthermore, it was shown that 
EPAC is a positive modulator of Schwann cell differentiation and myelination in the 
PNS (Bacallao et al. 2013). However, until the end of 2015, precedent literature provid-
ed no direct demonstration of EPAC as effector protein in oligodendrocyte differentia-
tion. 
The present study shows that pharmacological EPAC activation rescues the GPR17-
mediated MBP decrease in primary rat oligodendrocytes and Oli-neu cells. Further-
more, the selective EPAC inhibitor (ESI-05) diminishes the MBP expression in a signif-
icant manner. The obtained results demonstrated for the first time an influence of EPAC 
on oligodendrocyte differentiation. The achieved findings have received further support 
by a recent study that identified GPR37 as regulator of oligodendrocyte differentiation 
by an EPAC-dependent mechanism (Yang et al. 2016). Taken together, both pathways: 
(i) cAMP-PKA-CREB and (ii) cAMP-EPAC enhanced differentiation and myelination 
of oligodendrocytes. In contrast, a previous study showed that EPAC and PKA do not 
have any synergistic effect on Schwann cell differentiation in the PNS, EPAC activation 
has a positive impact on Schwann cell maturation, and alteration in PKA activity has no 
effect on Schwann cell differentiation (Bacallao et al. 2013). In contrast, Mogha and co-
workers showed the important role of GPR126 on Schwann cell myelination through 
Gαs-cAMP-PKA dependent mechanism (Mogha et al. 2013). 
These findings are also in line with the role of known EPAC effector proteins. EPAC 
has been shown to directly influence the RhoA pathway and the PI3 kinase-AKT cas-
cade, and to be a link between cAMP and the p38 MAPK signaling cascade (Chen et al. 
2012). For instance, the G protein-coupled bile acid receptor (TGR5) inhibits the 
RhoA/Rho kinase pathway by an EPAC-dependent mechanism to induce smooth mus-
cle relaxation (Rajagopal et al. 2013). EPAC enhances AKT functionality in primary 
cortical neurons (Nijholt et al. 2008) and controls the neuronal excitability in cerebellar 
neurons by a p38-dependent pathway (Ster et al. 2007). Interestingly, all three signaling 
pathways: i) the RhoA pathway, ii) the PI3 kinase-AKT pathway, and iii) the p38 path-
way have been recognized as key players in orchestrating oligodendrocyte maturation 
and myelination (Bhat et al. 2007; Flores et al. 2008; Pedraza et al. 2014). On the other 
hand, GPR37 blocks oligodendrocyte differentiation by an EPAC-ERK1/2-dependent 
5 Discussion 103 
 
mechanism (Yang et al. 2016). However, our results showed that GPR17 did not influ-
ence ERK1/2 long-term phosphorylation, thus indicating that GPR17 does not engage 
an EPAC-ERK1/2 dependent cascade. In addition, an increasing number of studies de-
scribe a marked difference between the roles played by each EPAC isoform (EPAC1 
and EPAC2) in different cell types. An interesting example is the positive impact of 
EPAC2 on astrocytic differentiation (Seo and Lee 2016). On the other hand, EPAC1 
controls vascular inflammation in an isoform-specific manner (Liu et al. 2015; Parnell 
et al. 2015). In summary, a closer examination should reveal whether one of the already 
mentioned signaling cascades (RhoA, PI3K-AKT or p38) or an unknown pathway is 
engaged by EPAC1 and/or EPAC2 to trigger oligodendrocyte maturation after GPR17 
activation. Therefore, further studies are required to clarify the precise downstream sig-
naling pathway of EPAC-activation mediated by GPR17. 
The achieved findings strongly suggest that EPAC might provide an attractive target for 
therapeutic strategies to promote oligodendrocyte remyelination, potentially allowing 
other cellular functions mediated by the cAMP-PKA signaling pathway to continue un-
disturbed. Moreover, in 2015, Parnell and co-workers reviewed the available data for 
promising EPAC-targeted therapies and concluded that a drug therapy may also benefit 
from selective targeting either EPAC1 or EPAC2 without influencing other pathways. 
This should result in reduced side-effects in drug therapy. The different expression pat-
terns of EPAC1 and EPAC 2 in the developing brain (Rooij et al. 1998) may suggest a 
distinguished role of both isoforms in oligodendrocyte differentiation. Thus, it would be 
of high interest to analyze whether a separate function of EPAC 1 and EPAC 2 is re-
sponsible for oligodendrocyte maturation and, therefore, whether an isoform-specific 
drug therapy may provide an innovative therapeutic approach to treat demyelinating 
diseases, such as MS. 
 Proposed model of GPR17-mediated pathway to impair 5.1.11
oligodendrocyte differentiation  
In conclusion, the present work demonstrates that the Gαi/o coupling of GPR17 in oli-
godendrocytes elicited by the synthetic agonist MDL29,951 is directly linked to de-
creased activity of the two cAMP effector proteins EPAC and PKA. Therefore, the pre-
sent study reveals for the first time a key player role of EPAC in oligodendrocyte devel-
opment. Additionally, diminished PKA activity reduces phosphorylation of the tran-
scription factor CREB after GPR17 activation. Consequently, both pathways, (i) cAMP-
PKA-CREB and (ii) cAMP-EPAC lessen the expression of MBP (Figure 44), which is a 
key marker for oligodendrocyte differentiation and myelination.  
Clearly, follow-up studies are required to verify to which extent the PKA and the EPAC 
pathways contribute to the oligodendrocyte maturation in vitro and in vivo in the CNS. 
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The sequential nature of both GPR17-activated pathways offers multiple target points at 
which the signaling cascade could be regulated. This provides the possibility of influ-
encing the cascade by various pharmacological interventions to promote oligodendro-
cyte differentiation in the presence of negative stimuli and to avoid side-effects in 
pharmacological treatment.  
 
Figure 44. Proposed model of GPR17-mediated pathway to impair differentiation 
of oligodendrocytes 
Stimulated GPR17 couples to Gαi/o proteins in oligodendrocytes to inhibit adenylyl cyclase (AC). In con-
sequence, this reduces intracellular cAMP levels and leads to a decreased PKA and EPAC activity. Less 
PKA activity diminishes CREB phosphorylation. Therefore, both pathways (i) cAMP-PKA-CREB and 
(ii) cAMP-EPAC impair oligodendrocyte differentiation, evidenced by lower MBP expression. 
5.2 GPR17: Still an orphan receptor? 
The current literature describes an increasing number of deorphanization reports, of 
which, unfortunately, several could not be verified by independent laboratories. An ex-
cellent example for such kind of failure represents the GPR39 deorphanization report. In 
2005, Zhang and co-workers reported obestatin as the endogenous ligand for GPR39 
(Zhang et al. 2005). However, several other laboratories could not confirm these results 
(Chartrel et al. 2007; Holst et al. 2007). Interestingly, in 2007 the original report was 
retracted by its authors (Zhang et al. 2007; Civelli et al. 2013) but the real nature of 
obestatin as GPR39 ligand is still controversially discussed (Zhang et al. 2008). 
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 Concept of dualistic receptor 5.2.1
The sequence similarity identification between receptors represents a common way to 
deorphanize GPCRs. However, prior literature describes the limits of GPCR deorphani-
zation by the pairing of orphan receptors with the known receptor ligands of the same 
phylogenetic cluster (Civelli et al. 2013). For instance, the opioid receptor-like 1 recep-
tor (ORL-1) now called Nociceptin/Orphanin FQ (N/OFQ) peptide (NOP) receptor was 
paired with dynorphin A, the endogenous agonist of the kappa-opioid receptor, consid-
ering the phylogenetic similarities of the receptors. However, poor affinity of dynorphin 
A was shown at the NOP receptor. Shortly afterwards the cognate eptadecapeptide 
N/OFQ, the first endogenous ligand discovered by reverse pharmacology, was inde-
pendently identified as NOP receptor agonist by two different laboratories (Meunier et 
al. 1995; Reinscheid et al. 1995). On the contrary, lysophosphatidic acid (LPA) acti-
vates both lysophosphatidic acid receptor 1 (LPA1) and GPR23 (also termed as LPA4), 
although these receptors share only 10% amino acid similarity (Civelli et al. 2013). 
GPR17 is phylogenetically located between CysLT and P2Y receptors and described as 
new dualistic receptor activated by uracil nucleotides and cysteinyl-leukotrienes, con-
sidering the sequence similarity identification deorphanization approach (Civelli et al. 
2013). In particular, (i) the P2Y receptor agonists UDP, UDP-glc, UDP-gal and (ii) the 
CysLT receptor agonists LTD4 and LTC4 have been reported to activate GPR17 with 
(i) EC50 values in the micromolar and (ii) nanomolar range, respectively. Several fol-
low-up studies by the same laboratory further confirmed the dualistic nature of GPR17 
(Daniele et al. 2011; Fratangeli et al. 2013). Recently, oxysterols, known as activators 
of Epstein Barr virus induced gene receptor-2 (EBI2) and the chemokine receptor 2 
(CXCR2), were reported as a third class of endogenous GPR17 activators (Sensi et al. 
2014). A recent report also demonstrated an activation of GPR17 by stromal cell-
derived factor 1 (SDF-1), a chemokine receptor (CXCR4 and CXCR7) ligand, increas-
ing the spectrum of proposed GPR17 activators (Parravicini et al. 2016).  
In contrast, different independent groups could not or just partially confirm GPR17 ac-
tivation by cysteinyl-leukotrienes and uracil-nucleotides. Already in 1998, Bläsius and 
co-workers reported that GPR17 is not activated by typical P2Y receptor agonists 
(Bläsius et al. 1998). Furthermore, Heise and co-authors found no evidence that GPR17 
responds to LTD4 or LTC4 (Heise et al. 2000). This was confirmed by a second inde-
pendent group (Wunder et al. 2010). Although Benned-Jensen and co-workers support-
ed in their study a GPR17 activation by uracil nucleotides in the micromolar range, they 
could not confirm a response to cysteinyl-leukotrienes (Benned-Jensen, Rosenkilde 
2010). Furthermore, the putative endogenous ligands established for CysLT receptors 
were unable to activate calcium flux in 1321N1 cells stably expressing GPR17 
(Maekawa et al. 2009). Qi et al. failed to recapitulate the activation of GPR17 by UDP, 
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UDP-gal, UDP-glc, and LTC4 in five different immortalized recombinant cell lines ex-
pressing the human GPR17 by both inhibition of forskolin-stimulated cAMP accumula-
tion and promotion of inositol phosphates alteration (Qi et al. 2013). In a later study, 
Hennen and co-workers were unable to measure an activation of the human GPR17 long 
version by the uracil nucleotides and cysteinyl leukotrienes by applying the holistic la-
bel-free DMR method (Hennen et al. 2013). Moreover, in a radioligand binding study 
with tritium-labeled MDL29,951 no competition of the tracer by UDP, UDP-glc or 
LTC4 could be detected, when membranes from Chinese hamster ovary (CHO) cells 
recombinantly expressing the receptor were used. However, the authors of this study 
cannot preclude that the proposed endogenous ligands may bind to another receptor 
binding site (Köse et al. 2014). Accordingly, the GPR17 activation by uracil-nucleotides 
and cysteinyl-leukotrienes is still controversially discussed by the scientific community.  
In the present study, neither uracil nucleotides nor cysteinyl-leukotrienes activate 
GPR17 in a direct G protein rearrangement assay, an early receptor activation readout. 
In contrast, MDL29,951-acivated GPR17 mediates a robust intramolecular G protein 
rearrangement. Furthermore, no evidence was found that GPR17 activated by the P2Y 
agonist or the CysLT agonist triggers G protein-dependent or -independent β-arrestin 
recruitment, although GPR17 mediates a time-dependent β-arrestin recruitment activat-
ed by MDL29,951. To amplify a possible low GPR17 response mediated by uracil nu-
cleotides and cysteinyl-leukotrienes, the ERK1/2 phosphorylation assay was used. 
However, no ERK1/2-phosphorylation is detectable after receptor activation by UDP, 
UDP-glc, UDP-gal, LTC4, LTD4 in contrast to a strong ERK1/2 phosphorylation medi-
ated by MDL29,951-activated GPR17. Together, the obtained results of different as-
says, (i) Gαi protein rearrangement, (ii) β-arrestin2 recruitment, and (iii) ERK1/2 phos-
phorylation, which anaylze three different events in the receptor downstream cascade, 
could not confirm an activation of GPR17 by uracil-nucleotide and cysteinyl-
leukotriene. Therefore, in line with the mentioned negative results of several independ-
ent laboratories, our findings did not verify the deorphanization of GPR17. Thus, fol-
lowing the deorphanization definition of the IUPAR: (i) confirmation of the endogenous 
activator by at least two independent working groups and (ii) potency of the proposed 
ligand should be plausible with a physiologic function of the receptor, we conclude that 
GPR17 still remains an orphan receptor. Consequently, more contribution of the scien-
tific community would be desirable to clarify the true nature of the cognate GPR17 lig-
and. 
 P2Y12 receptor antagonist and their effectiveness at GPR17 5.2.2
GPR17 acts as negative regulator of oligodendrocyte differentiation and was identified 
as innovative target to treat MS. Therefore, pharmacological therapy of MS may benefit 
5 Discussion 107 
 
from identification of a potent GPR17 antagonist to foster remyelination in demyelinat-
ed lesions. 
Considering the phylogenetic relationship between GPR17 and the receptors of the P2Y 
and CysLT receptor families, Ciana and co-workers identified CysLT1 and P2Y recep-
tor inhibitors as antagonist at the uracil-nucleotides- and cysteinly-leukotrienes-
activated GPR17 (Ciana et al. 2006). In particular, montelukast and pranlukast, both 
marketed as anti-asthmatic drugs targeting CysLT1, are reported to act as GPR17 an-
tagonists (Ciana et al. 2006). Hennen and co-workers confirmed pranlukast as 
MDL29,951-activated GPR17 antagonist. However, the IC50 value did not reach the 
reported nM range of the original study. In contrast, Hennen et al. failed to recapitulate 
the inhibition capacity of montelukast (Hennen et al. 2013).  
Additionally, cangrelor and ticagrelor, targeting the P2Y12 receptor to inhibit platelet 
aggregation, were as well identified as GPR17 antagonists (Ciana et al. 2006; Gelosa et 
al. 2014). Cangrelor was shown as potent antagonist at the rat, mouse, and human 
GPR17 (Lecca et al. 2008). Furthermore, cangrelor inhibits UDP-glc induced patch-
clamp recordings mediated by GPR17 (Coppi et al. 2013) as well as UDP-glc and 
LTD4-induced cAMP inhibition in immature oligodendrocytes (Fumagalli et al. 2011). 
The curiosity about the functional properties of the published antagonists was driven by 
the inactivity of the proposed endogenous ligands at GPR17 in the present study, and 
this led to the investigation of cangrelor and ticagrelor. 
The achieved data demonstrated that ticagrelor and cangrelor do not have the capability 
to inhibit the functionality of the MDL29,951-activated human, rat, and mouse GPR17 
in IP1 accumulation assays. Accordingly, the present study could not confirm the re-
ported antagonistic effects of P2Y12 inhibitors at GPR17 and revealed additionally a 
discrepancy between the obtained data and the previous results about reported GPR17 
modulators.  
Consequently, the question arises: why does the inconsistency in the GPR17 literature 
occur? Although initially the proposed endogenous agonists and synthetic antagonists 
were mainly characterized by [35S]GTPγS binding assays in an artificial cellular back-
ground, in several follow-up studies by the same group the pharmacology of the puta-
tive ligands and inhibitors was then tested in second messenger assays using immortal-
ized cells and primary rat oligodendrocytes (Ciana et al. 2006; Daniele et al. 2011; 
Fratangeli et al. 2013; Daniele et al. 2014). Except 1321N1 cells, a high number of im-
mortalized and native cells express P2Y receptors (Atwood et al. 2011). In particular, 
primary OPCs express the P2Y receptor subtypes 1, 2, 4, 6, 11, 12, 13, and 14 and, in 
addition, the CysLT2 receptor (Fumagalli et al. 2011; Fratangeli et al. 2013; Fumagalli 
et al. 2015b). Furthermore, P2Y12 receptor was found in premature oligodendrocytes 
by RT-PCR quantification (Fumagalli et al. 2011). Following this line of thought, de-
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termination of receptor activity in an environment with various endogenous receptors is 
often problematic. In consequence, this could lead to potentially incorrect pairing of 
GPR17 with ligands of the P2Y and CysLT receptor classes.  
Furthermore, P2Y receptors are extensively reported to build hetero-oligodimers that 
may change the receptor pharmacology compared to the parent receptor (Abbracchio et 
al. 2006). It has been published that CysLT1 and GPR17 built heteromers, whereby the 
functionality of the CysLT1 receptor is modulated by GPR17 (Maekawa et al. 2009). 
Thus, GPR17 activation by P2Y and CysLT agonists and inhibition by antagonist of 
both receptors classes observed in other studies might be explained by the occurrence of 
GPR17 heteromers in the used cell system.  
Taken together, seven years after the GPR17 deorphanization report was published, the 
receptor is still reported as orphan receptor by the International Union of Basic and 
Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classification 
(NC-IUPHAR) (Davenport et al. 2013) and this was confirmed in the present study. 
Thus, the pairing of GPR17 with its real natural modulator remains as an open chal-
lenge. In addition, the obtained results could not verify cangrelor and ticagrelor as 
GPR17 inhibitors. 
 GPR17 is inhibited by CysLT2 receptor antagonist 5.2.3
As mentioned before, pharmacological GPR17 inhibition is observed in vitro with 
pranlukast, a drug synthesized to target the CysLT1 receptor (Ciana et al. 2006; Hennen 
et al. 2013). In addition to the high receptor analogy between the human GPR17 and the 
human CysLT1 receptor (31%), GPR17 shows further 36% receptor similarity to the 
human CysLT2 receptor (Ciana et al. 2006; Maekawa et al. 2009). The phylogenetic 
proximity supports the hypothesis that CysLT2 antagonists may also effectively block 
GPR17 function. 
In 2010 Wunder and co-workers described HAMI3379 as the first potent and selective 
antagonist at the CysLT2 receptor, without any effect at the CysLT1 receptor (Wunder 
et al. 2010). In vivo, HAMI3379 blocks ischemic brain injury by acting as a CysLT2 
antagonist (Shi et al. 2015). One year later, Ni and co-workers pharmacologically char-
acterized a second selective CysLT2 antagonist, CAY10633 (BayCysLT2). Interesting-
ly, the authors described an attenuation of myocardial ischemia/reperfusion injury in 
mice after CysLT2 inhibition by CAY10633 (Ni et al. 2011). 
Both HAMI3379 and CAY10633 are isophthalic acid derivatives. Their structural dif-
ference is only an exchange of a benzyl ring to a cyclohexyl ring. Nevertheless, 
CAY10633 is described to be 10-fold less potent than HAMI3379 to inhibit LTD4-
induced CysLT2 receptor signaling (Ni et al. 2011). 
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Wunder et al. already hypothesized an antagonistic effect for HAMI3379 at GPR17. 
However, they could not prove their assumption because they failed to activate GPR17 
with the proposed endogenous ligands LTD4 and LTC4 (Wunder et al. 2010).  
Taking advantage of the GPR17 small molecule agonist MDL29,951, in the present 
study, the inhibitory potency of HAMI3379 and CAY10633 was measured at GPR17 in 
comparison with the already known GPR17 antagonist pranlukast. Both CysLT2 antag-
onists successfully block activated-human GPR17 in a recombinant cell system. Moreo-
ver, HAMI3379 evokes the most potent inhibition of MDL29,951 activity at the rodent 
GPR17 orthologs, closely followed by CAY10633 and pranlukast. Nevertheless, both 
CysLT2 antagonists show the highest potency at the human receptor. The activity of the 
human GPR17 is almost completely blocked by HAMI3397. 
Based on their similar capacity to inhibit GPR17, it could be envisaged that the common 
basic chemical structure of both CysLT2 antagonists may serve as lead for the discovery 
of higher potent GPR17 inhibitors. In addition to the ability of CysLT2 antagonists to 
counteract GPR17 function in vitro, further studies have also to exhibit whether the 
compounds are suitable to promote oligodendrocyte differentiation in primary cell cul-
tures and in vivo by acting as GPR17 antagonists. It should be emphasized that the use 
of CysLT2 antagonists in primary oligodendrocytes might be problematic due to the co-
expression of CysLT2 receptor and GPR17 during oligodendrocyte development (Fum-
agalli et al. 2011). 
Drug targeting of receptors in the CNS requires the penetration of the not intrathecal 
applied compounds through the blood brain barrier (BBB). The BBB is a selective 
physiological barrier, which protects the CNS against unwanted pathogens. According-
ly, the BBB represents a substantial hurdle for drugs targeting CNS receptors, such as 
GPR17 (Banks 2009). Interestingly, in a pharmacological study HAMI3379 reaches 
functional concentrations in the CNS after intraperitoneal injection in rats, which veri-
fied a successful penetration trough the BBB (Shi et al. 2015). This further supports the 
idea to use HAMI3379 as a lead structure in the GPR17 antagonist development.  
Taken together, for the first time, the achieved data exhibit a potent GPR17 inhibition 
by applying CysLT2 receptor antagonists. Further studies are required to evaluate 
whether the CysLT2 antagonists are suitable to block GPR17 activation in primary cells 
and in vivo. 
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6 Summary 
Multiple sclerosis (MS) is an inflammatory demyelinating disease, which is accompa-
nied with oligodendrocyte damage and terminated in axonal loss. A curative therapeutic 
goal is replacement of the lost myelin sheath because in MS, physiological remye-
lination, which requires mature myelinating oligodendrocytes, is either inadequate or 
fails completely (Franklin, Ffrench-Constant 2008). Accordingly, drug development 
would benefit by identification and characterization of CNS targets that promote oli-
godendrocyte differentiation and myelination. The G protein-coupled receptor GPR17 
was identified as such an innovative target (Chen et al. 2009; Hennen et al. 2013). 
GPR17 arrests oligodendrocytes in a pre/immature stage and thereby blocks develop-
ment of myelinating oligodendrocytes in the CNS. 
To gain more insight into GPR17 function, the first part of the present study focusses on 
the analysis of the GPR17 signaling pathway in primary rat oligodendrocytes and the 
immortalized mouse oligodendrocyte cell line Oli-neu. Consistent with the role of 
GPR17 in primary oligodendrocytes, the obtained data demonstrate a reduction of the 
oligodendrocyte myelination marker myelin basic protein (MPB) levels after GPR17 
activation by the recently discovered small molecule agonist MDL29,951 (2-carboxy-
4,6-dichloro-1H-indole-3-propionic acid) (Hennen et al. 2013). The achieved data iden-
tify the Gαi/o signaling pathway, one of the four main G protein pathways, as crucial for 
the GPR17-mediated arrest of oligodendrocytes in an immature stage. GPR17-activated 
Gαi/o proteins inhibit adenylate cyclase (AC) activity to decrease intracellular cAMP 
levels, and this impairs protein kinase A (PKA) and exchange factor directly activated 
by cAMP (EPAC) activity, two known cAMP sensors. In consequence, depressed PKA 
activation reduces the phosphorylation of the transcription factor CREB, known to con-
trol MBP transcription levels. In conclusion, the present study verifies GPR17-
dependent Gαi/o signaling as inhibiting stimulus for the AC-cAMP-PKA-CREB and the 
AC-cAMP-EPAC signaling cascades. Inhibition of both pathways blocks oligodendro-
cyte myelination and maturation, evident by the decrease of intracellular MBP levels. 
Consequently, the sequential nature of the signaling cascades provides multiple target 
points to foster remyelination of the CNS. Remarkably, this study also identifies for the 
first time EPAC as key player in oligodendrocyte differentiation. This provides the hy-
pothesis to investigate EPAC as new target in demyelinating disease to foster repair. 
Clearly, further studies are required to characterize the EPAC signaling pathway pro-
moting oligodendrocyte maturation in more detail.  
Identification of the endogenous ligand of GPR17 would further help to clarify its phys-
iological role and provide insight into receptor pharmacology. Based on its phylogenetic 
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relationship to P2Y and CysLT receptors, GPR17 has been described as a dualistic 
GPCR activated by ligands of both receptor classes: UDP, UDP-gal, UDP-glc, LTC4, 
and LTD4 (Ciana et al. 2006). However, the deorphanization could not be confirmed by 
several independent groups and thus, the real nature of the proposed endogenous ago-
nists for GPR17 is still enigmatic within the scientific community (Bläsius et al. 1998; 
Heise et al. 2000; Maekawa et al. 2009; Benned-Jensen, Rosenkilde 2010; Wunder et al. 
2010; Qi et al. 2013; Hennen et al. 2013; Köse et al. 2014). In consequence, the second 
part of the present work investigates the putative endogenous ligands of GPR17. The 
achieved data demonstrate that neither uracil nucleotides (UDP, UDP-gal, and UDP-
glc) nor cysteinyl-leukotrienes (LTC4 and LTD4) activate GPR17 signaling, which is 
shown by: (i) G protein rearrangement, (ii) β-arrestin recruitment, and (iii) ERK1/2 
phosphorylation assays. In contrast, robust activation is obtained across all assays when 
the receptor is stimulated with MDL29,951. Therefore, the obtained results confirm 
those reports which could not verify uracil nucleotides or cysteinyl-leukotrienes as en-
dogenous ligands for GPR17. In consequence, the present study supports the view that 
GPR17 is still an orphan receptor with unknown endogenous agonist. 
Based on the GPR17 signaling pathway, GPR17 inhibition may represent a novel strat-
egy to foster remyelination in the CNS. Therefore, the drug therapy of demyelinating 
diseases may benefit from potent GPR17 antagonists. The third part of the present study 
examines the potential of different compounds to antagonize GPR17 function. Both 
CysLT1 and P2Y receptor antagonists have been proposed as potent GPR17 inhibitors 
(Ciana et al. 2006; Gelosa et al. 2014), considering the phylogenetic relationship be-
tween GPR17 and the two receptor classes. Therefore, the potential of cangrelor and 
ticagrelor, both known as P2Y12 receptor inhibitors, was first analyzed. Surprisingly, 
neither cangrelor nor ticagrelor have the capability to block MDL29,951-activated 
GPR17 signaling in an inositol monophosphate (IP1) accumulation assay in recombi-
nant cells. In contrast, pranlukast, a CysLT1 receptor antagonist, inhibits the GPR17 
activity but with a low potency. Together, the obtained results do not confirm cangrelor 
or ticagrelor as GPR17 antagonist. Thus, identification of a GPR17 antagonist remains 
an existing challenge. Hence, two CysLT2 receptor antagonists with a high structural 
similarity, HAMI3379 and CAY10633 (Wunder et al. 2010; Ni et al. 2011), were sub-
sequently analyzed as potential GPR17 inhibitors. Remarkably, both HAMI3379 and 
CAY10633 potently inhibited GPR17-dependent IP1 accumulation in recombinant 
cells. Thus, the present study shows for the first time an inhibition of GPR17 by 
CysLT2 inhibitors. Further studies are required to analyze whether these or chemically 
similar compounds will be suitable to efficiently block GPR17 function in primary oli-
godendroglial cells and in vivo models. 
In summary, the present study provides detailed molecular insight into the GPR17 sig-
naling pathways: (i) AC-cAMP-PKA-CREB and (ii) AC-cAMP-EPAC, which block 
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oligodendrocyte differentiation. Furthermore, EPAC is identified for the first time as 
key player orchestrating oligodendrocyte maturation and myelination. In addition, the 
present work provides further support for the notion that GPR17 is not the elusive dual-
istic orphan receptor responding to uracil nucleotides and cysteinyl-leukotrienes. Final-
ly, cangrelor and ticagrelor are characterized as ligands that do not dampen functionality 
of GPR17 as opposed to the CysLT2 antagonists HAMI3379 and CAY10633, capacity 
of which to antagonize GPR17 function has been shown herein for the first time. Thus, 
both CysLT2 inhibitors represent new exciting starting points for the development of 
GPR17 antagonists with higher potency and selectivity. 
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7 List of abbreviations  
AC            adenylate cyclase  
ad            Latin word for up to 
ATP           adenosine 5’-triphosphate  
BRET           bioluminescence resonance energy transfer  
CB            Cannabinoid receptors 
CRE     cAMP response element  
CREB            cAMP response element-binding protein  
cAMP           cyclic adenosine monophosphate 
CNS            central nervous system  
CRC           concentration-response curve  
CNG channels         cyclic-nucleotide-gated ion channels  
CysL           cysteinyl-leukotriene  
CysLT1 receptor        type 1 cysteinyl-leukotriene receptor 
CysLT2 receptor        type 2 cysteinyl-leukotriene receptor 
CXCR           chemokine receptors  
DAG           diacylglycerol 
dH2O           demineralized water  
DMR           dynamic mass redistribution  
D2R           dopamine 2 receptor 
DRC            dose-response curve  
EAE   experimental autoimmune encephalomyeli-
tis (animal model of multiple sclerosis) 
EC 50   concentration of half maximum effect 
EPAC  cAMP-exchange Protein directly acitvated 
by cAMP  
EBI2           Epstein Barr virus induced gene receptor-2  
ERK  extracellular-signal regulated kinase 
114 7 List of abbreviations 
 
et al.            et alii, Latin word for and others  
FRET         fluorescence resonance energy transfer  
FSK         forskolin 
g           acceleration by gravity  
g           gram  
GDP          guanosine 5′-diphosphate  
GEF          guanine nucleotide exchange factor   
GFP          green fluorescent protein 
GPCR         G protein-coupled receptor  
G protein         guanine nucleotide-binding protein  
GPR17         G protein-coupled receptor 17 
GRK          G protein-coupled receptor kinases  
h          human  
h           hour(s)  
H3R    histamine 3 receptor  
HTRF®         homogeneous time resolved fluorescence  
IC50          concentration of half maximum inhibition  
NC-IUPHAR  International Union of Basic and Clinical Pharma-
cology  
IP1          inositol monophosphate 
IP3          inositol 1,3,4-trisphosphate  
JNK          c-Jun N-terminal kinase  
LINGO-1 Leucine rich repeat and Ig-like domain-containing 
Nogo receptor interacting protein 1 
log M          logarithm of molar concentration to base 10  
LTC4 leukotriene D4 
LTD4          leukotriene D4  
LPAR1        lysophosphatidic acid receptor 1 
M           molar concentration (mol/liter)  
m          murine/mouse 
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mAChRs (M) Muscarinic acetylcholine receptors (Muscarinic 
receptors) 
MAG          myelin associated glycoprotein 
MAPK         mitogen-activated protein kinase 
MBP         myelin basic protein 
MASS1        monogenic audiogenic seizure susceptible 1  
MOG         myelin oligodendrocyte glycoprotein 
MS          multiple sclerosis  
ms          millisecond  
µl           microliter  
µM          micromolar  
nm          nanometer  
nM          nanomolar 
NG2         neural/glial antigen 2 proteoglycan  
O4          O-Antigens 
OD          optical density  
Oli-neu cells       immortalized murine oligodendrocytes  
OPC         oligodendrocyte precursor cell  
PCR         polymerase chain reaction 
PDGFRα         platelet-derived growth factor receptor alpha 
PDE4         phosphodiesterase  
PI           phosphatidylinositol  
PI3          phosphatidylinositol 3-kinase  
PKA         protein kinase A 
PKC          protein kinase C   
PLC         phospholipase C  
PLP          proteolipid protein 
PNS          peripheral nervous system  
PTX    Pertussis toxin  
PY2 receptors   purinergic receptors  
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q.s.          quantum satis (as much as needed)  
RhoA         Ras homolog gene family, member A 
ROCK2        RhoA-Rho-associated kinase 2 
RLuc          Renilla luciferase  
rpm         rounds per minute  
RT          room temperature  
RT-PCR         reverse transcription polymerase chain reaction  
RWG          resonant waveguide grating   
s           second(s)  
SCI          spinal cord injury  
S.E.M         standard error of mean  
S1P          spingosine-1-phosphate 
SDF-1         stromal cell-derived factor 1  
siRNA    small interfering RNA  
TGR5   G protein-coupled bile acid receptor  
7TMR         seven transmembrane receptor  
UDP          Uridine 5′- diphosphate 
UDP-gal        Uridine 5′-diphosphogalactose 
UDP-glc         Uridine 5′-diphosphoglucose 
VLGR1        very large G protein-coupled receptor 1 
w/o          without  
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